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In order to optimize pregnancy rates during IVF cycle, we have to grow embryos in such a way to 
allow them to reach their full potential in-vitro. As IVF has evolved since the first live birth in 
1978, culture conditions have improved and we have reached a stage where embryos can thrive 
to the blastocyst stage in-vitro if programmed to do so. IVF cycles typically produce multiple 
embryos during one cycle. Establishing which embryo has a higher potential to result in a live 
birth than its sibling embryos has been attempted over the last 30 years by using non-invasive 
and invasive techniques. Methods to choose which embryo to transfer range from basic 
morphology to establishing ploidy status of each embryo by biopsy. 
 
 
Aneuploidy is the most common cause of implantation failure and miscarriage in human 
reproduction and increases with maternal age, however all maternal ages exhibit varying degrees 
of embryonic aneuploidy. While some non-invasive techniques have shown promise in predicting 
which embryos have the highest implantation potential, the only way currently to establish ploidy 
status of embryos in the embryology lab is to biopsy, then assay embryonic cells before transfer. 
 
 
To improve IVF success, original studies derived from retrospective analysis of clinic data, or 
prospectively designed studies are essential and a number of fundamental biological questions 
pertaining to chromosome abnormalities and their relationship to IVF embryo development 
remain unanswered. The overall aim of this thesis was thus to provide further insight into the 
cytogenetic basis of early human development by pursuit of the following specific aims: 







(1) To test the hypothesis that we can predict aneuploidy levels in human IVF embryos without 
embryo biopsy for PGS by analysis of basic morphokinetic criteria and spent media from cell free 
embryonic DNA, (2) to test the hypothesis that the ICSI technique may create aneuploidy in 
embryos, (3) to establish novel patient populations that may benefit from the use of PGS, 
specifically male factor infertility patients and young oocyte donors, (4) conducting a randomized 
controlled trial (RCT) to establish the optimal transfer strategy (fresh vs frozen) for euploid 
embryos in patients using their own oocytes,(5) to test the hypothesis that identifying mosaic 
embryos among a cohort of embryos could increase live birth rates and reduce miscarriage rates 
by avoiding these embryos for transfer and (6) to use the data generated from PGS/IVF cycles to 
provide a framework for creating realistic expectations for patients planning for their fertility 
future. 
The conclusions of each aim were as follows: I demonstrated that poorer quality embryos showed 
an increased rate of aneuploidy but not large enough to predict aneuploidy for each individual 
embryo. Analysis of cell free DNA in spent culture media is at its early stages of development, but 
the study presented in this chapter using a novel WGA technique, showed that there is potential 
for its future use as a non Winvasive PGS method. 
I found that aneuploidy rates were similar in embryos generated from normal sperm whether 
they were created using ICSI or standard insemination using a donor oocyte model to minimize 
the maternal age effect (aneuploidy rates of 21% for standard IVF vs 23% for ICSI. P=>0.05 NS) 
concluding that the ICSI technique does not create embryonic aneuploidy. 







Donor oocyte recipients (average age of donor 25) benefited from PGS in cryopreserved embryo 
transfer cycles by significantly increasing live birth rates per embryo from 36% with no PGS to 
59% per PGS screened embryo (p=0.0008). Male factor infertility patients presenting with 
oligozoospermia, were shown to exhibit a significantly higher incidence of sex chromosome 
abnormalities in pre-implantation embryos compared to patients with normal sperm using ICSI 
(6.1% for oligozoospermic samples vs 1.6% for normal semen samples. P=0.0007). Both of these 
patient groups could benefit from offering PGS as part of their IVF cycle. 
The RCT showed that freeze all cycles had higher live birth rates than fresh cycles (77% of frozen 
embryo transfers vs 59% of fresh embryo transfers. P=0.04). 
When comparing transfer of embryos screened by NGS with those screened by aCGH, the 
conclusion in the relatively small subset of patients was that live birth rates for embryos screened 
with aCGH and NGS appear to be similar, with a 2% trend in favor of NGS (61% aCGH vs 63% NGS 
live born offspring per embryo transferred. P=>0.05 NS). 
Lastly, the retrospective analysis of data using PGS cycles to calculate how many oocytes are 
required to create one euploid blastocyst depending on maternal age, resulted in a useful tool to 
advise patients on how many cycles of IVF they may need to complete their family. 
Taken together therefore, this thesis provides fundamental insight into the chromosomal basis 
of early human development, introduces new referral categories for PGS and informs the 
practical use of IVF/PGS in the future. 
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1.1 Infertility and IVF 
 
1.1.1 Definition and incidence 
 
/ŶĨĞƌƚŝůŝƚǇŝƐĚĞĨŝŶĞĚďǇƚŚĞtŽƌůĚ,ĞĂůƚŚKƌŐĂŶŝǌĂƚŝŽŶĂƐ “ĂĚŝƐĞĂƐĞŽĨƚŚĞƌĞƉƌŽĚƵĐƚŝǀĞƐǇƐƚĞŵ
defined by the failure to achieve a clinical pregnancy after 12 months or more of regular 
ƵŶƉƌŽƚĞĐƚĞĚƐĞǆƵĂůŝŶƚĞƌĐŽƵƌƐĞ ? ?ĞŐĞƌƐ-Hochschild et al., 2009). The ability to have a child is a 
basic desire for the majority of humans. We have a built-in biological urge to reproduce and if we 
are denied this by our inability to conceive readily or even at all then the psychological and social 
ramifications are far reaching and life changing (Poddar et al., 2014). Baker and Robert wrote in 
ƚŚĞŝƌďŽŽŬŽŶ,ĞĂůŝŶŐƚŚĞ/ŶĨĞƌƚŝůĞ&ĂŵŝůǇƚŚĂƚ “parenting is the bond that seals the generation 
together and the opportunity to pass along the life experiences to the next generation is what, 
for many of us, gives life its meaning ? (Baker LA, 1993). The occurrence of Infertility or subfertility 




1.1.2 Etiology and treatments for infertility 
 
The reasons for infertility or sub-fertility can be tubal factor, uterine factors, male factor 
infertility, endometriosis, ovulatory disorders, luteal phase defects, repeat pregnancy loss, 
unexplained, or advanced maternal age. Data compiled by the Center for Disease Control and 







Prevention (CDC) in the United States of America (USA) for 2014 shows there is a broad 
distribution of infertility etiologies of patients presenting for help with conception using Assisted 
Reproductive Technology (ART). ART includes all treatments where oocytes and embryos are 





























13% 6.2% 14.6% 31.7% 8.9% 33% 15.7% 12.7% 12.1% 17.3% 




Treatments to alleviate infertility range from simple interventions such as timing intercourse to 
occur at the time of ovulation, to In-Vitro Fertilization (IVF). 
 
 
More simple assisted conception treatments only apply to patients presenting with patent 
fallopian tubes, motile sperm available, normal hormone profiles and a functional uterus. These 
treatments would include, timed intercourse around the time of ovulation, clomiphene citrate 
(CC) administration during the follicular phase of the cycle to mildly stimulate follicle growth, hCG 
administration mid cycle to trigger ovulation, gonadotropin administration to encourage multiple 
follicle growth along with intra-cervical or intra-uterine insemination (ICI or IUI) of prepared 
sperm at the time of ovulation. These methods to assist conception have variable success rates 
which are also dependent on maternal age and sperm quality. 







There have been studies comparing timed intercourse with stimulated and unstimulated IUI and 
expectant management but the overall conclusion seems to be that for these patients who have 
largely unexplained infertility, no method has benefit over another (Bahadur et al., 2017; Gunn 
and Bates, 2016; Veltman-Verhulst et al., 2016). 
 
 
In one of the attempts to prove efficacy of each of these treatments, Bhattacharya et al 
performed a randomized controlled trial (RCT) comparing expectant management, oral 
clomiphene citrate (CC) and unstimulated intrauterine insemination (IUI) (Bhattacharya et al., 
2008). They randomized patients less than 35, with unexplained infertility with patent fallopian 
tubes and normal sperm to these 3 groups for 6 months of treatment. They showed cumulative 
live birth rates for each treatment regimen over the 6 months treatment period, was 17%, 14% 
and 23% for each group respectively. Ongoing pregnancy rates with stimulated IUI is reported as 
being around 16% per cycle dependent on maternal age and quality of sperm (Merviel et al., 
2010). Patients who have patent fallopian tubes and motile sperm will usually begin their 
infertility treatment plan with these less invasive methods to assist conception and if 
unsuccessful may move onto IVF. Patients who have non-patent fallopian tubes or severe sperm 
defects only have the option of attempting IVF to achieve conception. 







1.1.3 In-vitro Fertilization (IVF) 
 
A cycle of IVF involves hyper-stimulating the ovaries resulting in the recruitment of multiple 
follicles and subsequently the retrieval of an average of 10-20 oocytes per cycle (own 
unpublished data). Sperm are either inseminated or injected into each mature oocyte on the day 
of oocyte retrieval and the resulting embryos remain in culture until the blastocyst stage of 
development. The availability of multiple oocytes in one cycle increases the chance of finding a 
euploid oocyte to fertilize. 
 
 
One cycle of IVF represents multiple cycles of attempting pregnancy without intervention 
depending on the number of oocytes retrieved and maternal age. Live birth rates of IVF per cycle 
vary between centers. The national live birth rates per cycle published by the center for disease 
control (CDC) in the USA for 2014, according to maternal age are shown in table 2. 
 
 
Maternal age <35 35-37 38-40 >40 
Live birth rate 40.3% 20.5% 18.1% 21% 
Table 2: CDC national US data on live births per cycle for 2014 (208,604 cycles)(CDC, 2014) 
 
 
The number and type of cycles carried out in the USA in 2014 is shown in table 3. 
 
Cycle type Fresh embryos non 
donor eggs 
Frozen embryos non 
donor eggs 
Fresh or frozen 
embryos donor eggs 
# cycles 92,942 56,308 20,522 
% of all cycles 54.8% 33.2% 12.1% 
Table 3: CDC national US data showing the distribution of ART cycle types in the USA for 2014 
(CDC, 2014) 







1.1.4 Evolution of IVF 
 
The first live birth from an IVF cycle in 1978 gave hope to infertile patients that they may be able 
to have their own genetic offspring (Steptoe and Edwards, 1978). Since this first IVF birth, the 
percentage of positive outcomes per cycle have increased due to the evolution of methodologies 
at each stage of the process, including ovarian superovulation protocols, culture methods, 
micromanipulation techniques (Intra-cytoplasmic sperm injection (ICSI) and embryo biopsy). 
 
 
IVF Live birth rates per embryo transfer (ET) in 1982 were around 23% (Edwards and Steptoe, 
1983; Wang and Sauer, 2006) compared to the best centers in 2015 achieving live birth rates of 
over 60% per transfer in certain categories of patient (Oregon Reproductive Medicine 2015 
published CDC data (www.cdc.gov) 35-37 own oocytes, fresh ET 65%/ET). 
 
 
Ovarian superovulation was originally carried out using urinary derived follicle stimulating 
Hormone (FSH) and human menopausal gonadotropin (hMG) (Muasher et al., 1985). Oocyte 
retrievals were performed using laparoscopy at all times of the day and night due to naturally 
occurring uncontrolled LH surges. Gonadotropin Releasing Hormone (GnRH) agonists were used 
in the mid-1980s for poor responder patients to prevent premature luteinization and ovulation 
(Shaw et al., 1987) but by the 1990s this protocol was used worldwide for the majority of patient 
cycles, providing more manageable workflows for clinics and preventing premature ovulation 
occurring before retrieval. The basic stimulation protocol of artificial suppression followed by 
artificially stimulating multiple follicle growth by the use of gonadotropins has been modified to 







suit poor and good responders so that cycles can be optimized for each patient (Schoolcraft et 
al., 1997; Surrey et al., 1998). 
 
 
WĂƚƌŝĐŬYƵŝŶŶ ?ƐŐƌŽƵƉ ?YƵŝŶŶet al., 1985) developed more physiologically normal culture media 
based on what was already known about human tubal fluid based on studies by Lippes (Lippes et 
al., 1972). Henry >ĞĞƐĞ ?Ɛ group performed elegant human tube perfusion experiments (Tay et al., 
1997) to establish the composition of human tubal fluid in-vivo. This led to further refinements 
ĂĨƚĞƌĂǀŝĚ'ĂƌĚŶĞƌ ?ƐŐƌŽƵƉ ?'ĂƌĚŶĞƌ ?  ? ? ? ? )ŽďƐĞƌǀĞĚĚŝĨĨ ƌĞŶĐĞƐ ŝŶŶƵƚƌŝĞŶƚƌĞƋƵŝƌĞŵĞŶƚƐŽĨ
embryos beyond the early cleavage stage of development. This led to the development of 
sequential media to support optimal embryo growth for the entire pre-implantation period in- 
vitro (Gardner and Lane, 1998; Gardner and Schoolcraft, 1998). 
 
 
The use of low oxygen tension has been shown to be beneficial to embryo culture (Bavister, 2004; 
Karagenc et al., 2004) and is therefore now standard of care in many IVF labs throughout the 
world. Low oxygen and high CO2 is either supplied in a pre-mixed gas concentration (5% CO2, 5% 
O2 balance N2) or special tri-gas incubators are supplied with 100% CO2 gas to achieve the goal 
of 5-6% CO2 and 100% Nitrogen gas to displace atmospheric oxygen to 5%. 
 
 
When embryos are growing outside of the body, they have very little protection from potential 
toxic compounds in the surrounding air. Therefore embryology labs have attempted to minimize 
exposure to embryos in their care by using low Volatile Organic Compound (VOC) emitting 




Figure 1: Illustrating the ICSI process. A 
holding pipette steadies the oocyte during 




materials during construction and using carbon and HEPA filtration systems to scrub the air 
coming into contact with the embryos in-vitro. Studies have shown increases in pregnancy rates 
after the introduction of filtration and air handling units to IVF lab systems (Carre et al., 2016; 
Khoudja et al., 2013; Merton et al., 2007; Morbeck, 2015). 
 
 
Optimized culture conditions and stimulation regimens have combined to create an environment 
in which embryos can develop to their full potential in-vitro. Extended culture of embryos to the 
blastocyst stage allowed for better embryo selection and a reduction in the number of embryos 
transferred resulting in a reduction in the numbers of multiple births. 
 
 
The development and implementation of Intracytoplasmic Sperm Injection (ICSI) in the early 
1990s (Palermo et al., 1992) permitted severe male factor infertility patients to conceive their 
own genetically related offspring which prior to the advent of ICSI had been virtually impossible. 
ICSI involves the introduction of a single sperm across the oolemma into the ooplasm of a mature 
oocyte using a fine glass injection needle (pipette) 
(figure 1) 
 
Improvements in cryopreservation methods have 
resulted  in  better  survival  rates  of  embryos.  Slow 







freezing resulted in low embryo survival rates post thaw due to the formation of ice crystals 
during the freezing and/or thawing process, which translated to lower pregnancy rates post 
transfer. The introduction of vitrification (Kuwayama, 2007) resulted in an increase of survival of 
between 20-30% post thaw, from 60% with slow freezing to over 90% with vitrification (Fasano 
et al., 2014; Rienzi et al., 2016). 
 
 
Vitrification relies on brief exposure to high concentrations of cryo-protectants followed by ultra- 
rapid cooling to achieve a glass like state of intracellular fluid to avoid ice crystal formation. Much 
improved survival has resulted in higher pregnancy rates when transferring these 
vitrified/warmed embryos compared to slow frozen embryos (Richter et al., 2016; Rienzi et al., 
2016). 







1.2 Factors contributing to the success or failure of a cycle of IVF 
 
Although IVF has evolved over the last 30 years to the point where live birth rates can be as high 
as 60% per embryo transferred, there are still factors that contribute to implantation failure and 
miscarriage that we have yet to discover and remedy. Embryonic competency plays a large part 
in the success or failure of a cycle of IVF but if the uterine environment is suboptimal then a 
competent embryo is unable to implant and give rise to a live born infant (Katzorke et al., 2016; 
Teh et al., 2016). 
 
 
1.2.1 Factors affecting uterine receptivity 
 
For implantation to occur, endometrial development has to be in synchrony with embryo growth. 
Implantation occurs around 6-10 days post ovulation in-vivo (Wilcox et al., 1999). In-vitro 
cultured embryos have to be in the uterus, ready to implant at the time the uterus is receptive. 
This is termed the window of implantation (WOI). The uterus responds to either endogenous or 
exogenous hormonal control (Groenewoud et al., 2012). In order to discuss the importance of 
the endometrium as part of the IVF process, I have described in the next section how the natural 
cycle creates an endometrium suitable to receive an embryo. 
 
 
1.2.1.1 Preparation of the uterus for conception in the natural cycle 
 
On day 1 of the natural menstrual cycle, estrogen and progesterone are low. Low levels of 
estrogen signal the hypothalamus to release Gonadotropin Releasing Hormone (GnRH) which 
signals the anterior pituitary to produce Follicle Stimulating Hormone (FSH) and Luteinizing 







Hormone (LH). These hormones stimulate follicular development. As the follicular phase of the 
menstrual cycle progresses, rising estrogen produced by the growing follicle(s), proliferates the 
endometrium in preparation for implantation of the embryo. As estrogen reaches a peak, the LH 
surge is triggered and this causes the oocyte to mature in the follicle and then the follicle to 
rupture releasing the oocyte. A corpus luteum is created from the now empty follicle which 
produces progesterone to maintain the endometrium until implantation occurs. As progesterone 
rises the endometrium thickens and vascularizes further into the luteal phase of the cycle. If 
implantation occurs, the embryo will actively produce hCG which continues to maintain the 
endometrium. If the oocyte is not fertilized or implantation fails, then around 14 days after 




1.2.1.2 Preparation of the uterus in a stimulated IVF cycle for transfer 
 
During an IVF cycle to harvest oocytes, the pituitary gland may be downregulated by the use of 
GnRH agonist prior to cycle start so that endogenous hormones are suppressed. Alternatively the 
use of antagonist might be administered mid-stimulation to help prevent a premature LH surge. 
Exogenous administration of FSH and/or HMG results in multiple follicular recruitment and 
development. As these follicles increase in size they each produce estrogen which proliferates 
the endometrium. Once the follicles reach around 17mm in diameter, an artificial LH surge is 
created by administering human Chorionic Gonadotropin (hCG) or combination of high dose 
agonist  (Lupron, AbbVie inc,  Chicago, IL)  /low  dose  hCG   which has the same effect as  LH on 







oocyte maturation and subsequent ovulation. As the timing of hCG administration is controlled, 
IVF clinics are able to time procedures to harvest oocytes before the patient ovulates and loses 
the oocytes to the abdominal cavity. If an embryo transfer is to occur in the stimulation cycle 
then exogenous progesterone is administered post oocyte retrieval to maintain the 




1.2.1.3 Preparation of the uterus for a frozen embryo transfer 
 
Frozen thawed embryos can be transferred in a natural or artificial cycle. A recently published 
randomized non inferiority study showed no differences in outcomes between natural and 
programmed cycles during FET cycles (Groenewoud et al., 2016). Retrospective studies are 
unable to accurately decide which method gives the optimal outcome as patients who have 
regular cycles and can therefore achieve a natural cycle transfer are a different population to 
those who can only achieve an adequate lining using medication. 
 
 
In the natural transfer cycle, transfer is timed 7 days post hCG trigger or 6 days post LH surge 
allowing endogenous hormones to control endometrial development as described previously in 
this chapter. An artificial medicated cycle can involve downregulation of the pituitary gland and 
administration of exogenous estrogen to build the endometrium. Once the thickness and pattern 
of the endometrium are appropriate, progesterone administration will commence. The transfer 
is scheduled 7 days post progesterone commencement. 







1.2.1.4 Uterine receptivity 
 
Implantation is a complex process involving both the embryo and the endometrium. The 
glandular endometrium responds to hormonal signals during the menstrual cycle. Gene 
expression changes throughout the cycle and at the most receptive phase a myriad combination 
of compounds including growth factors, cytokines and glycoproteins are secreted into the uterine 




dŚĞ ŵŽƐƚ ƌĞĐĞƉƚŝǀĞ ƉŚĂƐĞ ŽĨ ƚŚĞ ĐǇĐůĞ ĨŽƌ ŝŵƉůĂŶƚĂƚŝŽŶ ŚĂƐ ďĞĞŶ ƚĞƌŵĞĚ ƚŚĞ  “ǁŝŶĚŽǁ ŽĨ
/ŵƉůĂŶƚĂƚŝŽŶ ? ?tK/ )ĂŶĚƚŚŝƐĂƉƉĞĂƌƐƚŽďĞĂƌŽƵŶĚ ?-7 days post ovulation in humans (Lessey, 
2000). Timing of embryo transfer during an IVF cycle aims to capture that window of implantation 
by placing embryos in the uterus around that time. The WOI may not however be the same for 
all women (Mahajan, 2015; Ruiz-Alonso et al., 2013). The endometrial receptivity array (ERA) was 
developed by analyzing an array of 238 genes found to be expressed at different stages of the 
menstrual cycle. An algorithm was devised to predict a personalized WOI for patients with 
repeated implantation failure (Ruiz-Alonso et al., 2012) so that embryo transfer could be delayed 
or moved forwards depending on the optimal day for implantation defined by the gene 
expression profile. Gomez et al (Gomez et al., 2015) states that the ERA has shown that one in 
four patients with repeated implantation failure have a displaced WOI. High circulating estradiol 
levels during the stimulated cycle have been reported to disrupt the cells of the endometrium 







around the time of implantation resulting in lower implantation rates than patients with lower 
estradiol levels (Basir et al., 2001). 
 
 
1.2.2 Factors affecting embryo development in-vitro 
 
Environmental factors influencing embryo growth in-vitro and the intrinsic viability of each 
embryo are interdependent and both influence the outcome of an IVF cycle. Growing embryos 
in-vitro exposes them to potential hazards otherwise not encountered if growing in-vivo. In-vivo, 
embryos are protected from environmental toxins by the maternal milieu and they are provided 
an ideal combination of nutrients, physiological pH, consistent temperature and oxygen tension 
to allow for optimal growth potential. The challenge over the last 30 years in the IVF laboratory 
has been to achieve a stress free environment for growth so that physiological equivalency is met 
(Swain, 2010; Swain et al., 2016). 
 
 
1.2.2.1 Culture media 
 
There is well documented evidence that nutrition in early gestation both in animal and human 
models can have long reaching effects on health into adulthood. Roseboom et al (Roseboom et 
al., 2006) studied over 2000 victims of the Dutch famine who were in-utero during that time 
period. Effects of maternal undernutrition on offspring in early gestation resulted in more 
coronary heart disease, a more atherogenic lipid profile, disturbed blood coagulation, increased 
stress responsiveness and more obesity. Women exposed to famine in early gestation also had 
an  increased  risk  of  breast  cancer.  Exposure  to  famine  during  any  stage  of  gestation was 







associated with glucose intolerance. Low birth weight for gestational age has been associated 
with higher incidence of coronary heart disease (Barker, 1995, 2007) and Barker revealed that 
this was largely due to poor nutrition during pregnancy resulting in epigenetic changes in embryo 
development. As there is strong evidence to support negative effects of suboptimal nutrition on 
fetal development in-vivo, culturing embryos for the first 5 -6 days post conception in-vitro in 
suboptimal culture media has to have  similar effects (Khosla et al., 2001; Kleijkers et al., 2016). 
 
 
Culture media in use today has been modified over the years but still is based loosely on mouse 
embryo culture media (Chronopoulou and Harper, 2015). As we are unable to test batches of 
culture media on human embryos, the culture media manufacturers have to rely on the readily 
available supply of mouse embryos to pass or fail each batch of media as it comes off the 
production line (Quinn and Horstman, 1998). Mouse embryos and human embryos however are 
not equivalent in their needs and sensitivity (Ackerman et al., 1985; Ackerman et al., 1984). The 
assurance to the end user by testing media on a mouse model is only that the media has no 




Composition of culture media today is still basically a balanced salt solution including various 
concentrations of glucose, pyruvate, and lactate to permit embryo development past traditional 
developmental blocks (Gardner and Lane, 1996). The evolution of more advanced formulations 
has included the addition of amino acids, chelating agents (EDTA) and growth factors. Media 







manufacturers are reluctant to share exact compositions of their commercially made media for 
ĨĞĂƌŽĨůŽƐŝŶŐŵĂƌŬĞƚƐŚĂƌĞŝĨƚŚĞŝƌ “ƐĞĐƌĞƚ ?ŝŶŐƌĞĚŝĞŶƚƐĂƌĞƌĞǀĞĂůĞĚ ? 
 
 
A review of the literature published in 2013 (Mantikou et al., 2013) of comparative studies of 
different culture media concluded that there is no evidence to show one media is better than 
another in human clinical IVF but there are some individual studies which do show differences 
from one media to another. A recent randomized controlled trial (RCT) by Keijkers et al (Kleijkers 
et al., 2016) showed an increase in the incidence of low birthweight offspring using G5 media (G- 
series, Vitrolife) compared to Human Tubal Fluid (HTF) (Irvine Scientific, Irvine, CA). 
 
 
The ESHRE working group on culture media recently carried out a review of the literature (Sunde 
et al., 2016) and concluded that based on background literature from animal models, human 
culture media may have the same potential to change the phenotype of offspring. They also 
recommended that there should be more transparency of media composition from media 





Maintaining constant and accurate temperature in-vitro is crucial to a successful culture system. 
In 1990, Sue Pickering and Peter Braude (Pickering et al., 1990) performed an experiment looking 
at the effect of oocyte cooling on the spindle apparatus. Cooling for 10 minutes resulted in 
ĚĂŵĂŐĞƚŽ ? ?A?ŽĨƚŚĞŽŽĐǇƚĞƐ ?ƐƉŝŶĚůĞƐĂŶĚĐŽŽůŝŶŐĨŽƌ ? ?ŵŝŶƵƚĞƐƌĞƐƵůƚĞĚ in all of the oocytes 







having damaged spindle apparatus. A study by Danadova and colleagues concurred with this 
observation and showed higher rates of chromosomal defects post cooling in mouse oocytes 
(Danadova et al., 2017). 
 
 
Incubators are typically maintained at 37oďƵƚ “ŶŽƌŵĂů ?ďŽĚǇƚĞŵƉĞƌĂƚƵƌĞŶĂƚƵƌĂůůǇĨůƵĐƚƵĂƚĞƐ
between 36.1oC to 37.2oC (NIH, 2017). With this in mind Hong et al (Hong et al., 2014) cultured 
805 sibling oocytes in two groups: one group at 37oC and one group at 36oC. The group cultured 
at 37oC resulted in a higher rate of blastocyst formation than the group at 36oC (48% vs 41%) but 






In order that intracellular pH of oocytes and embryos is maintained in-vitro, extracellular pH 
ideally should be maintained at a constant physiologically equivalent value so that stress to 
oocytes and embryos is minimized. However, the ideal pH of media used to culture human 
embryos is difficult to establish. Yedwab and colleagues (Yedwab et al., 1976) in 1976 performed 
experiments to test the intrauterine temperature, oxygen tension and pH of 66 women during 
their cycle. A pH on average of 7.2 and 7.1 was observed. As pH is not a stand-alone measurement 
and depends on other solutes in the media, differing media compositions may require different 
optimal pH values (Swain, 2012; Swain et al., 2016). Most culture media used for human IVF are 
buffered with bicarbonate and require equilibration in a 5-6% CO2 environment to reach a pH of 







7.2-7.3 but again these recommended upper and lower limits of pH in any given media are 
somewhat dependent on media composition. 
 
 
1.2.2.4 Oxygen tension 
 
Atmospheric oxygen is 21% but in-vivo oxygen saturation is much lower than this and is variable 
depending on which organ is under consideration. Ottosen et al (Ottosen et al., 2006) and 
Yedwab et al (Yedwab et al., 1976) found that human uterine oxygen tension was around 11%. 
Studies have been carried out comparing atmospheric and reduced oxygen tension in which to 
grow human embryos in-vitro (Kasterstein et al., 2013; Meintjes et al., 2009). In these studies, 
blastocyst formation and live birth rates were increased in low oxygen tension environments 
compared to room air. Many laboratories have adopted the practice of culturing in 5% oxygen in 
their incubators contributing to improved rates of blastocyst formation (Guo et al., 2014; 
Meintjes et al., 2009). Although the exact method of improvement in embryo growth is unknown, 
there seems to be only a benefit to lowering oxygen tension in the growing environment (Swain 
et al., 2016). 







1.3 Determining embryo viability 
 
Over the past 30 years many attempts have been and are still being made to define the 
implantation potential and viability of each embryo. As culture conditions have been optimized, 




As our goal is to minimize stress to the embryo in-vitro ? ƚŚĞ ŝĚĞĂů ǁĂǇ ƚŽ ƚĞƐƚ ĂŶ ĞŵďƌǇŽ ?Ɛ
implantation potential in-vitro would be to use a non-invasive rather than an invasive method. If 
a non-invasive method showed definitively the ploidy status of any given embryo then this would 
be our choosing tool of choice. Non-invasive testing methods are attractive because they do not 
detract from the embryo itself. In this section I present a summary of non-invasive methods that 
are currently used or have been used in the past, novel methods that have been proposed and 
how effective they are in relation to choosing that elusive baby making embryo. 







1.3.1 Embryo Morphology 
 
 
Figure 2: Embryo day 5 of development at the blastocyst stage. Discrete inner cell mass and multi- 
celled well expanded trophectoderm cell layer indicates a morphologically good quality embryo 
with good implantation potential (own image). 
 
 
This is the simplest tool used by embryologists to choose within a group of embryos. Historically 
the best available embryo is chosen from a cohort on day 2, 3 or 5 based on morphology alone. 
Leaving embryos in culture until day 5 enables better embryo choice for transfer as on average 
50% of all embryos stop growing after day 3 (own data). 
 
 
In figure 3, we have a picture of day 3 embryos from one patient grown in our laboratory. All 
the embryos look quite similar and some of these will continue to grow to form blastocysts and 
some will arrest at this early cleavage stage. We can only guess which will arrest and which will 
continue to develop by assessing morphology on day 3. If we were to replace one or two 
embryos on day 3 we would be much less likely to choose an embryo that is chromosomally 
normal than if we give the embryos chance to declare themselves by growing for another 2 -3 







days. At this point around half of the embryos will stop growing and the choice for transfer is 
narrowed down as illustrated in the next picture of the same cohort on day 5. 
 
 
(a) Day 3 cohort of embryos 









(b) Day 5 cohort of embryos 
 
Figure 3: Illustrating how embryo growth begins to be asynchronous after day 3(a). The best 
quality embryos are usually chosen for transfer to the uterus and the remainder that develop to 
the blastocyst stage (b )can be frozen if good quality. There are 2 clear leaders in this cohort above 
therefore the choice is relatively easy. 







If an embryo has successfully developed beyond day 3 at which stage the embryonic genome is 
activated (Niakan et al., 2012) and has managed to grow until day 5 or 6 it has at least a chance 
of implanting. If an embryo is chosen on day 3 we are still guessing which have continued to grow 
and which have already arrested. However, if an embryo grows to the blastocyst stage and has 
good morphological appearance it still does not tell us the whole picture about the 
developmental potential of an embryo. 
Blastocyst morphology and growth rate correlates to some extent with ploidy status but is not 
predictive definitively of aneuploidy. Some embryos with the best morphologic appearance are 
aneuploid while those with poorer appearance are found to be euploid (Alfarawati et al., 2011; 
Davies et al., 2012; Richter et al., 2001). Aneuploidy is discussed in section 1.4 
 
 
1.3.2 Pronuclear position and nucleoli pattern 
 
Many groups have studied pronuclear morphology and attempted to correlate this with 
blastocyst formation potential, implantation potential and ploidy status (Gianaroli et al., 2003; 
Kattera and Chen, 2004; Scott et al., 2000; Zollner et al., 2002). 
ZŝĐŚĂƌĚ^ĐŽƚƚ ?ƐŐƌŽƵƉ ?^ĐŽƚƚet al., 2000), used only nucleoli alignment as a secondary selection 
tool to morphology. Even numbers of nucleoli in each pro-nucleus distributed at the area that 
the pro-nuclei meet seemed to predict blastocyst formation with some accuracy and positively 
correlated with implantation. Zollner and colleagues (Zollner et al., 2002) looked at nucleoli 
alignment in conjunction with pro-nuclei placement to predict blastocyst formation which it did 
ŝŶ/s&ĞŵďƌǇŽƐďƵƚŶŽƚŝŶ/^/ĚĞƌŝǀĞĚĞŵďƌǇŽƐ ?ƌƌŽǇŽ ?ƐŐƌŽƵƉŽŶƚŚĞŽƚŚĞƌŚĂŶĚ ?ƌƌŽǇŽet al., 







2010) used only pronuclear morphology as a secondary selection tool and correlated patterns 





pronuclei in the ooplasm, the pattern of nucleoli in each pronucleus and the angle of the 
pronuclei from the polar bodies (figure 4). In this study FISH was used for ploidy determination 
and a association was only found between complex aneuploidies and the more chaotic 




Figure 4: pronuclear morphology and chromosomal status by permission of Gianoroli (Gianaroli 
et al., 2003). 







Interpreting nucleoli patterns is a time consuming practice and if an analysis is carried out in real 
time this may mean that zygotes remain outside the incubator for longer than they need to be 
resulting in stress to the developing embryos. Images could be captured to examine once the 
embryos have returned to the incubator but the 3 dimensional nature of pro-nuclei requires 
movement of the image or embryo to capture fully the pattern of nucleoli and the position of the 
pronuclei in the ooplasm. Time lapse microscopes are able to capture in real time the formation 
of pronuclei and would be able to allow captured data to be used to choose early cleavage 
embryos for transfer if required. 
 
 
If growing embryos to the blastocyst stage is not possible for whatever reason and if Pre- 
Implantation Genetic Diagnosis (PGS) is not possible in labs around the world, gross pronuclear 
morphology may be a relatively low cost, non-invasive adjunct to add to basic morphology to 
allow for better selection of early cleavage embryos for transfer. 









Embryos have a particular pattern of growth which can be monitored and correlated to some 
extent with embryo viability. The observation of morphokinetic events to use them as an 
indicator of embryonic competency began with monitoring early cleavage of day 2 embryos. 
Several groups have associated early embryo cleavage with increased implantation potential 
(Fenwick et al., 2002; Lundin et al., 2001). Embryos that underwent the first cleavage division 25- 
27 hours post insemination had a higher implantation rate than embryos cleaving later. ICSI 
derived embryos showed a stronger association with higher implantation potential probably due 
to more accurate timing of the sperm actually entering the oocyte. 
The timing of morphokinetic (MK) events has been taken to the next level by actually watching 
the whole developmental process from zygote to blastocyst by using time lapse photography. 
This has been achieved by installing small microscopes into existing incubators (Eeva, Auxogyn) 
and the development of a benchtop incubator that has the camera as part of the incubator 
(Embryoscope, Vitrolife, Sweden). These time lapse camera systems utilize dishes that have 
individual wells for identification purposes. 
 
 
Preliminary data suggests that observing the timing of MK events is unable to predict euploidy 
with any reliability but will predict good quality blastocyst formation (Kramer et al., 2014; Motato 
et al., 2015; Rienzi et al., 2015; Storr et al., 2015). Campbell and colleagues (Campbell et al., 2013) 
noted that the timing from the first signs of cavitation to complete expansion had the highest 
positive prediction of ploidy but not conclusively. Chavez et al (Chavez et al., 2012) analyzed MK 







events up to the 4 cell stage and demonstrated that only 30% of aneuploid embryos exhibit 
parameter values within normal timing windows. They also analyzed fragmentation formation 
and its reflection of aneuploidy and demonstrated that fragments sometimes hold chromosomal 
material which is then re-absorbed into the cells concluding that fragment removal could be 
detrimental to embryo development. 
 
 
Growth rates in embryos vary from lab to lab based on variations in culture conditions and 
stimulation regimen. Therefore implementation of time lapse incubation in any lab with any real 
effect in predicting embryo viability would have to involve each lab establishing its own 
acceptable time frames for each morphokinetic event. Establishing standardized times to events 
is difficult if not impossible due to clinic to clinic variations. 
 
 
1.3.4 Combining Morphokinetics with spent media analysis 
 
Many of the non-invasive techniques described earlier have some positive predictive potential 
for implantation so to combine some of those techniques has been proposed. ŽŵŝŶŐƵĞǌ ? group 
in 2015 (Dominguez et al., 2015) combined morphokinetic analysis with analysis of the proteome 
of the spent media surrounding the embryo. They found that their implantation rates if the 
second cell cycle division (the time from division to a 2 cell embryo to a 3 cell embryo) was within 
a certain time range and if Interleukin-6 were present in the spent media (figure 5). They also 
found a association with Stem Cell Factor presence in the media and with the absence of 
Interferon. 







1.3.5 Analyzing spent culture media 
 
Embryos are grown in droplets of culture media. These droplets can be analyzed for depletion 





Metabolomics is the analysis of metabolites produced or utilized in the surrounding media by the 
embryo as it develops. Establishing which metabolic markers can be used reliably as an indicator 
of embryo health in-vitro is a challenge that has been attempted by many groups over the last 20 
years. Conaghan et al (Conaghan et al., 1993) carried out the first clinical studies analyzing 
pyruvate uptake levels from culture media as a metabolic evaluation of embryo health. The 
studies only looked at a snapshot of time in culture from day 2 to 3, and found some association 
with pyruvate uptake and embryonic potential but not conclusively and concluded that 
morphology still remained the best indicator of implantation potential. Hardarson et al looked at 
Near Infrared (NIR) spectroscopy as a tool for identifying embryos with increased viability rates 
(Hardarson et al., 2012). The NIR spectral profile of spent media was analyzed during IVF cycles. 
Two groups were compared, the control group with embryos chosen for transfer using 
morphology alone and the test group utilizing the NIR profile to choose embryos for transfer. 
There was no difference in pregnancy outcome between the control group and the test group. 
 
 
Henry Leese (Leese et al., 2008), proposed ŚŝƐ  “ƋƵŝĞƚĞŵďƌǇŽŚǇƉŽƚŚĞƐŝƐ ?ǁŚŝĐŚĚĞƐĐƌŝďĞƐƚŚĞ
principle that an embryo that has a lower level of metabolic activity is less stressed in its 







environment. So an overall low production of waste products and uptake of nutrients is a sign of 
a healthy embryo. His work with glucose and pyruvate uptake and lactate production in spent 
media (Butcher et al., 1998; Conaghan et al., 1998; Leese, 2002) has shown some association 






Proteomics is the analysis of amino acid turnover by pre-implantation embryos from spent 
culture media. The turn-over of amino acids varies at different stages of development. 
Picton et al (Picton et al., 2010) showed that aneuploid embryos have a different pattern of 
uptake and excretion to that of euploid embryos but not consistently so therefore turnover rates 
are probably unable to predict implantation potential alone. Dominguez et al (Dominguez et al., 




Brison et al (Brison et al., 2004) used reverse phase HPLC to analyze the change in concentration 
of 18 amino acids in spent culture media over a 24 hour period. Embryos were cultured singly in 
4ul drops from day 1 to day 2 at which point 2 embryos were transferred to the ƉĂƚŝĞŶƚ ?Ɛ uterus. 
The spent media drops were frozen and sent for analysis and the results were retrospectively 
correlated with implantation and live birth rates. 







A previous study by Houghton et al (Houghton et al., 2002) had studied amino acid turnover as a 
prediction of blastocyst formation. In that study the amino acids whose turnover predicted 
blastocyst formation in-vitro were not the same as those that predicted pregnancy and live birth 
in the Brison 2004 study following transfer. Blastocyst formation from early cleavage human 
embryos developing in-vitro was predicted by Alanine (Ala), Arginine (Arg), Glycine (Gln), 
Methionine (Met) and Asparagine (Asn) turnover between days 2 and 3 (Houghton et al., 2002) 
whereas pregnancy was predicted by Asn, Gly and Leucine(Leu) between days 1 and 2 (Brison et 




Botros et al in 2008 (Botros et al., 2008) reviewed the literature from research carried out over 
the last 20 years and concluded that overall embryos with higher implantation potential altered 
their environment differently to those embryos that had a lower implantation potential. 
 
 
1.3.6 Cumulus gene expression 
 
ƐĐƵŵƵůƵƐĐŽŵƉůĞǆĞƐĂƌĞŝŶĐůŽƐĞĐŽŶƚĂĐƚǁŝƚŚƚŚĞŽŽĐǇƚĞĚƵƌŝŶŐŝƚƐ ?ĚĞǀĞůŽƉŵĞŶƚĂŶĚƉůĂǇĂ
huge role in the maturation of the oocyte, Fragouli et al (Fragouli et al., 2012) looked at the 
follicular environment as a possible indicator of embryo health. The hypothesis was that cumulus 
complexes regulate oocyte maturation in-vivo and the close communication between the oocyte 
and cumulus cells may show some specific gene expression that correlates with the ploidy status 
of an oocyte. The expression of 96 genes was analyzed and 2 specific genes showed a significant 







difference in their expression in the cumulus cells of euploid and aneuploid oocytes. One of these 
genes is involved in intracellular signaling and homeostasis, and the other regulates carbohydrate 
metabolism and apoptosis. 
 
 
Oocytes from older women have been shown to have a different cumulus cell gene expression 
profile compared to cumulus cells from younger women (McReynolds et al., 2012). We now know 
that cumulus cells and the oocyte communicate with each other and the genes expressed 
correspond with oocyte quality (Fragouli et al., 2014). Further research may show this to be a 
reasonable non-invasive method to quantify implantation potential in the oocyte. 
 
 
1.3.7 MicroRNA in follicular fluid 
 
A study by Machtinger et al (Machtinger et al., 2017), proposed that profiles of extracellular 
Micro RNAs (exmiRNAs) in follicular fluid may correlate with embryo viability. They analyzed the 
exmiRNA profiles of follicular fluid of oocytes from 40 patients and did find association with 
oocytes that failed to fertilize and those that fertilized normally. They also found four exmiRNAs 
that were preferentially expressed when a good quality day 3 embryo developed versus a poor 
quality day 3 embryo. This area of research has potential for future advancement but is at the 
very earliest stages of investigation. 







1.3.8 Mitochondrial DNA quantification 
 
Mitochondria are the primary energy manufacturing organelles for all cells. The number of 
mitochondria in a mature oocyte is by far the highest of any cell at around 2 x 106. This is at least 
twice the copy number found in somatic cells such as muscle or nerve, which also have a high 
energy requirement (St John et al., 2010). Embryonic mitochondria are inherited from the oocyte. 
Paternal derived mitochondria introduced via the sperm at fertilization are doomed for 
destruction by ubiquitin-ĚĞƉĞŶĚĞŶƚƉƌŽƚĞŽůǇƐŝƐĂƐĚĞƐĐƌŝďĞĚ ĨŝƌƐƚďǇ^ĐŚĂƚƚĞŶ ?ƐŐƌŽƵƉ ŝŶ  ? ? ? ?
(Sutovsky et al., 1999; Sutovsky et al., 2004). During oogenesis mitochondrial replication ensues 
resulting in the highest concentration of mitochondria per cell once the oocyte matures. Once 
fertilization has taken place, mitochondrial replication pauses resulting in fewer mitochondria 
per cell with each cell division. Once blastulation commences (around day 4-5 in humans), the 
cells forming the trophectoderm begin to replicate mtDNA and the concentration per cell 
increases. The inner cell mass remains at a constant density of mtDNA. The high concentration 
of mitochondria in the trophectoderm serves as an energy source for the Na+ pump 
transportation system bringing nutrients to the relatively quiescent inner cell mass (Hewitson 
and Leese, 1993; Houghton, 2006). 
 
 
It has been proposed that embryos that are aneuploid, derived from oocytes of advanced 
maternal age or are growing in a suboptimal environment generate a higher number of energy 
producing mitochondria per cell in response to those stresses. This corresponds with the idea of 
ƚŚĞ “ƋƵŝĞƚĞŵďƌǇŽŚǇƉŽƚŚĞƐŝƐ ?ƉŽƐƚƵůĂƚĞĚďǇ,ĞŶƌǇ>ĞĞƐĞ ?>ĞĞƐĞ ? ? ? ? ? ) ?ǁŚŝĐŚƐƚĂƚĞƐƚŚĂƚĂŶ 







embryo in a physiologically ideal state needs less energy to develop than an embryo in 
suboptimal conditions. With this in mind, the hypothesis that a high number of mitochondria per 




As mitochondria each have between 1-10 copies of their own DNA (mtDNA) this has been 
explored as a way to measure the number of mitochondria per cell in human embryos and 
correlate that with implantation potential in a clinical setting. Several genetics companies have 
begun to offer the test as an adjunct to whole chromosome analysis with names such as 
 “DŝƚŽƐĐŽƌĞ ? ?/ŐĞŶŽŵŝǆ )ĂŶĚ “DŝƚŽŐƌĂĚĞ ? ?ZĞƉƌŽŐĞŶĞƚŝĐƐ-Cooper Surgical). 
 
 
Trophectoderm biopsy involves removing between 3-10 cells from the blastocyst. To establish 
how many cells are present in the biopsy tube, the total amount of nuclear DNA is determined 
which can then be divided by the known amount of nuclear DNA in one euploid human cell to 
arrive at the number of cells in the biopsy. The total quantity of mtDNA in the sample tube is 
measured, then the total quantity of mtDNA can then be divided by the number of cells to arrive 
at the amount of mtDNA per cell. 
 
 
ĂŐĂŶ tĞůůƐ ? ŐƌŽƵƉ  ?&ƌĂŐŽƵůŝet al., 2015b) examined day 3 early cleavage embryos and 
blastocysts that had been biopsied from several IVF laboratories. The ploidy status for each 
embryo was established and the amplified DNA was then analyzed for the quantity of mtDNA per 







cell using qPCR or NGS. In this study, euploid embryos exhibiting a high level of mtDNA above a 
threshold never implanted whereas embryos with levels below this threshold implanted and gave 
rise to viable pregnancies in 59% of the cases. They also concluded that embryos from patients 
of advanced maternal age exhibited higher levels of mtDNA per cell compared to embryos from 
younger women. In another study by Diez-Juan et al (Diez-Juan et al., 2015) the association 
between increasing maternal age and corresponding increases in levels of mtDNA were not seen. 
 
 
The most recent publication by Victor and colleagues (Victor et al., 2016) is a large single center 
study analyzing data from a total of 1,396 embryos derived from 259 patients. They established 
ploidy status and mtDNA quantification by NGS and qPCR. In order to accurately establish mtDNA 
amounts in any one cell the group developed a calculation to correct for embryo ploidy and 
gender. Previous studies have used a standard male euploid genome as a known template to 
establish sample size (Diez-Juan et al., 2015; Fragouli et al., 2015b). This group observed that as 
nuclear genomes are not all equal in length (diploid female human genome is composed of 
6,072,607,692 base pairs, whereas the male counterpart is 5,976,710,698 base pairs long, a 
difference of 1.58%) then without correcting for embryo gender the calculation of mtDNA 
quantity per cell would be inflated by 1.58% in male embryos. The same can also be said for 
aneuploid embryos which would all have different sized genomes depending on the chromosome 
error or errors. With the correction factor applied this group found no difference between the 
amount  of  mtDNA  per  cell  in  euploid  or  aneuploid  embryos,  of  embryos  generated  from 







advanced or young maternal age and they also found no association between mtDNA levels in 
embryos that implanted and those that did not. 
 
 
The other issue with establishing the number of mitochondrial organelles by using mtDNA 
quantification is that each mitochondria has a variable mtDNA copy number of between 1-10 per 
organelle (Satoh and Kuroiwa, 1991). Therefore the copy number of mtDNA probably does not 
correlate well with the number of mitochondria per cell. 
 
 
1.3.9 Summary of factors contributing to the success or failure of an IVF cycle 
 
In order to achieve a successful conception, embryos have to be grown with the minimal amount 
of stress in-vitro, the embryo with the most potential has to be chosen by the embryologist for 
transfer and the uterus has to be receptive. While there may be other factors to consider when 
choosing an embryo for transfer, the main reason for implantation failure is aneuploidy (Harton 
et al., 2013) which is discussed in section 1.4. 









Aneuploidy is the main cause of implantation failure and non-viability in human embryos 
(Spandorfer et al., 2004; van den Berg et al., 2012). An aneuploid cell has extra or missing 
chromosomes. Aneuploidy of embryos occurs in all humans to a greater or lesser degree 
depending primarily on maternal age but can be affected by other factors. In this chapter I discuss 
the mechanisms of aneuploidy and how the detection of aneuploidy in human pre-implantation 
embryos has contributed to improvements in IVF outcomes (Dahdouh et al., 2015b; Forman et 
al., 2013b; Forman et al., 2012b; Schoolcraft et al., 2010; Scott et al., 2012; Tan et al., 2014). 
 
 
1.4.1 Mechanisms of chromosomal mal-segregation 
 
Chromosomal mal-segregation can occur during meiotic or mitotic division. Paired chromosomes 
that become dissociated from one another too early or too late in the cell cycle, or fail to separate 
during the correct sequence of meiotic or mitotic events, result in aneuploid cells with extra or 
missing chromosomes  (Angell, 1997; Cupisti et al., 2003). 
There are numerous mechanisms by which chromosomal mal-segregation occurs however the 
primary ones in this context are: 
x Non disjunction (at meiosis I or II, or mitosis (cleavage)) 
 
x Anaphase lag 
 
x Precocious separation of sister chromatids 









Either paired chromosomes fail to separate during meiotic anaphase 1 or sister chromatids fail 
to separate at meiosis 1 or meiosis 2 resulting in a whole chromosome moving to the same pole 
ĂƐ ŝƚƐ ? ŚŽŵŽůŽŐƵĞ ? EŽŶ ĚŝƐũƵŶĐƚŝŽŶ ƌĞƐƵůƚƐ ŝŶ ŵŝƐƐŝŶŐ Žƌ ĞǆƚƌĂ ĐŚƌŽmosomes in the resulting 
oocytes or sperm and therefore monosomy or trisomy in the resulting embryo (Angell, 1997; 
Cupisti et al., 2003) (figure 5). 
 
 
Figure 5: showing non-disjunction at both meiosis I and II, resulting in the formation of aneuploid 
and euploid gametes 







1.4.1.2 Anaphase lag 
 
If a chromatid is delayed in ŝƚƐ ? movement during anaphase and fails to attach to the spindle with 
ŝƚ ?Ɛ ? chromosome group, it may lag behind the other chromosomes and sometimes gets lost. The 
rogue chromosome or chromatid becomes incorporated into a micronucleus and eventually 
degrades (Coonen et al., 2004). Anaphase lag results in a monosomy only (figure 6). 
 
 
Figure 6: Anaphase lag: showing the loss of one chromosome as it fails to attach to the spindle 
and is then lost during cell division. 







1.4.1.3 Precocious separation of sister chromatids (PSSC) 
 
Precocious separation of chromatids is when the chromatids separate at the wrong point in the 
cell cycle (figure 7). 
 
 
Figure 7:  Example of PSSC resulting in a monosomic and trisomic cell 
 
 
Precocious separation of sister chromatids appears to account for 11 times more chromosomal 
defects in oocytes than non-disjunction (Gabriel et al., 2011). PSSC occurs primarily because 







cohesin proteins which are responsible for keeping sister chromatids together begin to degrade 
to some extent over time (Revenkova and Jessberger, 2005). Degrading cohesin proteins result 
in sister chromatids falling apart before their allotted time in the meiotic process leading to 
random segregation and age related aneuploidy (Yun et al., 2014). There may also be an increase 
in defects of other parts of meiosis occurring with advanced maternal age including the formation 





1.4.2 Oocyte aneuploidy 
 
Oocytes are formed during the fetal phase of development beginning around week 10. The 
process of primary oocyte formation resulting in several million primordial follicles is complete 
by around the 5th month of pregnancy (Wallace and Kelsey, 2010). There is then a prolonged 
resting phase in oogenesis which ends shortly before ovulation. Oocytes in the form of primordial 
follicles can remain in the ovary for up to 50 years. No other cell in the human body remains 
viable for so long. The average maximum population at 18-22 weeks post conception of 
primordial follicles is around 300,000, dropping to 180,000 at 13 years old, 65,000 at aged 25, 
16,000 at age 35 and at menopause (average age 49) there may only remain around 1000 
primordial follicles in the ovaries. 
1.4.2.1 Advanced maternal age and its effect on oocyte aneuploidy 
 
The maternal effect on oocyte aneuploidy is well documented. As maternal age increases so does 
the aneuploidy rate in preimplantation embryos  (Franasiak  et  al., 2014b;  Harton  et al., 2013; 







Hassold et al., 1980; Munne et al., 2007a). As described in the section above, the cell that is a 
precursor to a mature oocyte is formed in-utero and has remained dormant from 11 to 50 years 
prior to each primordial follicle being recruited to produce a mature oocyte. Therefore, a likely 
explanation of the increase in aneuploidy with maternal age is due to the degradation of bonds 




















Figure 8: Graph showing the effect of advancing maternal age on the percent of embryonic 
aneuploidy (own data) 
 
 
1.4.2.2 Environmental effects on oocyte aneuploidy 
 
Aneuploidy can be initiated by environmental influences on the developing oocyte. Patricia 
,ƵŶƚ ?Ɛ group (Hunt et al., 2003), discovered an increase in meiotic aneuploidy in murine oocytes 
after inadvertent exposure to 2,2-(4,4-dihydroxy-diphenol)propane or Bisphenol A (BPA)  which 
Percent of blastocyst embryos diagnosed as euploid according to maternal age. 






























is an estrogen mimicking compound used in the manufacture of poly-carbonate plastic products 
and resins, such as those used to line cans containing food and beverages and also used in dental 
sealants. This compound disrupts meiosis by promoting non-disjunction resulting in a dramatic 
ŝŶĐƌĞĂƐĞŝŶĂŶĞƵƉůŽŝĚǇ ?,ƵŶƚƐ ?ŐƌŽƵƉƉŽƐƚƵůĂƚĞĚƚŚĂƚƚŚĞƐĂŵĞŝŵƉĂĐƚĐŽƵůĚďĞƐĞĞŶŝŶŚƵŵĂŶ
reproduction and this work contributed to the current awareness of the damage that BPA has 
the potential to do with extended exposure. Many plastics are now manufactured without BPA 
because of this work. 
 
 
A study in 2012 (Ehrlich et al., 2012), investigated serum BPA levels in patients undergoing IVF 
and found that higher levels of serum BPA correlated directly with reduced numbers of 
developing oocytes and suboptimal embryonic development. Other estrogenic imitators or 
carcinogenic compounds in the environment have the potential to disrupt meiotic or mitotic 
division in similar ways to BPA (Mandrioli et al., 2016). 
 
 
1.4.3 Sperm aneuploidy 
 
Sperm are produced in the coiled seminiferous tubules of the testis. They are constantly 
generated from precursor cells (germ/stem cells) which line the tubules. Approximately 120 
million sperm are produced per day (equivalent to making about 1200 sperm per heartbeat). This 
process of spermatogenesis has been shown by Turek et al to take approximately 64 days in 
humans.   http://theturekclinic.com/services/male-fertility-infertility-doctor-treatments-issues- 







zero-sperm-count-male-doctors/spermatogenesis-production/.  A  review  by  Amman  in 2008, 
 




1.4.3.1 Advanced paternal age and its effect on sperm aneuploidy 
 
Because sperm cells are created constantly, increasing paternal age does not have the same 
dramatic effect on sperm ploidy status as advanced maternal age has on the chromosome 
complement of oocytes, however a study by Griffin et al in 1995 (Griffin et al., 1995) did show a 
direct association with increased sperm disomy for the sex chromosomes and increasing paternal 
age. Precocious separation of chromatids is not common in sperm due to the constant renewal 
of sperm cells, however it has been observed but not as frequently as within aging oocytes (Uroz 
et al., 2008). 
 
 
A 2011 review of the literature on the paternal age effect on sperm aneuploidy by Fonseka and 
Griffin (Fonseka and Griffin, 2011) had conflicting conclusions from many studies reviewed. They 
concluded that there is some evidence to support the existence of a paternal age effect on sperm 
disomies of chromosome 1, 9, 18, 21, X and Y, although other chromosomes (3, 6 W8, 10 W14, 17) 
do not seem to have age-related patterns. A more recent review of the literature by Sagi-Dain in 
2015, concluded that advanced paternal age is not associated with a reduction in pregnancy 
rates. The review considered only studies using donor oocytes to limit the well documented 
maternal age effect (Sagi-Dain et al., 2015). 
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Data generated from blastocyst biopsy cases in our own lab concur with the conclusions of the 
Sagi-Dain data and figure 9 shows the difference quite dramatically when analyzing overall 
euploidy rates of embryos using only young donor oocyte cases to illustrate the effect of paternal 



















Figure 9: ORM own data showing the difference in paternal age effect on embryonic aneuploidy 
compared to maternal age effect 
 
 
1.4.3.2 Sperm quality and sperm aneuploidy 
 
The incidence of aneuploidy in sperm of male factor infertility patients however has been well 
documented (Bernardini et al., 2005; Griffin and Finch, 2005; Ioannou and Griffin, 2011; Tempest 
and Griffin, 2004). Patients with poor semen parameters are more likely to have a higher ratio of 
aneuploid to euploid sperm in their ejaculates than patients with normal semen parameters. The 





















anaphase lag or precocious separation of chromatids leading to missing or extra chromosomes 
in the gamete cell. 
 
 
1.4.3.3 Environmental effects on sperm aneuploidy 
 
Exposure to known estrogenic imitators or carcinogens such as Bisphenol-A (BPA) has been 
shown to have a negative effect on ploidy status of sperm. As BPA is used in the manufacture of 
thermal paper used in receipts, cashiers were targeted as a group to study to see if dermal 
transfer during receipt handling increased levels of urinary BPA (Lv et al., 2017). Male cashiers 
were studied and were found to have 3 times the pre exposure levels of urinary BPA after 
handling receipts compared to urinalysis prior to exposure. As BPA has been previously shown to 
be a meiotic disruptor (Hunt et al., 2003) resulting in non-disjunction errors in gametes it has 
been assumed that sperm aneuploidy rates could be affected by BPA exposure. Other 
compounds such as pyrethroids (Radwan et al., 2015) used in agriculture are associated with 
increased sperm aneuploidy and phthalates, used as plasticizers in many products in have been 
shown to affect sperm quality (Pant et al., 2011). 







1.4.4 Embryonic (post zygotic) aneuploidy 
 
Most embryonic aneuploidy originates from the combination of genetic material from aneuploid 
gametes, aneuploidy oocytes, sperm or both. However, an embryo can originate from a euploid 
sperm and euploid oocyte creating a euploid zygote and then become aneuploid during 
subsequent mitotic division. Non disjunction or anaphase lag (section 1.4.1) can occur post fusion 
of gametes in individual cells during mitosis, creating embryos that have multiple different cell 
lines. These different cell lines can be a combination of euploid/aneuploid or 
aneuploid/aneuploid mosaics. With euploid/aneuploid mosaics there is potential for the 
aneuploid or euploid cells to dominate embryonic development and for the developing fetus to 
have one or both cell lines. The earlier the error occurs post fertilization, the higher the 
percentage of the embryo that will be abnormal and in fact, if only the aneuploid cells proliferate, 
in theory the embryo could present as 100% aneuploid. 
 
 
1.4.4.1 Advanced maternal age and its effect on embryonic aneuploidy 
 
As maternal age increases so does the rate of occurrence of full aneuploidy (Harton et al., 2013; 
Munne et al., 2007a) caused by errors during meiotic divisions during oocyte formation (section 
1.4). Embryonic (post zygotic) aneuploidy which gives rise to mosaicism does not increase with 
advancing maternal age as illustrated in figure 10, using data from 6690 blastocysts from 955 
PGS cycles  W January 2016-March 2017 (own unpublished data). 






























Figure 10: showing how full (meiotic) aneuploidy rates increase with advancing maternal age but 
mitotic mosaic aneuploidy does not. 
 
 
1.4.4.2 Environmental effects on embryonic aneuploidy 
 
It has been postulated that post zygotic aneuploidy could be caused by suboptimal 
environmental conditions during in-vitro culture. Potential environmental in-vitro stresses 
include high or low pH of media, temperature or osmolarity, high oxygen concentration, toxins 
in culture media or oil, presence of volatile organic compounds in the lab air, embryo toxic plastic 
ware, toxins in gas supply to incubators. 
 
 
Terry ,ĂƐƐŽůĚ ?Ɛ group in 2002 (Bean et al., 2002) noted that mosaicism due to non-disjunction or 
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and room air. When O2 levels were decreased to 5% the mosaic rate decreased to in-vivo levels. 
This study illustrated that changes to culture parameters can affect ploidy status of embryonic 
cells and could be extrapolated to the human model. 
 
 
Significantly variable rates of embryonic mosaicism were found in 4 different IVF centers in a 
study by Munne et al (Munne et al., 1997). They examined early cleavage frozen-thawed embryos 
donated for research. In one clinic the mosaic rate increased in embryos created after 1991 
which could have correlated with a change in culture methods in the lab or an introduction of a 
new micromanipulation technique creating non- disjunction or anaphase lag during mitosis. Any 
stress placed on the embryo during its in-vitro development has the potential to disrupt mitosis 
and create aneuploidy in those cells (Swain, 2010; Swain et al., 2016). Hickman et al, performed 
a sibling oocyte study where half of each patients embryos were grown in one culture media 
(group 1) and the other sibling embryos were grown in a different culture media (group 2) 
(Hickman C. , 2016). Embryos grown in group 2 reached the blastocyst stage quicker than in group 
1 and the rate of euploid embryos was double in group 2 (29%) compared to group 1(16%) 
(p=0.02). This study illustrates beautifully that variations in culture conditions has the potential 
to affect embryonic (post zygotic) aneuploidy. 







1.5 How do we detect aneuploidy in pre-Implantation embryos? 
 
In order to screen for aneuploidy embryonic DNA has to be obtained and analyzed. Embryo 
biopsy involves removing whole cells from an embryo to analyze nuclear DNA however a novel 
hypothesis is currently under investigation to establish if cell free DNA expressed by embryos in- 
vitro can be detected and reliably represent the embryo proper. This cell free DNA can be found 
in the blastocoel cavity and spent culture media. 
 
 
1.5.1 Non-Invasive PGS detecting cell free DNA in spent culture medium 
 
A proof of concept study by Shamonki et al (Shamonki et al., 2016) was published in 2016 to 
investigate if cell free DNA could be detected in spent culture medium and if so did this correlate 
with the ploidy status of the corresponding embryo. They cultured 57 embryos hatched on day 
3, in 15ul drops from day 3 -5/6 and then removed the embryos, biopsied and froze the embryos 
and attempted to amplify any cell free DNA that had been released by the embryo into the media. 
55/57 of the samples had detectable DNA levels from 2-642ng/ul. 6 of the samples that had the 
highest level of DNA (from 52-642 ng/ul) were tested with aCGH. All 6 gave a result but only the 
embryo with the highest amount of DNA at 642ng/ul gave a reliable result. This corresponded 
with the trophectoderm biopsy of 45XY -13. Another of the samples did correlate with the 
trophectoderm biopsy but the result could not be classed as reliable. The amplification method 
used in this study was Repli-G single cell kit (Qaigen) which is an MDA platform, and the products 
were analyzed with aCGH. 







Xu et al (Xu et al., 2016) performed a study analyzing spent media for cell free DNA and 
completed the first clinical transfers of embryos to patients based on the spent media DNA 
analysis alone. They termed the method Non-Invasive Chromosome Screening or NICS. They 
carried out an initial study establishing concordance between biopsy results and NICS. To validate 
their results, 43 embryos were cultured from day 3 to day 5 and the spent media drops and biopsy 
samples were analyzed concurrently. 21 embryos diagnosed as euploid from the biopsy had a 
concurrent result from the NICS.16 embryos diagnosed as aneuploid from the biopsy had an 
aneuploid result from the NICS (although only 6/16 had the exact same losses or gains). There 
were 2 false negative results where the NICS was euploid and the biopsy was aneuploid and 4 
false positives where the NICS was aneuploid and the biopsy was euploid. 86% of the embryos 
therefore had a concurrent result between the biopsy and the NICS and 14% of embryos had a 
non-concurrent result overall. Their clinical application involved 7 patients and 9 embryo 
transfers replacing embryos solely diagnosed as euploid by NICS. The 9 transfers resulted in 6 live 
born allegedly chromosomally normal babies (authors stated that a karyotype had been 
performed). The DNA amplification method used in this study was the MALBAC (Multiple 
Annealing and Looping Based Amplification Cycles (Zong et al., 2012)) WGA method and the 





A recent study by Feichtinger et al (Feichtinger et al., 2017) biopsied both polar bodies post 
fertilization of 22 embryos reaching the blastocyst stage. They analyzed the pooled PB DNA with 







aCGH and grew the resulting embryos in single 25ul drops, to day 5-6 in a single step medium. 
They sampled 5ul of spent media at the blastocyst stage. Eighteen of 22 samples amplified and 
achieved concurrent aneuploidy/euploid results in 13 of 18 samples (72%). Cell free DNA is 
fragmented in segments of around 200bp in size (Fan et al., 2010). Traditional amplification 
methods may not be as accurate in amplifying these smaller fragments and may be the cause of 
incongruous results between nuclear DNA and cell free DNA. An alternative modified MDA based 
amplification method is currently being investigated and preliminary results from our own 
laboratory are described in section 2.1.2 of this thesis. 
 
 
1.5.2 Blastocoel fluid biopsy ;͞ůĂƐƚŽĐĞŶƚĞƐŝƐ͟Ϳ 
 
As an embryo progresses beyond the multicellular stage and 2 separate cell lines begin to form 
(inner cell mass and trophectoderm) the embryo begins to blastulate. The proliferation of the 
trophectoderm cell layer is directly correlated with an increase in the production of intracellular 
ATP which powers sodium ion pumps in the trophectoderm layer (Houghton et al., 2003). An 
increase of Na ion concentration on the inside of the trophectoderm layer instigates the intake 
of water by osmosis across the membranes leading to an expansion of the blastocoel cavity. 
 
 
Artificial blastocoel collapse before cryopreservation has been shown to improve survival of 
blastocysts post thaw by reducing the formation of ice crystals during freezing/vitrifying (Darwish 
and Magdi, 2016; Van Landuyt et al., 2015). Because of this evidence, many IVF labs have adopted 
this process into routine practice either by the use of an ICSI pipette aspirating fluid from the 







cavity or by a laser pulse applied to the trophectoderm layer. As blastocoel fluid is being routinely 
removed, it was proposed that this fluid could be collected and analyzed for the presence of cell- 
free DNA in the hope that this could be used to determine ploidy status of the blastocyst. 
 
 
Several groups have attempted to aspirate blastocoel fluid to assess the DNA complement and 
potentially correlate that with the karyotype of the embryo (Gianaroli et al., 2014; Magli et al., 
2016; Tobler et al., 2015). Tobler et al (Tobler et al., 2015) analyzed the blastocoel fluid from 96 
donated embryos to compare cell-free DNA in the fluid with the ploidy status of the ICM or 
trophectoderm. They were only able to read the DNA complement in 68% of the embryos and 
with the ones that resulted in a read they found a high level of discordance between the fluid 
composition and nuclear DNA. Sureplex amplification was used with aCGH for all of these studies, 
the combination of which has been postulated to be suboptimal for cell free DNA analysis due to 
the small sized fragments of DNA (see cell-free DNA section 1.5.1). Discordant results between 
the fluid and trophectoderm biopsy may be due to errors in amplification of the smaller cell free 
DNA segments than nuclear DNA from a biopsy. The issue of suboptimal amplification of these 
small sections may be overcome by alternative amplification methods currently under 
investigation (Wells et al 2017 unpublished). The blastocoel cavity often contains small fragments 
or whole cells that are not incorporated into the embryo itself (figure 11). 









Figure 11: Blastocyst with free cells in the blastocoel cavity, unincorporated in the blastocyst 
proper (own observation). 
 
 
If these are aspirated with the fluid and analyzed this may be a reason for discordant results 
between the fluid and biopsy. For this reason and the technically challenging nature of the 
process in a clinical setting, blastocentesis may not be a viable alternative to trophectoderm 
biopsy to determine ploidy status of an embryo. 







1.5.3 Embryo Biopsy 
 
Biopsy is possible at different pre-implantation developmental stages as a means of determining 
the aneuploidy status of the embryo but also for preimplantation genetic diagnosis (PGD) of 
single gene disorders. 
x Polar body biopsy 
 
x Blastomere biopsy 
 
x Trophectoderm biopsy 
 




1.5.3.1 Polar body biopsy 
 
Polar bodies (PB) are created during meiosis and are extruded from the oocyte is it matures (PB1) 
and is subsequently fertilized (PB2). Removal of these packets of DNA and analyzing the DNA 
complement is a relatively non-invasive technique for establishing ploidy status as the oocyte or 
zygote itself remains intact. In a proof of principle study by Geraedts (Geraedts et al., 2011) both 
polar bodies were biopsied from 226 zygotes and their chromosome complements were analyzed 
using aCGH. Predictive ploidy status was established in 86% of these zygotes. 
 
 
Polar bodies are not always discrete in structure and it is not uncommon to find a fragmented 
polar body which may or may not contain all of the chromosomal material that has been extruded 
from the oocyte. Biopsy of the first polar body alone has been shown to be poorly predictive  of 







ploidy status of the resulting biopsy but predictive of the oocytes potential to reach the blastocyst 
stage (Grifo et al., 2015a). 
 
 
Polar body biopsy is useful in countries which allow limited numbers of embryos to be grown 
past the zygote stage such as Germany. The advantage of PB biopsy is that it is relatively non- 
invasive compared to day 3 or blastocyst biopsy. 
 
 
1.5.3.2 Day 3 (blastomere) biopsy 
 
One or 2 cells are removed on day 3 of development and analyzed for chromosome complement. 
In theory, the whole embryo should be represented by one cell, unless the embryo is mosaic. 
Hanson et al (Hanson et al., 2009) reanalyzed 199 embryos diagnosed using FISH as 
chromosomally abnormal or with no result post day 3 biopsy 34% of the embryos diagnosed as 
aneuploid had at least one cell that had the same original diagnosis. 96% of the embryos 




Figure 12:  biopsy of single blastomere from day 3 embryo 







All cells on day 3 are not necessarily incorporated into the blastocyst itself. Frequently rogue cells 
are seen on day 5 and 6 outside of the blastocyst itself inside the zona pellucida. These cells are 














Figure 13: examples of cells not incorporated into the blastocyst proper which could be sampled 
on day 3 and may not represent the embryo. a) Completely hatched embryo showing cells not 
incorporated into the blastocyst left behind in the discarded zona post hatching 
b) Thawed embryo still in zona with large cell outside of the blastocyst. 
 
 
To remove cells on day 3 may mean testing cells that would never have become part of the final 
embryo. To use information from these cells to assess the chromosomal complement of the 
embryo can give rise to a false diagnosis. Barbash-Hazan et al (Barbash-Hazan et al., 2009) 
showed 18% of embryos diagnosed on day 3 as aneuploid were mosaic and by day 5 10% of the 
original cohort had self Wcorrected. Northrop et al (Northrop et al., 2010) re-analyzed 50 
blastocysts previously diagnosed as aneuploid on day 3 using FISH, and found that that 58% of 
these embryos were diagnosed as euploid. They concluded that cleavage-stage FISH technology 
is poorly predictive of aneuploidy in morphologically normal blastocysts. 







Disadvantages of day 3 biopsy are that removal of one or two cells on day 3 has been shown to 
be detrimental to embryo growth and development. The rate of growth is slowed post biopsy 
(Kirkegaard et al., 2012; Tarin et al., 1992) the dynamic sequence of events is disrupted by 
blastomere biopsy therefore reducing implantation and pregnancy rates (Bar-El et al., 2016; Scott 
et al., 2013c). 
 
 
The only perceived advantage of day 3 biopsy are that embryos can be grown out to day 5 post 
biopsy and transferred fresh to the uterus. Fresh transfer in a stimulated uterus however may 
not be an optimal environment for embryos to thrive (Bhattacharya, 2016; Maheshwari and 
Bhattacharya, 2013; Roque et al., 2015; Shapiro et al., 2011). 







1.5.3.3 Trophectoderm biopsy 
 
Around half of the oocytes that fertilize typically arrest after day 3. An embryo that develops to 
the blastocyst stage has begun to differentiate into 2 distinct types of cells; trophectoderm 
(placenta and membrane precursor cells) and inner cell mass (ICM) (fetal precursor cells). 
 
 
Figure 14: Blastocyst hatched on day 3 to allow trophectoderm cells to extrude, cells removed 
utilizing a laser on day 5. 
 
The trophectoderm layer can be biopsied and tested for ploidy status avoiding the inner cell 
mass. The trophectoderm has to be sufficiently expanded to allow the removal of several cells 
(approximately 3-10) for analysis. Cells for testing are removed using laser pulses to separate the 
cell junctions (figure 17). The excised piece of tissue is placed in a microfuge tube until DNA 
amplification and the embryo is placed back in culture to recover before transfer or freezing. 







Embryos seem to recover very well from the biopsy procedure itself, self-sealing the 
trophectoderm layer and re-expanding the cavity within an hour (personal experience). Long 
term effects of trophectoderm biopsy on offspring have not been studied. Embryos that have 
been biopsied implant at high rates when transferred to the uterus. Ongoing pregnancy rates are 
also high and therefore the short term disruption of the trophectoderm layer during the biopsy 
seems to have no detrimental effect on pregnancy rates. 
 
 
A study in 2012 (Olcha et al.), showed lower initial BhCG levels from singleton pregnancies 
resulting from embryos that had been biopsied at the blastocyst stage compared to singleton 
pregnancies resulting from un-biopsied embryos. The study demonstrated that while the initial 
levels were low they eventually caught up with the non-biopsied pregnancies and birth weights 
and gestational age at birth were the same for the 2 groups. This is not a surprising finding as we 
are removing a part of the trophectoderm for testing. 
 
 
ŝƐƌƵƉƚŝŶŐƚŚĞĐĞůůůĂǇĞƌŝŶƚŚĞŽƌǇĐŽƵůĚŚĂǀĞĂŶĞŐĂƚŝǀĞĞĨĨĞĐƚŽŶƚŚĞĞŵďƌǇŽ ?ƐƉŽlarity during 
implantation. Placentation may be affected resulting in a higher rate of abnormal placenta 
placement or cord insertion which is already observed at a higher rate in IVF pregnancies 
compared to naturally conceived pregnancies (Englert et al., 1987; Healy et al., 2010). This 
supposition has yet to be studied, however this was outside the scope of this thesis. 







Trophectoderm biopsy has become a widely used technique in clinical IVF laboratories for the 
detection of aneuploidy, single gene defects and chromosomal imbalances (Capalbo et al., 2016a; 
Chen et al., 2011; Kokkali et al., 2005). 







1.6 The evolution of PGS 
 
The original purpose of PGD was to identify embryos affected with a particular single gene defect 
from families with a known heritable disease. An unaffected embryo would be selected and 
transferred to the uterus resulting in a child without the particular disease. 
 
 
Research began in the UK in the 1980s into methods to successfully diagnose single gene defects 
in pre-implantation embryos (Handyside et al., 1989; Penketh et al., 1989; Winston et al., 1989). 
Couples who carry or are affected by diseases caused by specific genetic mutations have 
previously had the option of choosing to terminate an affected fetus or giving birth to an affected 
child after positive identification of the defect at amniocentesis or CVS months into the 
pregnancy. Researchers used donated spare embryos left over from IVF cycles to establish the 
techniques of removing one-two cells from day 3 embryos, amplifying the DNA and using PCR to 
identify the mutation. 
 
 
The first applications were to avoid X-linked disease by sexing embryos and only transfer female 
embryos to the uterus. Sexing of human embryos was successfully carried out in 1989 
identifying the Y chromosome via Florescent In-situ Hybridization (FISH) (Griffin et al., 1991; 
Griffin et al., 1992; Handyside et al., 1989; Penketh et al., 1989). The first clinical PGD cycles 
were performed to sex select embryos in 7 couples with X-linked mutations. One couple carried 
a mutation for adrenoleukodystrophy, one couple X-linked mental retardation and the other 5 
couples were all at risk of transmitting other X-linked diseases to male offspring. Seven cycles of 







IVF/PGD resulted in 5 live birth events; 4 sets of female twins and one singleton female 
(Handyside et al., 1990; Hardy and Handyside, 1992). 
The ESHRE PGD consortium began collecting valuable follow up data on PGD and PGS cycles in 
1997. The first data collection rounds I-III, collated data from 787 cycles which were all day 3 
biopsies. PGS was mainly limited to patients of advanced maternal age at this time. During the 
first 10 years of data collection summarized in a paper by Harper and Harton (Harper et al., 
2012) data had been collected from 89,373 biopsied embryos and 21,543 transferred embryos. 
Both day 3 and day 5 biopsies were included in the data sets over this time period but the 
majority of cycles considered were day 3 biopsy and FISH or aCGH. In 2017 many laboratories at 
least in the USA, are using blastocyst biopsy and NGS for ploidy determination, therefore the 
conclusions of the data collections by the ESHRE consortium are not applicable to the latest 
methodology in use today. 
 
 
1.6.1 Specific single gene mutation detection 
 
Identification of a specific single gene defect in embryos created from parents with known family 
histories of a particular inherited genetic mutation was successfully carried out in 1992 
(Handyside et al., 1992). Day 3 embryos were biopsied and the single gene mutation, p.Phe508del 
(delta F508), responsible for cystic fibrosis, was identified in time for a transfer of a non-affected 
embryo to the ƉĂƚŝĞŶƚ ?Ɛ uterus on day 5 of development. Three couples where both parties were 
carriers for the mutation underwent IVF to create multiple embryos for testing. Embryos from 
each couple were biopsied on day 3 with 1-2 cells being removed from a slit in the zona pellucida. 







The cells were lysed and the DNA amplified and the mutation was identified using PCR. 
Unaffected or carrier embryos were transferred to the uterus of 2 of the patients resulting in a 
live birth of one single unaffected child. 
 
 
Single gene mutation identification has been revolutionized in the last few years by the 
development of a SNP array based chip technology called Karyomapping (Handyside et al., 2010). 
This technology does not require extensive test preparation to establish linkage for each 
mutation but is an off the shelf chip that comes with over 30,000 SNPs specifically chosen as they 
are near known mutation sites. Parental DNA is required to establish linkage and the location of 
the mutation has to be known. 
 
 
1.6.2 Aneuploidy detection 
 
Aneuploidy detection was borne out of sex selecting embryos for preventing sex linked disease 
and the number of chromosomes identified has increased with the use of advancing genomic 
technology. 
 
1.6.2.1 Fluorescence In-situ Hybridization (FISH) 
 
Aneuploidy detection in preimplantation embryos was initially limited to a restricted number of 
chromosomes utilizing FISH. FISH was first applied to preimplantation embryos to detect the sex 
chromosomes (Griffin et al., 1991). Overtime, several improvements increased the efficiency of 
the test, such  as scoring criteria  (Munne  et  al., 1998b)  and fixation  techniques  (Velilla et al., 







2002); however, the most beneficial improvement and was the increase in number of  
chromosomes screened. This was achieved in 1993 (Schrurs et al., 1993) by autosomal 
chromosome specific detection in embryos using one probe to detect chromosome 18 and then 
multiple probe FISH labeling chromosomes 18, X and Y by Munne et al (Munne et al., 1993). The 
number of chromosomes that were able to be identified from a single cell increased up to a limit 
of 12 chromosomes (Munne et al., 1998a). However, it still remained that FISH was limited to 
screening less than 24 chromosomes. The highly skilled nature of the technique to fix cells and 
the advancement of multi-celled sampling at the blastocyst stage, contributed to the decline in 
FISH usage in clinical IVF cases. 
 
 
1.6.2. 2 Quantitative-Polymerase Chain Reaction (qPCR) 
 
This technique involves a direct PCR amplification on the sample, rather than whole genome 
amplification of the DNA sample, therefore reducing the chance of allele dropout. The 
turnaround time of the assay is only 4 hours making it an attractive method for clinical use (Treff 
et al., 2012). The number of data signals is sufficient to count whole chromosomes; however, 
segmental aneuploidies from translocations require additional targeted assays, which itself 
involves time, and additional validations. The test is offered by several clinical groups resulting 
in improved clinical outcomes compared to using embryos with unknown ploidy status (Forman 
et al., 2013a; Forman et al., 2012a; Forman et al., 2012b; Scott et al., 2012). 







1.6.2.3 Whole Genome Amplification 
 
Sampling single (day 3 biopsy) or between 3-10 cells (blastocyst biopsy) from an embryo is 
challenging because of the small amount of original DNA available for analysis. Some platforms 
for pre-implantation genetic screening (PGS) (aCGH, CGH, NGS and SNP arrays) require further 
amplification of the DNA before analysis. There are two commonly used WGA methodologies for 
PGS: 
PCR based amplification methods: Primer Extension Pre-amplification (PEP) and Degenerate 
Oligonucleotide PCR (DOP-PCR). PEP is now most commonly used for PGS for aneuploidy 
(Sureplex, Illumina). These techniques have been found to exhibit incomplete genome coverage 
and amplification bias when a sequence is overrepresented in the amplified DNA due to 
preferential binding of the primers to specific regions but the technique works well for ploidy 
determination. 
Multiple Displacement amplification (MDA) (Repli-g,Qiagen). MDA provides a more uniform 
amplification across the whole genome and reduces amplification bias compared to PEP PCR. This 
method is more commonly used for single gene mutation detection rather than ploidy 
determination. 
Novel Amplification method (NAM). This method is a modified version of MDA developed for the 
capture and amplification of short sections of cell free DNA. It has been used for the spent media 
study in chapter 2.2.2.  The method is currently awaiting patent approval. 







1.6.2.4 Comparative Genomic Hybridization (CGH) 
 
Comparative genomic hybridization (CGH) was the first 24-chromosome screening method 
applied to pre-implantation embryos, polar bodies, and oocytes, carried out by Wells et al (Wells 
et al., 2002; Wells et al., 1999). WGA was carried out using DOP-PCR. CGH allows the comparison 
of two DNA samples from 2 different sources, known euploid control and test sample, to establish 
if they have gains or losses of whole or parts of chromosomes. The method involves isolating DNA 
from 2 sources, one a known euploid sample, the other the test sample. Each sample is labelled 
with fluorescent molecules of different colors (usually red and green). The DNA is denatured so 
it becomes single strands and then is hybridized to a euploid metaphase spread of chromosomes. 
A fluorescence microscope and computer software are used to compare the colored fluorescent 
signals emitting from the DNA. If red and green fluorescent molecules are used to label the 2 DNA 
samples then the presence of both chromosomes will display as yellow. If there is a loss or gain 
then the color will be red or green. The whole procedure requires around 3-5 days to complete 
testing making it a clinically challenging time consuming process. 
 
 
1.6.2.5 Micro-Array Comparative Genomic Hybridization (aCGH) 
 
Micro-Array CGH works on the same principle as CGH, but at a lower cost and a faster processing 
set up. WGA is again used to create more DNA product for testing. However, where CGH uses a 
metaphase spread of control DNA for hybridization, aCGH uses an array of spots of DNA attached 
to a slide each which constitutes around 150,000 bases of unique sequences from a specific 
chromosome.  The  amplified  sample  is  hybridized  to  these  small  pieces  of  DNA  and  the 







fluorescent color product indicates loses or gains in each chromosome. A validation study 
comparing aCGH with PCR and FISH (Gutierrez-Mateo et al., 2011) concluded that this method 
has the same accuracy as m-CGH but with a faster turnaround time. The first clinical utilization 
of aCGH for PGS was used in 2010 to establish ploidy status in combination with blastocyst biopsy. 
/ůůƵŵŝŶĂ ?Ɛ aCGH method uses two sets of DNA (sample/reference) that are uniquely labeled with 
fluorescent dyes (cy3 and cy5) and subsequently hybridized to bacterial artificial chromosomes 
(BACs-which are set mapped sequences). The ratio of the intensities of each fluorochrome is 
computed, and compared to the reference. This is not a direct copy number computation, and 
therefore mosaicism cannot be interpreted with aCGH without extra bioinformatics. 
 
 
Figure 15:  showing the principle of aCGH. by permission of (Harper and Harton, 2010). 







1.6.2.6 Single Nucleotide Polymorphism (SNP) arrays 
 
Individual variations contained within the genome, are termed Single Nucleotide Polymorphisms 
(SNPs). SNPs occur most commonly in non-coding regions of the genome. SNPs found in coding 
regions of the genome are responsible for traits such as height and eye color or inherited disease 
causing mutations. In order to find a trait SNP or disease SNP on the genome a comparison has 
to be made between a genome without the disease or trait causing SNP. 
The use of SNP arrays for whole chromosome copy number relies on parental DNA to create SNP 
markers for each chromosome in the specific region determined for identification of each 
chromosome during analysis. WGA is required for this technique (Xiong et al., 2014). Hetero- 
zygosity and quantification of the SNP alleles allows for the identification of losses or gains based 
on parental DNA. SNPs are also able to determine uniparental isodisomy (Handyside, 2011; Treff 
et al., 2011). As of 2010 over six million SNPs had been identified in the human genome (Javed 
and Mukesh, 2010). SNP array technology for whole chromosome copy number determination, 




1.6.2.7 Next Generation Sequencing (NGS) 
 
The newest method for PGS utilizes a low-pass whole-genome sequencing approach using the 
Ion Torrent Personal Genome Machine (PGM) (Life technologies)(Kung et al., 2015), the MiSeq, 
NexSeq and HiSeq (Illumina)(Fiorentino et al., 2014; Victor et al., 2016; Wang et al., 2014). The 
core concepts of next generation sequencing (NGS) is the ability to massively parallel sequence 







small DNA fragments, until an appropriate depth of coverage is achieved per sample. This 
method requires whole genome amplification. An aliquot from the amplified DNA sample is 
removed for library preparation where the amplified DNA strands are fragmented into small 
pieces (36-200 bps). Each sample is then ligated with a  ? ?and  ? ?unique adapter, with subsequent 
purification and size selection steps in preparation for sequencing. The principal advantages of 
NGS is the ability to detect copy number variation allowing for the detection of mosaicism 
(Munne and Wells, 2017), simultaneous testing of samples reducing the cost per sample, and the 
potential for future clinical applications, such as simultaneous detection of aneuploidy and 
monogenic diseases (Wells et al., 2014). 
 
 
1.6.2.8 Summary of available aneuploidy detection techniques 
 
The following table summarizes all the techniques used for counting chromosomes with the 
number of data signals and details of what can be detected with each method. Each technology 
has its advantages and disadvantages, and there is currently much debate in the IVF community 
about which technology is optimal for the determination of aneuploidy and if the high resolution 
methods used are producing too much information for the purpose of counting chromosomes. 
The biggest disadvantage that all of these technologies have in common is that the sample size 
of the biopsy is very small with between 3-10 cells available to analyze. 














Total # independant 
data signals 
11 96 2,700 32,000 100,000 700,000 
Full chromosome 
analysis? 
No Yes Yes Yes Yes Yes 
Deletions/Duplications No No Yes Yes Yes Yes 
Unbalanced 
translocations 
No No Yes Yes No Yes 
Parental DNA required No No No Yes No No 






1.7 Is aneuploidy always unequivocal? 
 
As the number of data signals or reads has increased per chromosome with the evolution of 
genomic technology, the ability to detect partial deletions and duplications, translocations and 
mosaic cell lines in the trophectoderm sample is now possible. The detection of mosaicism means 
that there are now 3 classifications of ploidy status; Euploid, aneuploid and mosaic. 
 
 
1.7.1 What is a mosaic embryo? 
 
If one or more cells in an embryo at any stage of growth has become aneuploid during mitosis 
due to PSSC or non-disjunction, there may develop 2 or more distinct cell lines resulting in a 
mosaic embryo (figure 17). 













1.7.2 Detecting mosaicism in blastocysts 
 
It is not possible to detect mosaicism for PGS in a day 3 embryo which is to be used for transfer 
as only 1 cell is removed for testing. If this cell is aneuploid or euploid then this will be the 
assumed diagnosis for the whole embryo. Mosaicism does exist in early cleavage embryos as has 
been shown by dis-aggregating donated embryos and analyzing all cells (Chow et al., 2014). The 
most important question to ask when we sample cells from the trophectoderm of a blastocyst is 
are we removing cells that accurately represent the embryo as a whole? A pre-implantation 
blastocyst embryo consists of approximately 120 cells, around 30 of which are discrete inner cell 
mass  cells  and  the remainder form the trophectoderm layer  (Hardy et  al., 1989). A blastocyst 







biopsy involves taking between 3-10 cells from the trophectoderm layer of the embryo which in 
theory should be a better representation of the whole embryo than a single cell from a day 3 
embryo. However, it is only possible to detect mosaicism in a blastocyst if the biopsy is removed 
at the junction of euploid and aneuploid cells within the trophectoderm. 
 
 
Figure 18:    = possible areas to be biopsied on the trophectoderm layer. This diagram shows that depending 
on where the biopsy is taken from, this embryo could be classified as euploid (A), mosaic (B) or aneuploid(C). 
Abnormal cells can be distributed through the trophectoderm either in nested groups where the 
abnormal cells form a discrete area of aneuploidy or a more generalized distribution where 
aneuploid cells are dispersed throughout the trophectoderm layer (Scott and Galliano). If the 
aneuploid cells are nested then the likelihood of sampling those cells is more haphazard. If the 
aneuploidy is more generalized then the sampling may be more representative of the whole 
embryo. 
As the only way to truly realize the extent of mosaicism in a blastocyst is to completely dissect 
the whole embryo (Taylor et al., 2016) which results in the embryos demise, the result from the 
small biopsy sample has to be accepted. 







1.7.3 Rate of mosaicism in blastocysts and in pregnancy 
 
Reported rates of mosaicism in pre-implantation blastocysts vary depending on which platform 
and assay is used. When Array CGH was used for PGS, mosaicism was observed but not reported 
and results were classed as aneuploid (over 50% mosaic aneuploidy) or euploid (less than 50% 
mosaic aneuploidy). If the NGS result profile is clean and artefacts have not been introduced 
during sequencing or amplification (see figure 28) then a true mosaic result is easy to categorize 
but if the results are noisy then a mosaic result is more difficult to call and could be attributed to 
DNA degradation or sample mishandling. Critics of mosaic results argue that there is not enough 
evidence that these results firstly are fact or artifact and if they are fact what effect these results 
have on pregnancy outcome and the phenotype and genotype of live born offspring. Mosaic 
thresholds above and below which an embryo will be classified as mosaic rather than aneuploid 
or euploid have been established within the PGS community. PGDIS mosaic reporting guidelines 
(PGDIS 2016), were based on the Illumina platforms (MiSeq, NexSeq) with VeriSeq assay and 
these thresholds had little clinical data to support their determination. Other NGS platforms such 
as the Ion Torrent PGM platform will also detect mosaicism but the threshold for classifying a 
mosaic result is higher than with the Illumina platform. In our own lab, the Ion Torrent platform 
resulted in isolated mosaic rates of around 10% of all blastocysts screened for aneuploidy 
compared to 20% with the MiSeq Illumina platform. Both of these rates are higher than the rate 
seen in ongoing pregnancies. Fetal-placental mosaicism in pregnancy exists and is found during 
confirmation studies of Chorionic Villus Sampling (CVS) used as a diagnostic screen for aneuploidy 
at 9-11 weeks of pregnancy. CVS involves 2 stages, direct preparation and long term culture. 1.3% 







of CVS cases are discordant from the direct to the long term preparation. The most common 
discordance being aneuploid placenta (direct preparation) and euploid fetus (confirmed in the 
long term preparation) (Malvestiti et al., 2015; McGowan and Blakemore, 1991). 
According to a study of 4000 CVS samples by Stetten et al, (Stetten et al., 2004) confined placental 
mosaicism where only part of the placenta is chromosomally different to the fetus, occurs in 0.7% 
of  pregnancies. There are many permutations of placental mosaicism that can exist: 
x Mosaicism only in the placenta which does not affect placental function, 
 
x Mosaicism only in the placenta which affects placental function 
 
x Mosaicism in the placenta and the fetus 
 
x Mosaicism only in the fetus but not in the placenta 
 
x Complete fetal/placental discordance with aneuploid fetus, euploid placenta or vice versa 
 
 
1.7.4 Where do the cells of the trophectoderm originate from? 
 
Trophectoderm in a blastocyst gives rise to chorionic ectoderm (Bianchi et al., 1993). These cells 
are not derived from any part of the inner cell mass. A trophectoderm biopsy to screen for 
aneuploidy only analyzes the precursor cells that give rise to the cells of the placenta. 
The Chorionic Villus consists of chorionic ectoderm (derived from trophectoderm) and chorionic 
mesoderm (derived from the inner cell mass). Once a CVS biopsy is received in the cytogenetics 
lab, the maternal cells are removed, and the fast dividing cells of the chorionic ectoderm are 
spread and examined. As these cells are in such a rapid growth phase, many of them will be in 
metaphase  and  therefore  their  chromosomes  can  immediately  easily  be  seen  (Mhairi  G. 







MacDonald). As these cells are not derived from the inner cell mass they do not necessarily 
represent the developing fetus. Subsequent long term culture of a CVS biopsy allows 
multiplication of the slower dividing mesenchymal core cells which are derived from the inner 
cell mass. Long term culture of the CVS biopsy therefore is a more reliable form of analysis of the 
fetus itself. As we are limited to sampling trophectoderm from blastocysts, there is the potential 
for similar misdiagnosis rates if mosaicism is present, as with a direct preparation with CVS. 
 
 
Figure 19:  origin of extra-embryonic mesoderm: used by permission of (Bianchi et al., 1993)) 
(1)= fertilized egg gives rise to (1b) trophoblast precursor (trophectoderm) and (2) totipotent stem 
cell. (1b) trophectoderm gives rise to trophoblast (chorionic ectoderm) = CVS direct prep 
(2) gives rise to(2b) second trophoblast cell line and (3) stem cell inner cell mass 
(3) gives rise to (3b) hypoblast (CVS culture) and (4) epiblast (amniocentesis) 







1.7.4.1 Risk of discordant cell lines in the ICM versus trophectoderm 
 
Capalbo (Capalbo et al., 2013) reanalyzed cells from 66 embryos previously screened for 
aneuploidy by aCGH. By isolating ICM cells from the trophectoderm and analyzing their individual 
ploidy status using FISH, they were able to conclude that 79% were concordant and 21% were 
discordant for both cells lines. Only 3% of the embryos had a euploid/aneuploid discordance 
between the ICM and trophectoderm. 
In contrast, when mosaic aneuploidy was detected in trophectoderm, it was only indicative of 
aneuploidy in the corresponding ICM in 58% of embryos, although for complex mosaics this 
increased to 83% (Munne and Wells, 2017). 
 
 
1.7.5 Does the ratio of euploid to aneuploid cells matter to the ͞ƐĞǀĞƌŝƚǇ͟ of the 
mosaic diagnosis? 
The Preimplantation Genetic Diagnosis International Society (PGDIS) position statement on 
chromosomal mosaicism, published in 2016 (PGDIS, 2016), stated that less than 20% mosaic 
aneuploidy should be considered euploid, greater than 80% mosaic aneuploidy should be 
considered aneuploid and between 20-80% mosaicism should be classified as a mosaic result. 
 
 
The proportion of aneuploid cells in any mosaic sample may or may not reflect the extent of 
mosaicism in the whole embryo. If 10 cells are biopsied and one/ten is aneuploid, the percent of 
mosaicism would be stated as 10%. If 5/10 of the cells are aneuploid then the percent of 







mosaicism observed would be 50%. However this could have been the same embryo and the 
biopsy could have been taken at different places on the trophectoderm (figure 18). 
 
 
In a 2015 communication published by Greco et al (Greco et al., 2015), they described transferring 
known mosaic embryos to patients after appropriate consent. The percentage of mosaic 
aneuploid cells seen in each biopsy sample was stated. Eighteen embryos were transferred and  
6 gave rise to live born offspring. The percentage of mosaicism ranged from 35%-50% in the live 
born group and the remaining 12 embryos which did not result in a viable pregnancy ranged from 
30-50%. 
To consider the degree of mosaicism in a sample when deciding whether to preferably transfer 
an embryo diagnosed as  “ŵŝůĚůǇ ? mosaic or  “ŚŝŐŚůǇ ? may not be helpful in avoiding possible fully 
aneuploid or mosaic aneuploid conceptions from these embryos. 
 
 
1.7.6 Should patients transfer mosaic embryos and, if so, does the affected 
chromosome matter? 
Some IVF clinics have elected to transfer embryos diagnosed as mosaic with patient consent and 
extensive counselling. The aforementioned PGDIS position statement on mosaicism (PGDIS, 
2016), stated that mosaic designated embryos should only be considered for transfer if no other 
embryos exist for a particular patient. 'ƌĞĐŽ ?Ɛpreviously mentioned New England Journal of 
Medicine communication (Greco et al., 2015) reported that 18 embryos classified as mosaic were 
transferred to consenting patients and 6 of these resulted in a live birth with a normal karyotype. 







This alerted the IVF community to the possibility that if we discard mosaic embryos we may be 
discarding embryos that could give rise to an apparently normal fetus with an abnormal placenta 
(confined placental mosaicism CPM) or that the abnormal cells may not proliferate past the early 
pre-implantation stage resulting in a euploid conception overall. 
Munne et al (in press 2017) recently analyzed data from multiple centers that have elected to 
transfer known mosaic embryos to patients. The data was split into the following categories: 
mosaic monosomy, mosaic trisomy, complex mosaic (i.e. multiple chromosomes involved) and 















34 20 50 39 143 
#   with  negative 
pregnancy test 
12 7 34 16 69 
# miscarriages 6 1 3 8 18 












Table 4: Showing outcomes of transferring known mosaic embryos to patients. Munne et al in 
press 2017. *Mosaic segmental= part of the chromosome not the whole chromosome in some of 
the cells is affected 
 
 
The PGDIS guidelines (PGDIS, 2016) stated that mosaic results of certain chromosomes should be 
considered for transfer in preference to other chromosomes based on their ability to give rise to 
a live born offspring based on the phenotype of a full aneuploid result for a particular 
chromosome. The logic behind this reasoning is to assume that if the fetus were to become a full 
aneuploid for a particular chromosome deletion or duplication detected in the biopsy, then 







embryos should only be transferred that are not capable of live born viability with a full 
aneuploidy. For example, trisomy 21, 18 and 13 mosaics would not be recommended for transfer 
as they give rise to viable offspring in the full aneuploid state. The guidelines also state that a 
monosomy mosaic is of lower risk of giving rise to a live born compared to a trisomy mosaic 
embryo due to the fact that no full monosomy aneuploids give rise to viable live borns apart from 




The prioritization of mosaic embryos for transfer based on their affected chromosome may not 
be useful in a clinical setting, as mosaicism in viable offspring has been demonstrated to exist for 
almost every chromosome (monosomy and trisomy) with varying degrees of phenotypic 
expression. Even if a live born infant with a normal peripheral karyotype results from a mosaic 
embryo they may harbor confined mosaicism in an organ or tissue which may have an adverse 
effect on the long term health of the child itself or the ĐŚŝůĚ ?Ɛsubsequent offspring (Campbell et 
al., 2014b). Examples of mosaicism existing in live born offspring are summarized in table 5. 











1 Live born mosaic trisomy 1 severe developmental delays, facial dysmorphism (Lo et al., 2016) 
2 Complete trisomy 0.16% of first trimester losses. Mosaics if CPM survive well, maybe IUGR, if detected in fetus have 
poor survival.(Chen et al., 2013; Tug et al., 2017) 
3 Complete trisomy lethal. Mosaics if CPM survive well, mosaic trisomy 3 offspring have multiple anomalies, mental 
retardation etc. (Kekis et al., 2016) 
4 Complete trisomy 4 responsible  for 2-3% of SABs. Mosaics  result  in multiple  anomalies  in  live  borns. May  be tissue 
limited.(Brady et al., 2005) 
5 Complete trisomy lethal. Mosaics if CPM survive well. Mosaics result in multiple anomalies in live borns. May be tissue 
limited (Sciorra et al., 1992) 
6 Complete trisomy rare and lethal. Case of  mosaic trisomy 6 with heart defect (Cockwell et al., 2006). 
7 Live born complete trisomy 7 has never been observed. Mosaic trisomy 7 in the fetus associated with multiple defects 
and developmental delay. CPM associated with normal infants. Mosaicism found in fibroblasts of skin cells. Mosaic 
monosomy 7 characteristics: syndrome with hyperplasia of the bone marrow, genetic males may have some degree of 
feminization of the external genitalia, may have dysmorphic features, may have adrenal hypoplasia(Flori et al., 2005) 
8 Complete trisomy 8 occurs in 0.8% of SABs. Monosomy 8 presents in live borns with various malformations and 
retardation levels. Mosaic trisomy 8 in the fetus associated with multiple defects and developmental delay. CPM 
associated with normal infants. Chromosome 8 carries two oncogenes, which may account for the development of 
cancer among some patients with trisomy 8 mosaicism 
https://rarediseases.info.nih.gov/diseases/5359/mosaic-trisomy-8 
9 Trisomy 9 syndrome (full trisomy), mental retardation, multiple anomalies,facial features include bulbous nose, small, 
deep set eyes, ear anomalies, small jaw and large fontanels. Mosaic trisomy 9 can be CPM or in the fetus(Sanchez 
Zahonero et al., 2008) 
10 Trisomy 10 is detected in approximately 1.8% of SABs. Full trisomy is lethal. Mosaic trisomy 10 common features: growth 
retardation, feeding problems, failure to thrive, distinct facial features, high arched palate, a long slender trunk, cardiac 
defects, renal, skeletal and central nervous system abnormalities, and early death. 
11 Mosaic trisomy 11 rare but has been seen. Renal anomalies (Balasubramanian et al., 2011) 
12 Mosaic trisomy 12 presents with facial abnormalities, behavior disturbances, developmental delay etc.(Bischoff et al., 
1995) 
13 Trisomy 13 (Patau syndrome) occurs in approximately 1 in 10,000 live births and mosaic trisomy 13 is thought to account 
for about 5% of these cases (Eubanks et al, 1998). Full trisomy exhibits mental retardation, multiple anomalies mosaicism 
has variable traits 
14 Trisomy  14  lethal.  Mosaic  trisomy  and  monosomy  14  features  in  offspring,  multiple  facial  anomalies,  and short 
neck.(Eventov-Friedman et al., 2015; Johnson et al., 1979) 
15 Mosaic trisomy 15 has been reported in an IVF fetus, multiple anomalies.(Bennett et al., 1992) 
16 Full trisomy 16 occurs in 1% of all clinical pregnancy losses. Usually caused by UPD. Mosaic trisomy 16 tissue specific 
(Garber et al., 1994) 
17 Mosaic trisomy 17, rare but reported in live born 
(Baltensperger et al., 2016) 
18 Mosaic  chromosome 18q partial  deletion syndrome with bilateral full-thickness corneal disease(Cammarata-Scalisi  et 
al., 2017; Galvin et al., 2015) 
19 Mosaic Trisomy 19 with ring chromosome, spectrum of anomalies (Novelli et al., 2005) 
20 Mosaic trisomy 20, Rare in live borns, common detection prenatally, case report of live born: (Powis and Erickson, 2009) 
Trisomy 20 in amniocytes, normal fetus (Maeda et al., 2015) 
21 DŽƐĂŝĐƚƌŝƐŽŵǇ ? ?ĂƐƐŽĐŝĂƚĞĚǁŝƚŚůǌŚĞŝŵĞƌ ?Ɛ ?WŽƚƚĞƌet al., 2016) 1-2% of live born offspring with Down Syndrome are 
mosaic (Leon et al., 2010) 
22 Mosaic trisomy 22, rare but some live born offspring (Abdelgadir et al., 2013) 
Sex 
chrom 
XO- 7% of losses, less than 1% of XO conceptions survive to term. Mosaic XO exists with varying phenotypes. 
Mosaic XXY, XYY, XXX, all present in live borns with varying issues. 
Table 5: examples of mosaic live born offspring for all chromosomes. 
SAB= spontaneous abortion, CPM=confined placental mosaicism 







1.7.7 Reanalyzing DNA samples from transferred embryos diagnosed as euploid 
with aCGH 
When using aCGH for aneuploidy determination, over 40% mosaicism was classified as aneuploid 
and less than 40% the embryo was classed as normal. Next Generation Sequencing (NGS) is able 
to categorize more definitively a mosaic result and has been validated for mosaicism detection 
by analyzing different ratios of normal to abnormal cell lines even stating percentages of 
mosaicism in a sample. 
 
 
All embryos tested in our own clinic prior to November 2014 were tested with aCGH. Amplified 
DNA from 136 transferred embryos originally diagnosed as euploid with aCGH, was reanalyzed 
with NGS on the Ion Torrent platform (Life Technologies). Only embryos resulting in a live birth 
or miscarriage, were re-analyzed for this retrospective study. Mosaicism was detected in 30% of 
embryos that miscarried and 9% of embryos resulting in live births (Table 6). 
 
 
Retesting of DNA from aCGH tested embryos with NGS has been carried out by 2 other groups. 
Fragouli et al re-analyzed the DNA from 94 embryos that had been transferred and had a clinical 
outcome (Fragouli et al., 2015a). Forty three of these embryos were found to be mosaic after 
reanalysis with NGS. Of these mosaic embryos, 26 (60%) did not implant, 6 (14%) miscarried and 
11 (26%) gave rise to ongoing pregnancies. Grifo et al reanalyzed only patients who had a 
miscarriage post transfer of supposed euploid embryos tested by aCGH (Grifo et al., 2015b). Some 
miscarried pregnancies had testing on products of conception (POCs) and some did not. Of those 







who did not the amplified DNA from each original biopsy was reanalyzed with NGS. Of the 39 
embryos that miscarried and on retesting gave a valid result, 17 embryos were euploid (43%) and 
22 were found to be mosaic (56%). These studies give us a unique insight into how embryos 
designated as mosaic may behave post embryo transfer as the embryos since found to be mosaic 
would not have been transferred if they had been originally tested using NGS. 
 Embryos transferred resulting in a 
Biochemical or miscarriage 
Embryos transferred resulting in a 
Live birth 
# FET cycles   
# embryos 
transferred 
 ? “ĞƵƉůŽŝĚ ?ǁŝƚŚ 
aCGH) 
69 67 
# mosaic post 
retest with NGS 










Mosaic Partial Trisomy 20pter-q13.2 
Mosaic Monosomy 10q26.13-qter 
Mosaic Monosomy 5 
Mosaic Monosomy 21 
Mosaic Monosomy 14 
Mosaic Partial Trisomy 5q32-qter, Mosaic 
monosomy 1 
Mosaic Partial Trisomy 10pter-p13 
Mosaic Monosomy 13 
Mosaic Partial Monosomy 4q34.1-qter 
Mosaic Monosomy 16 
Mosaic Monosomy 15 
Triploid 
Mosaic Partial Monosomy 18q21.32-qter 
Mosaic Trisomy 9 
Mosaic Partial Trisomy 1 
Mosaic Monosomy 15 
Mosaic Monosomy 3pter-q12.2 
Mosaic Monosomy 6 
Mosaic Partial Monosomy 5 
Complex Mosaic 
Mosaic Nullisomy Y (Y copy number 0.63) 
x Mosaic Partial Trisomy 7pter-p21.1, 
Mosaic Monosomy 15= 7lb 8oz boy 
x Mosaic Monosomy 14 = boy VSD 
x Mosaic Partial Monosomy 5pter- 
p15.1,mosaic partial Trisomy 8q11.21- 
qter= 6lb 14oz boy 
x Mosaic Partial Trisomy 8q11.21-qter = 
6lb boy 
x Mosaic Monosomy 6, Mosaic 
Monosomy 21 = 7lb boy 
x Mosaic Trisomy 4= 5lb baby, has either 
2 vessel cord or umbilical cyst 
Table 6: Profiles of embryos designated as euploid prior to transfer and diagnosed as mosaic post 
retrospective analysis of the same DNA products with NGS (own unpublished data) 







1.8 Supplementing PGS with non-invasive testing 
 
All embryos defined as euploid do not have the ability to create a live born offspring. The search 
for an adjunct to PGS that would further define embryo viability is ongoing. In this section I 




1.8.1 Combining Morphokinetics and PGS 
 
As far as is known, there only been one study utilizing both PGS and morphokinetics to choose 
embryos for transfer. Yang et al (Yang et al., 2014) recruited 138 patients undergoing IVF with 
PGS and cultured half the sibling zygotes in a regular big box incubator (Group B) and half in an 
Embryoscope time lapse incubator (Group A). All embryos reaching the blastocyst stage were 
biopsied and screened using aCGH. The study showed a significant difference in ongoing 
pregnancy rate and implantation rate in favor of euploid embryos cultured in the Embryoscope 
before biopsy however the numbers in the study were small. Of the 127 transfers, 45 transferred 
a mixture of one embryo from each group. 
While there was an increase in implantation and ongoing pregnancy rates in the time lapse group, 
this may have been attributable to the very different culture conditions between the two groups. 
Group A was grown in 5% Oxygen and Group B was grown in atmospheric oxygen (20%) and 
embryos grown inside a time lapse incubator remain relatively undisturbed for the culture period 
compared to a conventional incubator. 







A better design of the study would have been to reduce the number of variables by also culturing 
the control embryos (Group B) in a time lapse incubator and blind the embryology team to the 
time lapse data for that group. Although benefits were essentially seen from this study using both 
technologies in conjunction, more research is needed to find one morphokinetic event that may 
add to the selection process between known euploid embryos. 
 
 
1.8.2 Combining static morphology and PGS 
 
A study by Irani et al (Irani et al., 2017) showed that there was a association between blastocyst 
ŵŽƌƉŚŽůŽŐǇŝŶĞƵƉůŽŝĚĞŵďƌǇŽƐĂŶĚƉƌĞŐŶĂŶĐǇŽƵƚĐŽŵĞ ?ŵďƌǇŽƐŐƌĂĚĞĚĂƐ “ĞǆĐĞůůĞŶƚ ?ďĞĨŽƌĞ
ďŝŽƉƐǇ  ? ? ? ƚƌĂŶƐĨĞƌƐ ) ƌĞƐƵůƚĞĚ ŝŶ ĂŶ  ? ? ? ?A? ŽŶŐŽŝŶŐ ƉƌĞŐŶĂŶĐǇ ƌĂƚĞ ǀƐ  ? ? ? ?A? ĨŽƌ  “ŐŽŽĚ ?  ? ? ?
transfers) 5 ? ? ?A?ĨŽƌ “ĂǀĞƌĂŐĞ ? ? ? ? ?ƚƌĂŶƐĨĞƌƐ )ĂŶĚ ? ? ? ?A?ƵƐŝŶŐĞŵďƌǇŽƐŐƌĂĚĞĚĂƐ “ƉŽŽƌ ? ? ? ? ?
transfers). These differences all reached significance. Capalbo however (Capalbo et al., 2014a), 
in a study with 213 patients showed that the only predictive value for embryo quality was 
aneuploidy rate which also concurred with our finding in section 2.1.1 of this thesis. In ĂƉĂůďŽƐ ?
study, once an embryo was deemed to be euploid, the quality prior to biopsy seemed to have no 
ĞĨĨĞĐƚŽŶŝƚƐ ?ĂďŝůŝƚǇƚŽƉƌŽŐƌĞƐƐƚŽĂŶŽŶŐŽŝŶŐ pregnancy. 







1.9 Limitations of the embryo biopsy and testing process 
 
Removing 3-10 cells from the trophectoderm layer on day 5 or 6 of development is a small 
representation of the embryo as a whole and only the cells present in the biopsy tube can be 
analyzed for any particular embryo that is destined for clinical use. Patients need to be aware 
that there is a small error rate when sampling such small numbers of cells. 
 
 
1.9.1 Risks of misdiagnosis 
 
Establishing error rates in embryos that have been diagnosed as euploid is not simple. In order 
for an embryo to be tested post transfer, products of conception post miscarriage have to be 
analyzed or live born offspring would have to be karyotyped. Even if a live born baby is apparently 
phenotypically normal, there may be underlying chromosomal aberrations that may be in mosaic 
form and may go undetected until later in life. Many embryos transferred will never implant but 




A 2014 study by Werner et al (Werner et al., 2014) re-examined the transfers of 4,794 CCS euploid 
embryos diagnosed by qPCR. Of the embryos that implanted 10 were identified as aneuploid 
conceptions. Only embryos that were able to be analyzed post miscarriage were able to be 
considered and the dataset was certainly not complete. To have an accurate picture of possible 
misdiagnosis for whatever reason, analysis would have to be done on all the embryos transferred 
rather than just the few which were able to be sampled at miscarriage. In this study, while 2979 







embryos developed a fetal sac, there were 1818 embryos that did not result in a clinically 
recognized pregnancy. One could assume that at least some of these 1818 embryos were 
undiagnosed mosaics or misdiagnosed in some way. The group did not state how many products 
of conception or live born offspring they were able to analyze which would have given a 
percentage of the samples analyzed rather than the percentage of embryos transferred (10/4794 
a rate of 0.2%). 
 
 
Wilton et al (Wilton et al., 2009) reviewed a large ESHRE PGD consortium dataset of day 3 biopsy. 
15,158 cycles, had 24 misdiagnoses and adverse outcomes reported: 12/2538 cycles after 
polymerase chain reaction (PCR) and 12/12,620 cycles after fluorescence in-situ hybridization 
(FISH). The causes of misdiagnosis include confusion of embryo and cell number, transfer of the 
wrong embryo, maternal or paternal contamination, allele dropout, use of incorrect and 
inappropriate probes or primers, probe or primer failure and chromosomal mosaicism. 
Unprotected sex during IVF treatment was also mentioned as a cause of adverse outcome not 
related to technical and human errors. 
 
 
A retrospective cohort study of 520 embryo transfers using embryos designated as euploid after 
trophectoderm biopsy and aCGH by Tiegs et al (Tiegs et al., 2016) showed a less than 1% error 
rate in live born offspring and 17% error rate in miscarried embryos. Cycles were included in the 
analysis if the outcome could confirm the PGS diagnosis, such as live birth after single embryo 
transfer, or in the case of  spontaneous  abortion  where products  of  conception  (POCs)  were 







obtained and sent for cytogenetic analysis. Cycles without available outcome data were 
excluded. Of 282 live births, 280 were apparently normal and the gender concurred with the 
original PGS diagnosis. Of POCs available for testing, 14 of 17 karyotypes agreed with the PGS 
result. The 3 miscarriages with discrepant results all showed autosomal aneuploidy post 
karyotype and the 2 live born infants had sex chromosome errors; one was 47XYY (PGS 46XY) and 
the other was 46XY (PGS 46XX). 
 
 
1.9.2 Risks of using Whole Genome Amplification (WGA) for PGS 
 
The majority of techniques used for whole chromosome copy number determination require 
Whole Genome Amplification (WGA) to create more DNA for testing (section 1.6.2). WGA is 
accomplished using Polymerase Chain Reaction (PCR) techniques such as Sureplex (Illumina) and 
multiple displacement amplification (MDA) (Spits et al., 2006) which are both routinely used for 
PGS. These methods create copies from copies which has the potential to perpetuate mistakes 
made during original copying stages. This risk is greater when using WGA for single gene mutation 
detection as a smaller part of the chromosome is under detection (Kung et al., 2015). 
 
 
1.9.3 Risks of biopsy to the embryo 
 
The removal of cells from the trophectoderm is an invasive procedure which appears to cause 
minimal damage to the developing embryo. Embryos that have been biopsied continue to 
develop once transferred to the uterus at a high rate and 60% of euploid embryos will give rise 
to a live born offspring (own data). During the biopsy, a laser pulse is applied to the cell junctions 







of the trophectoderm in order to remove the tissue for analysis. Cells in contact with the laser 
can be damaged possibly disrupting the chromosomes. In theory this could lead to an erroneous 
mosaic result. This has been postulated by Ilkevitch et al (Illkevitch Y1, 2017) who developed a 
laser free method of biopsy. However in their small dataset they did not detect any mosaic results 
in the laser or alternate biopsy method groups. 
 
 
The biopsy procedure will rarely result in loss of an embryo at the time of biopsy. In our own 
laboratory there have only been 2 instances out of over 12,000 (0.01%) embryos biopsied where 
the embryos have degenerated at the time of the biopsy. 
 
 
Scott et al (Scott et al., 2013b) studied the effects of day 3 and trophectoderm biopsy on 
subsequent implantation rates. Day 3 biopsied embryos had significantly lower implantation 
rates than non-biopsied day 3 embryos (30% vs 50%) whereas trophectoderm biopsied 
blastocysts implanted at a similar rate to non-biopsied blastocysts (51% vs 54%) concluding that 




There has not been a study to date of the long term outcome of blastocyst biopsy on resulting 
development of offspring. 







1.10 Referral categories for PGS 
 
The reasons for patients undergoing testing as part of their infertility treatment are diverse. 
There are two overall categories of patient, those that have higher risk factors for embryonic 
aneuploidy and receive medical advice to have their embryos tested and those patients who elect 
to have testing and have a lower risk of embryonic aneuploidy. 
 
 
1.10.1 Higher risk patients 
 
The first group includes repeated pregnancy loss patients, patients of advanced maternal age, 
patients who have had failed IVF cycles and patients who have had a previous aneuploid 
conception and wish to avoid that experience again. 
 
 
1.10.1.1 Advanced maternal age 
 
As the incidence of aneuploidy is lower in embryos of younger women, the pregnancy rate with 
embryos of known or unknown ploidy status is almost equal. Without pre-screening embryos, as 
maternal age increases the implantation and ongoing pregnancy rates decrease (Franasiak et al., 
2014a, b; Harton et al., 2013; Munne et al., 2007a). 
 
 
The graph below shows that replacing only euploid embryos in an embryo transfer cycle removes 
the maternal age effect on live birth rates. A euploid embryo from a 40 year old woman will 
implant with the same frequency as a euploid embryo from a 25 year old woman. PGS has been 
shown to reduce miscarriage rates in older patients (Forman et al., 2012b). Aneuploidy is the 







major cause of miscarriage (van den Berg et al., 2012) therefore only transferring euploid 




Figure 20: Live birth rates of fresh untested embryos vs frozen thawed PGS embryos. Own data 
showing rate of live born offspring per transferred embryo comparing fresh untested blastocysts 
(n=2356) vs frozen thawed PGS blastocysts (n=597). Illustrating beautifully how the maternal age 
effect can be removed if a euploid embryo can be found for transfer. 
 
 
Patients of advanced maternal age have fewer euploid embryos than younger women and 
therefore testing these embryos allows the laboratory to find a chromosomally normal embryo 
for transfer or avoids replacement of an abnormal embryo to the uterus. These patients are less 
likely to have a normal embryo in their cohort and therefore more patients in this category will 




Percent of each transferred embryo resulting in a baby, fresh untested vs frozen 
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1.10.1.2 Previous history of aneuploid conception 
 
Patients who have had a termination of an aneuploid pregnancy in the past may psychologically 
benefit from the early detection of another aneuploid conception before the embryo is replaced 




1.10.1.3 Failed IVF cycles 
 
Patients who have had previous failed IVF cycles may elect to have subsequent embryos tested 
to see if they are aneuploid and if this is the reason they are not achieving a pregnancy. If all 
embryos are abnormal this can be useful information that may encourage the patient to move 
on with other options for family building. 
 
 
1.10.1.4 Recurrent Pregnancy Loss 
 
Recurrent pregnancy loss (RPL) is categorized as 2 consecutive losses before 20 weeks gestation. 
In theory, the ideal patient to be offered aneuploidy testing during the IVF cycle is the repeated 
pregnancy loss patient who produces multiple embryos. Cytogenetic analysis of products of 
conception from spontaneous abortions in late first trimester demonstrate around 60% of 
conceptuses are aneuploid (Zhang et al., 2009). Aneuploidy screening during the IVF cycle is used 
as a tool to choose the correct embryo for transfer and reduce the chances of miscarriage 
happening again if aneuploidy were the cause (Farahmand et al., 2016; Munne et al., 2005; 
Shahine and Lathi, 2014). 







A recent paper by Murugappan et al (Murugappan et al., 2016) compared IVF with PGS versus 
expectant management (EM) for the treatment of RPL. They compared one cycle of IVF with PGS 
to 6 months of EM. They reported that per attempt, PGS is not effective in improving LB rate or 
decreasing clinical miscarriage rate compared with expectant management except in those PGS 
cycles that complete transfer of a euploid embryo. Once a euploid embryo was transferred 
however the live birth rates were higher than spontaneous attempts at conception. They 
concluded that in the intention to treat analysis, the time to viable conception was 6 months for 
PGS and 3 months for EM however the parameters of study participants were not equally 
matched in each group. Partners of females with a history of RPL have been found to have 
increased rates of sperm aneuploidy for certain chromosomes such as chromosome 16 which is 
associated with miscarriage (Neusser et al., 2015). 
 
 
1.10.2 Lower risk patients 
 
Patients in this group have a lower risk of embryonic aneuploidy than the previous group of 
patients and they opt for testing by personal choice. These patients include maternal age of less 
than 35, use of young donor oocytes (fresh or freeze all cycles) and fertile patients wishing to 
balance the gender of their family. 
1.10.2.1 Young maternal age (less than 35 using own oocytes  and donor oocyte) 
 
The incidence of aneuploidy in blastocyst embryos in young women less than 35 is around 40%. 
(own data) Therefore the risk of replacing an aneuploid embryo without screening with PGS is 
still 40%. 







1.10.2.2 PGS before cryopreservation 
 
Frozen embryo transfer without determining ploidy status has historically been lower than fresh 
transfer in all age groups. If biopsy is carried out before embryos are vitrified the implantation 
rate and ongoing pregnancy rates are significantly higher in some patient categories than 
cryopreserving without testing. In the dataset below all culture and vitrification protocols were 
the same. The method used for chromosome analysis changed from aCGH to NGS in January 
2014. 






































Table 7: Data showing percentages of live births of FET with and without PGS (ORM own data 





1.11   Perspectives on the potential to further improve IVF 
 
IVF is a treatment that has improved over the last 30 years to a point where in the best programs 
we can achieve live births at a rate of 60% per transferred euploid embryo. However this still 
leaves around 40% of embryos diagnosed as euploid that will either fail to implant or will result 
in a miscarriage. There is clearly room for further improvement. 







2 Specific aims of this thesis 
IVF is a major part of reproductive medicine and has become far more widespread since its 
inception in 1978. Clinics are constantly seeking to improve the efficiency of the IVF procedure 
and basic research is essential (much of which can be gleaned from existing data in clinics) to 
advance the field further. Much of this can be achieved by original studies derived from 
retrospective analysis of clinic data, or by prospectively designed studies. Indeed a number of 
fundamental biological questions pertaining to chromosome abnormalities and their relationship 
to IVF embryo development remain unanswered. With this in mind the overall aim of this thesis 
is to provide further insight into the cytogenetic basis of early human development (with a view 
to improving IVF care for practitioners and patients) by pursuit of the following specific aims: 
1. To test that hypothesis that we can predict aneuploidy levels in human IVF embryos 
without direct PGS by the following approaches: 
a. Analysis of basic morphokinetic criteria 
 
b. Analysis of spent media from cell-free embryonic DNA 
 
2. To test the hypothesis that patients undergoing ICSI (many of whom have previously been 
demonstrated to have elevated sperm aneuploidy levels) display significantly elevated 
embryo aneuploidy levels. 
3. To establish novel patient populations that may benefit from the use of PGS: 
 
a. Population number 1: Male factor infertility patients 
 
b. Population number 2: Young oocyte donors 







4. To establish the optimal transfer strategy (fresh vs frozen) for euploid embryos in patients 
using their own oocytes 
5. To test the hypothesis that using NGS for PGS increases live birth rates and lowers 
miscarriage rates by detecting mosaicism compared to using aCGH which does not. 
6. To provide a framework for creating realistic expectations for patients planning for their 
fertility future 







2.1 General Materials and Methods 
 
Patients undergoing IVF treatment at Oregon Reproductive Medicine (ORM), Portland, Oregon, 
USA, were counseled to have their embryos tested as part of our routine protocol to assess the 
chromosomal status of pre-implantation embryos before transfer to the uterus. Indications for 
PGS included advanced reproductive age of the female patient, history of repeated pregnancy 
losses, history of failed IVF cycles, history of previous aneuploid pregnancy, diminished ovarian 




2.1.1 Timeline of data collection 
 
The data collection for the research featured in this manuscript was an ongoing process. Each 
chapter includes data from different time periods during November 2010 to December 2016 and 
the specific dates are stated in each chapter summary. Data has been included in multiple studies 
between different dates and these dates are stated in each chapter of this thesis. 
 
 
2.1.2 Changes to protocol during the data collection timeline 
Changes   to   protocols   over   that   time   frame   were   as   follows: 
DNA analysis platform: 
x November 2010-January 2014 array CGH used exclusively 
 
x February 2014- November 2015 a mixture of aCGH and NGS (Ion Torrent platform) 
used. This was the start of the RCT described in specific aim 4 where non study 








to determine aneuploidy. 
x December 2015-December 2016 all patients underwent NGS to determine aneuploidy 
How results were affected: Euploidy rates are lower with NGS than with aCGH due to the 
increased detection of mosaicism with NGS. 
DNA sample transportation: 
 
x aCGH was carried out offsite at a reference lab in Los Angeles. Embryo biopsies were sent 
from Portland, Oregon via courier on gel cold packs to LA where they were amplified and 
analyzed. 
x NGS was carried out onsite on the ORM premises in Portland, Oregon. All embryo biopsies 
were amplified and analyzed here onsite. 
Vitrification method: 
 
x Vitrification using a non-DMSO method was used from November 2010-December 2012 
 
x Vitrification using DMSO as a cryoprotectant was used from January 2013 onwards 
 
How results were affected: Vitrification using DMSO results in higher survival rates post thaw 
(97% DMSO vs 85% non-DMSO) 
All other culture methods and stimulation protocols remained the same for the entire data 
collection period. 







2.1.3 Stimulation and embryo culture protocols 
 
Oral contraceptive (OC) administration was initiated 2 W3 weeks before stimulation. A GnRH 
antagonist protocol was preferentially used unless the patient had previously had a suboptimal 
response to this protocol. The antagonist was started on day 6 of stimulation. Ovarian stimulation 
ǁĂƐĂĐŚŝĞǀĞĚǁŝƚŚďŽƚŚ&^,ĂŶĚŚD'ƉƌĞƉĂƌĂƚŝŽŶƐ ?tŚĞŶƚŚĞůĞĂĚĨŽůůŝĐůĞǁĂƐA? ? ?ŵŵ ? ? ? ? ? ? ?
IU of hCG (Novarel) was used for final oocyte maturation. Serum progesterone levels were 
obtained on the day of trigger. Oocyte retrieval was performed 36 hours after trigger shot. On 
ĐŽŵƉůĞƚŝŽŶŽĨƚŚĞƌĞƚƌŝĞǀĂůƉƌŽĐĞĚƵƌĞ ?ŽŽĐǇƚĞƐǁĞƌĞƉůĂĐĞĚŝŶYƵŝŶŶ ?ƐĚǀĂŶƚĂŐĞ&ĞƌƚŝůŝǌĂƚŝŽŶ
Medium (Origio, USA) supplemented with 5% Human Serum Albumin (HSA) (Irvine Scientific, 
USA) under oil (Ovoil, Vitrolife, USA). 
Fertilization was achieved by either Intra Cytoplasmic Sperm Injection (ICSI) (Palermo et al., 1992) 
or standard insemination performed approximately 4 hours after retrieval . The criteria for each 
method of insemination were as follows: 
x Normal  sperm  (>20  million  per ml with normal  morphology  and  % motility) would 
undergo standard insemination 
x Suboptimal sperm/ frozen sperm/ patients with long history of unexplained infertility 
would undergo ICSI 
Once all oocytes had been either inseminated or injected, they were returned to the incubator 
ĨŽƌŽǀĞƌŶŝŐŚƚĐƵůƚƵƌĞ ?ůůĞŵďƌǇŽƐǁĞƌĞŵŽǀĞĚƚŽYƵŝŶŶ ?ƐĚǀĂŶƚĂŐĞůĞĂǀĂŐĞDĞĚŝƵŵ ?^ĂŐĞ ?
Origio, USA) supplemented with 10% HSA (Irvine Scientific) from days 1-3 and subsequently 







moved to YƵŝŶŶ ?Ɛ Advantage Blastocyst Medium (Sage, Origio, USA) supplemented with 10% HSA 
from days 3-6. 
Assisted hatching was performed on all embryos on day 3 post-retrieval using a Hamilton Thorne 
Zilostm laser with 1-2 800um pulses to breach the inner and outer zona layers. The embryos were 
transferred back to culture media until day 5 or 6 of development. 
 
 
2.1.4 Embryo grading and morphological analysis 
 
Blastocysts were graded using the Gardner method (Gardner DK and WB, 1999). This method 
relies on a 3 part grading system. A number indicates the degree of expansion of the blastocoel 
cavity and 2 following letters indicate the quality of the inner cell mass and the trophectoderm 
respectively. So a good quality blastocyst would be denoted as a 4AA, (fully expanded cavity =4; 
good quality ICM =A; good quality TE=A). Embryos were not biopsied if an ICM was not seen. 
 “ĂƌůǇďůĂƐƚŽĐǇƐƚ ?ĚĞƐĐƌŝďes an embryo showing the first signs of blastulation and is not graded 
at this point. Compacting embryos with no visible sign of blastulation were classified as morulae, 
which is the stage before the embryo begins to cavitate and cell outlines begin to merge. Embryos 
classified as  “ƉŽŽƌ ƋƵĂůŝƚǇ ? with a C grade of either ICM and/or TE were not typically biopsied and 
tested as we routinely only freeze embryos of average or good quality that have a good chance 
of implanting. 







2.1.5 Embryo biopsy 
 
Embryos were only considered suitable for biopsy when at least 10% of the trophectoderm (TE) 
was protruding from the breach in the zona pellucida made on day 3. All embryos that were not 
hatching by day 5 were cultured until day 6 and then biopsied. Embryos were only biopsied if 
there was a visible Inner cell mass (ICM) and multi-celled TE protruding from the zona pellucida. 
Embryos that grew to an expanded blastocyst stage had an estimated 3-8 TE cells excised using 
a Hamilton Thorne Zilostm laser with 1-2 800um pulses to break apart cell junctions in the 
trophectoderm layer for tissue removal . Tissue samples were placed in 2ul of non-stick buffer 
solution in individual microfuge tubes labelled with the appropriate embryo number. If embryos 
were to undergo fresh embryo transfer, biopsied day 5 embryos were kept in culture overnight 
to await results of the PGS results before 12 midday of day 6. If embryos were to be 
cryopreserved post biopsy, they were individually vitrified using Irvine Vitrification media with 




2.1.6 Reducing contamination of samples 
 
Face masks, hats and sterile gloves were worn at all times during biopsy and tubing of the cells 
to eliminate operator DNA contamination of the embryo tissue sample. Cumulus cells were 
removed at the time of ICSI on egg collection day, or for standard insemination, at the time of 
fertilization check on day 1 of development. Standard insemination results in multiple sperm 
attaching to the zona pellucida. These residual sperm remain attached throughout the growth 







period and can be a possible source of sperm DNA contamination during embryo biopsy. 
However, as the blastocyst expands and extrudes from the zona pellucida, the zona is left behind 
and the trophectoderm does not come into contact with the outer layer of the zona. If a rogue 
sperm becomes detached in the biopsy media it can be observed easily and avoided when tubing 
the trophectoderm sample. 
 
 
2.1.7 DNA analysis 
 
Biopsied cells were whole genome amplified (WGA) using the Sureplex DNA Amplification System 
(Bluegnome) according to the ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ protocol. The WGA products were then processed 
for aneuploidy analysis by NGS or aCGH. 
 
 
Testing by aCGH was processed using Bluegnome 24sure V3 protocol (Illumina, Inc.) according to 
ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƉƌŽƚŽĐŽů ?t'ƉƌŽĚƵĐƚƐǁĞƌĞĨůƵŽƌĞƐĐĞŶƚůǇůĂďĞůĞĚǁŝƚŚǇ ?ĂŶĚǇ ?ĚǇĞƐ
and random primers and subsequently were prepared to be hybridized to 24sure V3 array slides. 
Aneuploidy data analysis was performed using BlueFuse Multi Software. 
 
 
Testing by NGS was processed using Ion Torrent PGM (Ion Torrent) technology. Libraries were 
prepared by fragmenting WGA products with DNA concentrations of 100 ng using Ion Xpress Plus 
Fragment Library Kit (Life Technologies). Library fragments were selected at 200 bp using E-Gel 
SizeSelect Gels (Life Technologies) and then were normalized to 100 pM using Ion Library 
Equalizer kit (Life Technologies). Libraries were subsequently pooled together into a mastermix, 







and clonal amplified on the Ion One Touch 2 system. The template was then loaded into a 316 
V2 chip (Life Technologies) and sequenced at 200 bp. Aneuploidy data analysis was performed 
using Ion Reporter software, using Low-coverage Whole-Gnome workflow. 







2.2 Specific aim 1 
 
To test the hypothesis that we can predict aneuploidy levels in human IVF 
embryos without direct PGS by the following approaches: analysis of basic 
morphokinetic criteria and analyzing spent media from cell free embryonic DNA 
 
2.2.1 Specific aim 1a 
 
To establish if static morphology correlates with ploidy status 
 
Static morphology as a predictor of ploidy status is considered in a paper, entitled  ?DŽƌƉŚŽůŽŐŝĐĂů
and Kinetic Embryological Criteria and Association with Aneuploidy Rates: How Might they Be 
hƐĞĚ ƚŽ ŚŽŽƐĞ ƚŚĞ ĞƐƚ /s& ŵďƌǇŽ ĨŽƌ dƌĂŶƐĨĞƌ ? ? ƵƚŚŽƌƐ P ůŝƐŽŶ ŽĂƚĞƐ ? ƌĞĂŶŶĞ ŽĂƚĞ ?




2.2.1.1 My Personal Contribution to the Work 
 
For this study I cultured and biopsied embryos, I conceived the idea for the study, I retrospectively 
analyzed the data and I wrote and edited the paper. 
 
 
2.2.1.2 Chapter Summary 
 
The purpose of this retrospective analysis was to establish if static morphology of blastocysts at 
the time of biopsy could be used to predict aneuploidy in our own patient population. The original 







study submitted for publication in 2014, included 1686 blastocysts from 295 IVF cycles 
undergoing PGS for aneuploidy during July 2010 to August 2013. A subsequent analysis of data 
post manuscript publication,from September 2013 to December 2015 was added to the original 
data, to assess day 5 vs day 6 aneuploidy rates resulting in a total of 8,015 embryos. Embryos 
were graded prior to trophectoderm biopsy using the Gardner grading system. Once results PGS 
results were received the data was analyzed. 
 
 
Speed of growth and ŝƚƐ ? effect on ploidy status was studied by analyzing aneuploidy rates of day 
5 vs day 6 embryos without consideration of static morphology. Day 5 ready embryos had a 
significantly higher chance of being euploid than day 6 embryos. While the differences between 
day 5 and day 6 embryos was small (Donor egg: 5%, <35: 5%, 35-37: 6%, 38-40:13%, 41-42: 11% 
and >42:4%) all the differences noted reached a level of significance apart from the <35 group 
which almost reached significance and the >42 age group which was not significantly different 
possibly due to the small data sample. 
 
 
A subset of embryos from the original study that had not reached expanded blastocyst stage by 
day 5 were analyzed separately. Embryos at the morula stage on day 5 but which continued on 
to make a blastocyst by day 6, were more likely to be euploid than an embryo that had reached 
the early blastocyst stage by day 5. This finding was statistically significant for the younger (donor 
oocyte) group only (although in the 35-39 and the 40-42 age groups the difference was borderline 
significant). 









Static morphology of the inner cell mass (ICM) and trophectoderm (TE) was considered and 
correlated with rates of aneuploidy. AA grade (excellent quality) embryos had the lowest rate of 
aneuploidy in all maternal age groups. In poorer quality embryos (AB,BA,BB) the rates of 
aneuploidy were higher. The conclusion of the study was that static morphology alone is unable 





The ability to culture human embryos in-vitro, ultimately to lead to viable live births, has 
improved over the last 20 years, mostly through the evolution of culture media and methods. 
The development of physiological culture media similar to human tubal fluid improved culture 
conditions of human embryos (Quinn, 1995) and further modifications using sequential media 
allowed for successful extended culture to the blastocyst stage (Gardner and Lane, 1997; Marek 
et al., 1999). Unlike the sophisticated development of culture media the method of choosing 
which embryos to transfer using basic morphological criteria has remained similar since the 
inception of IVF. That is, the subjective judgment of the embryologist is still the major driver in 
embryo selection and, if this aspect could be improved, there is still potential for further increases 
in IVF pregnancy rates. Other more empirical, approaches to inform embryo choice have, in 
recent years, gained in popularity: preimplantation genetic screening (PGS) for aneuploidy, and 
morphokinetic analyses following time-lapse photography. 







There are a number of referral categories for PGS in a clinical IVF setting, advanced maternal age 
recurrent pregnancy loss, recurrent implantation failure and prolonged periods of infertility (e.g. 
related to elevated sperm aneuploidy). Of these the maternal age effect for aneuploidy is the 
most well-described in preimplantation embryos as well as oocytes, spontaneous abortions and 
live born individuals and thus remain the largest referral category for PGS (Harton et al., 2013; Qi 
et al., 2014). Moreover, while the appearance of an embryo tells us which, among a cohort, may 
be the most likely to be viable in early embryonic stages, aspects of visual assessment have yet 
to be fully established as reasonably accurate predictors of ploidy status. Blastocyst biopsy 
followed by PGS for aneuploidy has been shown to reduce, but not eliminate the risk of 
miscarriage (Munne et al., 2005; Munne et al., 2006b) when transferring chromosomally normal 
embryos and the chance of choosing a karyotypically normal embryo for transfer based on 
appearance alone becomes less likely as the patient ages. Embryo biopsy followed by PGS thus 
remains the only method of accurately detecting aneuploidy in pre-implantation embryos. 
 
 
Studies involving transfer of chromosomally normal embryos have resulted in higher 
implantation rates per embryo transferred in older patients than transfer of non-tested embryos 
chosen by morphology alone (Alfarawati et al., 2011; Capalbo et al., 2014b; Hardarson et al., 
2001; Schoolcraft et al., 2011; Scott et al., 2012; Scott et al., 2013b; Yang et al., 2012). A further 
aspect of PGS is that it tells us which chromosome is involved and this can be important in 
predicting obstetric outcome. For example, the absence of monsomies (apart from XO) among 
spontaneous abortion material suggests that monosomy is a leading cause of embryo arrest or 







implantation failure. The preponderance of trisomy of most chromosomes (and XO) in first 
trimester miscarriages makes aneuploidy the leading cause of pregnancy loss. The potential for 
stillbirth or congenital abnormalities in live borns for certain aneuploidies (e.g. trisomy 21, 22) 
make chromosome specific screening useful to minimize the likelihood of an aneuploid embryo 
being transferred to the uterus (reviewed in Griffin 1996). 
 
 
Recent advances in time-lapse technology with cameras installed inside incubators have allowed 
constant, undisturbed observation of embryo growth patterns. Evidence suggests that timing of 
one cell division to the next at the early cleavage stage is somewhat predictive of blastocyst 
formation but not ploidy status (Chavez et al., 2012; Ebner et al., 2003; Fenwick et al., 2002; 
Kroener et al., 2012; Lundin et al., 2001). Campbell and colleagues demonstrated that the most 
predictive morphokinetic events were the timing of the beginning to the end of blastulation and 
that was able to give an overall risk (i.e. low vs. high), of an embryo being aneuploid. 
 
 
Despite these impressive results, although we may be able to provide crude estimates of the risk 
of embryos being chromosomally normal or abnormal based on morphokinetics, further 
refinements are needed if non-invasive methods are to replace invasive ones for preimplantation 
genetic screening. In other words, there is still a need to investigate further morphological and 
morphokinetic parameters (either by static or time-lapse analysis) to establish which, if any, 
might be correlated with specific aneuploidy risk. While direct analyses of time-lapse images 
offers the potential to correlate these morphokinetic events and potentially establish thresholds 







and ranges within which a lab can predict ploidy status of an embryo, there is not a definitive 
event which predicts aneuploidy accurately. 
 
 
While direct analyses of time-lapse images offer an opportunity to address the above questions, 
static analysis in the traditional manner nonetheless remains useful in identifying the criteria 
through which time-lapse studies might be directed. This is particularly true for clinics that have 
not yet installed a time-lapse facility and/or if pre-existing data, that can be analyzed 
retrospectively, is used to identify factors that might pre-dispose to aneuploidy. Moreover, it is 
essential that such analysis is performed in specific maternal age windows, given the association 
of maternal age and aneuploidy. For this reason we have compared aneuploidy rates following 
PGS by static analysis of specific morphological and morphokinetic parameters; namely the 
quality of the trophectoderm and inner cell mass individually and the speed of growth as 
manifested by the day that the embryo achieves full expansion of the blastocoel cavity (i.e. is it 
 “ďůĂƐƚŽĐǇƐƚ ďŝŽƉƐǇ ƌĞĂĚǇ ? ďǇ ĚĂǇ  ? ) ? ĞĐĂƵƐĞ ŽĨ ƚŚĞ ůŝŶŬ ƚŽ ŵĂƚĞƌŶĂů ĂŐĞ ?each analysis is 
performed on 5 distinct age groups. 







2.2.1.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
 
 
Chesapeake IRB review (September 6th 2013) determined IRB approval was not required; the 





Mann-Whitney (for 2 way comparison) and Kruskal-Wallis tests (for 3 way comparison) (non- 
parametric ANOVA tests) were used to determine significance. P values of <0.05 were considered 





In the initial study, a total of 1686 Embryos from 295 cycles of IVF carried out from July 2010 to 
August 2013, were successfully biopsied; successful array CGH traces were seen in 97% of 
embryos. Mean age, number of cycles and mean embryo biopsied per cycle are noted in Table 8. 
There was no significant difference in the proportion of embryos that did not give a result in each 
age group. In the subsequent analysis, data from a further 6,329 embryos generated from 
September 2013 to December 2015 was added to the original dataset. 










Group number 1 2 3 4 5 
Maternal Age Donor oocyte* <35 35-39 40-42 >42 
Mean age 24.8 31.4 35.5 41 43.5 
No. of cycles 82 46 107 53 7 
No. of embryos biopsied 685 284 509 236 25 
Mean no. of embryos 8.4 6.2 4.8 4.5 3.6 




















2.2.1.5.1 Aneuploidy and developmental stage at a fixed time point 
 
/ŶƚŚĞĨŝƌƐƚĂŶĂůǇƐŝƐ ?ĨŽƌ ?ŽĨƚŚĞĂŐĞŐƌŽƵƉƐ ?ǁĞĐŽŵƉĂƌĞĚƚŚĞŽǀĞƌĂůůĂŶĞƵƉůŽŝĚǇƌĂƚĞƐŽĨ “ĚĂǇ ?
ƌĞĂĚǇ ? ǀƐ ?  “ĚĂǇ  ? ƌĞĂĚǇ ? ĞŵďƌǇŽƐ ? ƚŚĞ ůĂƚƚĞƌ ďĞŝŶŐ ƚŚĞ ƐůŽǁĞƌ ŐƌŽǁŝŶŐ ? ZĞƐƵůƚƐ ŝŶ ƚŚĞ ĚŽŶŽƌ
oocyte (youngest) and 40+ oldest age groups show that faster growing embryos i.e. those that 
ǁĞƌĞƐƚƌƵĐƚƵƌĂůůǇƌĞĂĚǇĨŽƌďŝŽƉƐǇŽŶƚŚĞŵŽƌŶŝŶŐŽĨĚĂǇ ? ? “ĚĂǇ ?ƌĞĂĚǇ ? )ǁĞƌĞŵŽƌĞůŝŬĞůǇƚŽ
be chromosomally normal than ones that were slower growing and ready for biopsy by day 6 
 ? “ĚĂǇ ?ƌĞĂĚǇ ? ) ?/ŶƚŚĞAM ? ?ĂŶĚ ? ?-39 groups rates of aneuploidy between the two groups were 
not signficantly different ?dŚĞƌĞǁĞƌĞ ƚŽŽ ĨĞǁ  “ĚĂǇ  ? ƌĞĂĚǇ ?ĞŵďƌǇŽƐ  ?ŽŶůǇ  ? ) ŝŶ ƚŚĞAN ? ? ĂŐĞ
group and therefore this group was not included for this particular analysis. 
























Figure 21: Aneuploidy rates vs developmental stage. % Aneuploidy rates (Y axis) of embryos 
according to the day they reached the stage of development ready to biopsy (day 5 or 6). Donor 
oocyte: p= 0.001 (significantly different); <35: p=>0.05 (not significant); 35-39:p=>0.05 (not 
significant); 40-42: p=0.04 (significantly different - Mann-Whitney test). 
 
 
In this particular dataset, results thus suggest an association between aneuploidy rate and speed 
of growth, but only in embryos of younger and older mothers. 
 
 






<35 35-37 38-40 41-42 >42 
Total # embryos 
biopsied 
3907 1191 1199 1139 455 124 
% day 5 biopsied 62% 51% 46% 51% 46% 30% 
% day 5 euploid 77% 71% 66% 35% 36% 19% 
P value (5 vs day 6) : 0.0004 0.07 0.04 <0.0001 0.01 0.6 
% day 6 euploid 72% 66% 60% 22% 25% 15% 
Table9:  Rate of growth compared to aneuploidy rates according to maternal age 
 
While the differences in aneuploidy rates between day 5 and day 6 embryos was small (Donor 










Day 5 embryos 
Day 6 embryos 





























% aneuploid morulae 
% aneuploid early blasts 





reached a level of significance apart from the <35 group which almost reached significance and 
the >42 age group which was not significantly different possibly due to the small data sample. 
 
 
In a second analysis in the original study, a subset of the embryos not ready for biopsy until day 
6 were taken forward for analysis (figure 22). Aiming to correlate aneuploidy and speed of 
growth, levels of aneuploidy in each age group were compared. This particular subset of embryos 
was either morulae or early blastocysts on day 5. They were individually tracked and the ones 
that subsequently grew to fully expanded blastocysts by day 6 were able to be biopsied. In all age 
groups the early blastocysts (quicker growing embryos) were more likely to be aneuploid than 
the morulae (slower growing). Again there were too few embryos biopsied (only 5) in the >42 
age group and therefore this group was not included. This finding was statistically significant for 
the younger (donor oocyte) group only (although in the 35-39 and the 40-42 age groups the 


































The aneuploidy rates of blastocysts resulting from morulae on day 5 appeared to be lower in each 
age group than aneuploidy rates from embryos that had just begun to cavitate on day 5 (early 
blastocysts). Donor oocyte: p=0.009 (significantly different); <35: p=>0.05 (not significant); 35- 
39: p=0.08 (not significant); 40-42: p=0.08 (not significant - Mann-Whitney). 
 
 
Taken together therefore, a complex pattern emerges in that, in the whole data set, it is the 
slower growing embryos that appear to be more likely to be aneuploid. By isolating the slower 
growing cohort (those not ready to biopsy until day 6) however, it seems that the relatively faster 
ones that continue to grow to day 6 are more likely to be aneuploid. 
 
 
2.2.1.5.2 Aneuploidy rates compared to overall embryo grade 
 
For this analysis, the quality of the embryo was classified by the quality of its trophectoderm (TE) 
and inner cell mass (ICM) separately. With AA grade as the highest quality and BB the lowest for 
both germ layers AB or BA referred to embryos with one good quality layer. Embryos classified 
as good quality (AA) had the lowest rate of aneuploidy in all age groups: (19%, 24%, 42%, 52% 
and 57% respectively) compared to embryos with at least one poorer quality part (AB or BA), 
which had higher rates (37%, 36%, 45%, 73% and 58% respectively). Embryos with the poorest 
quality overall (BB) had the highest aneuploidy rates (36%, 42%, 61%, 76% and 92% respectively). 









Figure 23: Rates of aneuploidy according to overall grade of embryos. Donor oocyte: p=0.0001 
(significantly different), <35: p=0.06 (not significant); 35-39:p=0.02 (significantly different); 40- 
42: p=0.006 (significantly different); >42: p=0.04 (significantly different - Kruskal-Wallis test). 
 
 
2.2.1.5.3 Inner cell mass and trophectoderm quality compared to aneuploidy 
 
The quality of the inner cell mass correlated with aneuploidy levels in three of the five age groups 
(the <35 and 35-39 age groups not being statistically significantly different). The quality of the 
trophectoderm correlated with aneuploidy status in four of the five age groups (the 40-42 age 
group not quite reaching statistical significance (p=0.06)). In all cases the aneuploidy levels in the 
B grade germ layers were higher than the A grade. Taken together therefore the results seem to 
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Figure 24: Inner cell mass (ICM) quality and rates of aneuploidy. 
 
 
Aneuploidy rates of embryos with a B grade ICM were significantly higher than A grade ICM in 
the donor oocyte group (average age 24) and the over 40 age groups. Donor oocyte: p=0.048 
(significantly different); <35: p=>0.05 (not significant), 35-39: p=>0.05 (not significant), 40-42: 























































Figure 25: Rate of aneuploidy and quality of trophectoderm (TE). 
 
Aneuploidy rates of embryos with a B grade TE were significantly higher than A grade TE in all but 
one age groups. Donor oocyte: p=0.0001; <35: p=0.0007; 35-39: p=0.039; 40-42: p=0.06 (not 





Choosing the embryo most likely to lead to a baby is the ultimate goal in any IVF cycle. The 
development of more physiological culture media (Marek et al., 1999; Quinn, 1995) has enabled 
successful growth of embryos to the blastocyst stage. Better culture conditions eliminate the 
cohort of embryos that arrest at day 3 and improves implantation rates per embryo. In our own 
hands (current data 2009-2012) implantation rates of fresh untested blastocyst embryos are 
typically 56% in patients <35 compared to 35% if day 3 embryos are transferred. However, 





































accurately predict which embryo to choose based on its appearance. Embryo grading by an 
experienced embryologist also remains a subjective art rather than an exact science. The 
difference between an A grade and a B grade TE or ICM can be open to interpretation and the 
exact grading of embryos is acknowledged to be of questionable utility. 
A recent study illustrated beautifully how choosing an embryo based on appearance alone is a 
fairly arbitrary choice if there are many to choose from (Forman et al., 2013c). Embryos were 
chosen using morphological criteria and then tested the embryos before transfer to see if the 
morphological choice was correct. The embryos were biopsied to assess chromosome 
complement and transferred on day 6 if the embryo was euploid. If the original choice was 
aneuploid another embryo would be selected for transfer. Selection of an aneuploid embryo by 
ĐŚĂŶĐĞďĂƐĞĚŽŶĂƉƉĞĂƌĂŶĐĞĂůŽŶĞǁĂƐŚŝŐŚĞƌŝŶƉĂƚŝĞŶƚƐA? ? ĐŽŵƉĂƌĞĚƚŽAM ? ?ǇĞĂƌƐŽůĚ ? ? ?A?




Morphology was related to aneuploidy in a study of 500 embryos from 93 patients (Alfarawati et 
al., 2011). A association was found between embryo quality and ploidy status but this was not a 
strong association. That is, 50% of higher grade embryos were euploid compared to 37.5% of 
poorer quality embryos. Inner cell mass and trophectoderm grades were also affected by 
aneuploidy in a negative way. However some of the best quality embryos were aneuploid and 
some of the poorer quality embryos were chromosomally normal. A moderate relationship was 
shown in a retrospective study between blastocyst morphology and aneuploidy using PGS data 







(Capalbo et al., 2014b) but implantation ability was governed by the chromosomal complement 




Trophectoderm and ICM quality have been correlated with live birth outcome in two single 
embryo transfer studies. The conclusions were that TE quality was the most important factor in 
predicting live birth outcome but neither study specified the age of patients. (Ahlstrom et al., 
2011; Hill et al., 2013) In the current study, TE quality appears to be more indicative of ploidy 
status than ICM quality whereas in patients 40 and older, ICM quality is more indicative of ploidy 
status when choosing embryos for transfer. However, when using a more detailed classification 
of ICM morphology, implantation potential has been predicted more accurately, with the shape 
and size being clinically important as a predictor of success (Richter et al., 2001). Day 5 expanded 
blastocysts with slightly oval ICMs implanted at a higher rate (58%) compared with those with 
either rounder ICMs (7%) or more elongated ICMs (33%). Implantation rates were highest (71%) 
for embryos with both optimal ICM size and shape. In the current study a detailed classification 
of the ICM was not performed and a gross overall appearance of the ICM as a distinct cohesive 
clump of cells was classed as a good quality ICM. 
 
 
The technique for choosing embryos that perhaps has received the most attention in recent years 
is the study of morphokinetics. Precursors to the latest morphokinetic studies using time-lapse 
photography, involved taking the embryo out of the incubator at certain developmental junctions 







and observing if an event had occurred. One study showed that if the first cleavage division 
occurred before 25 hours post insemination an embryo was twice as likely to develop to an 
expanded blastocyst compared to an embryo that failed to cleave within 25 hours post 
insemination (32% vs 16%) (Fenwick et al., 2002). Recent advances in time-lapse technology have 
allowed constant, undisturbed observation of embryo growth patterns. Timing of early cleavage 
events predict with some accuracy embryos which will ultimately form a blastocyst but not 
embryos that are chromosomally normal (Herrero and Meseguer, 2013; Meseguer et al., 2012; 
Paternot et al., 2013). The development of a risk classification system using time-lapse 
photography in conjunction with biopsy and chromosomal analysis showed that the timing from 
the start to the end of blastulation is predictive of ploidy status and resulted in live birth rates 
per embryo similar to those seen after replacing known euploid embryos (61% with 
morphokinetics blastulation assessment vs 69% using chromosome analysis)(Campbell et al., 
2014a). Interestingly using our own data , morulae on day 5 (pre-blastulation) that continued to 
grow to fully expanded blastocysts on day 6 had a much lower rate of aneuploidy than embryos 
that had just begun to blastulate on day 5. This supports previous findings (Kroener et al., 2012) 
which found that delayed blastulation does not in itself result in higher rates of aneuploidy but 
that, if blastulation does not occur at all the rates of aneuploidy are high. Therefore if a morula 
carries on growing to an expanded blastocyst then it has a good chance of being chromosomally 
normal as shown by our own data. The convention has been to choose more advanced embryos 
using traditional static morphology for transfer from a cohort. If all that were available on day 5 
were early blastocysts or morulae then an embryologist would be far more likely to choose the 







early blastocyst over a morula. One might conclude that if all that are available on day 5 are early 
blasts or morulae then maybe the transfer should be carried out on day 6 if the embryos continue 
to progress and choose for transfer the embryos that were at the morula stage on day 5. 
 
 
Our own data set suggests that, although there may well be associations between growth rate 
and aneuploidy, the relationship is by no means a simple one. Finding, as we did, that faster 
growing embryos ready for biopsy by day 5 were more likely to be chromosomally normal than 
slower growing embryos not ready for biopsy until day 6, suggests a simple association, albeit in 
only certain age groups. Finding an apparently paradoxical phenomenon when looking at the day 
6 ready group only (i.e. that the ones that reached early blastocyst on day 5 were more likely to 
be chromosomally abnormal compared to embryos that had not yet begun to cavitate on day 5) 
however suggests a complex pattern that needs further investigation. In other words, growth 
rate criteria (whether determined by time lapse or, as in this case, by static criteria) need to be 
viewed with caution and skepticism when trying to draw conclusions about levels of aneuploidy. 
 
 
In conclusion, it seems that there is yet to be found a morphokinetically based assessment that 
will predict with accuracy which embryo to choose without analyzing the chromosome 
complement of an embryo; this can currently only be achieved by embryo biopsy. Moreover, 
correlating the end point morphology of an embryo to its ploidy status tell us that embryos that 
we may have dismissed as poorer quality may often be euploid and embryos that we deem to be 
good quality may be  aneuploid  (Alfarawati et  al., 2011;  Capalbo et  al.,  2014b). Static Embryo 







morphology assessment thus has a place in predicting embryo viability but has limitations in 
predicting the likelihood of an embryo being euploid. It is possible that we should be looking at 
different parameters for different patient populations, perhaps for instance choosing embryos 
with better quality ICMs for the >40 patients (if there is a choice) but focusing on the 
trophectoderm in other age groups. Time lapse evaluation of morphokinetic events should be 
viewed with caution when using that alone to attempt to decide ploidy status as further studies 
need to be performed to establish association between morphokinetic event timing and ploidy 
status (Natesan S, 2014). A combination of chromosomal analysis and time-lapse observations of 
morphokinetic criteria or more detailed static morphological observations may help inform 
future studies aimed at choosing the best embryo for transfer. For the moment however, the use 
of morphology or growth rate for the prediction of aneuploidy remains ineffective. 







2.2.2   Specific aim 1b 
 
To test the hypothesis that we can use cell free DNA in spent media to quantify ploidy 
status non-invasively: A study of 3 different amplification methods and cell free DNA 
stability. 
ŶĂďƐƚƌĂĐƚƐƵďŵŝƚƚĞĚƚŽ^,Z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2.2.2.1 My Personal Contribution to the Work 
 
I collaborated with the Oxford laboratory team, thawed and biopsied embryos, tubed spent 
media, directed clinic study protocol. Contributed to abstracts and wrote this manuscript. 
 
 
2.2.2.2 Chapter Summary 
This is an ongoing project designed to establish if cell free DNA in spent culture medium 
correlates with ploidy status of the blastocyst. The study was performed on 33 cryopreserved 
embryos from 7 patients that had been previously diagnosed as euploid or aneuploid by NGS and 







were donated to research according to patient wishes and 45 fresh embryos from 4 patients 
analyzed as part of the IVF cycle. All of these embryos were created using intra-cytoplasmic sperm 
injection (ICSI). Cryopreserved embryos were thawed and individually cultured in 3ul droplets for 
24 hours. Fresh embryos were individually cultured in 3ul droplets from day 3 to day 5 for 48 
hours. All spent media samples were collected using single use stripper tips(origio)once the 
embryo had been removed and were placed in individual microfuge tubes labelled with the 
corresponding embryo number. Samples were frozen in a -20oC freezer post biopsy for varying 
lengths of time before amplification with 3 different methods. The novel amplification method 
based on modified MDA resulted in the highest rate of successful reads (38/40 95%) followed by 
Sureplex (12/19 63%) and lastly traditional MDA (5/19 26%). All the amplification methods fared 
best when the time between sampling and amplification was only 12 hours compared to 17-28 
days. From this initial experiment, the most concurrent results were from frozen thawed embryos 
cultured for only 24 hours using the novel amplification method. 32/36 (89%) embryos amplified 
with the NAM gave a concurrent ploidy status between the spent media and the biopsy sample. 
When gender was inconcurrent, all of the spent media samples were female and the biopsies 
were male. Non concurrent gender was only seen in the fresh embryos cultured for 48 hours. As 
all of these were female in spent media and male in the biopsy proper, this could be attributed 
to cumulus contamination. This would be more likely to have been present in the spent media 
on day 3-5 compared to embryos that had been biopsied, frozen and thawed before placing in 
spent media, thus more thoroughly removing potential cumulus contamination before placing in 







the media to be subsequently tested. Further experiments are needed to refine the technique 
but results are encouraging for this novel strategy for noninvasive PGS. 
2.2.2.3 Introduction: 
 
Spent culture media has been considered as a source of embryonic DNA. If concurrence could be 
achieved between nuclear DNA from a trophectoderm biopsy and cell free DNA in the spent 
media then the need for invasive biopsy to determine ploidy status may be superfluous. Only 2 
studies have been published to date. The first study was a proof of concept study by Shamonki 
et al (Shamonki et al., 2016). They placed day 3 embryos in single 15ul culture drops and grew to 
day 5, at which point the embryo was removed and the spent media was tubed and the embryo 
was biopsied. The spent media and biopsied cells were amplified using Repli-G (Qiagen). 55 of 
the 57 spent media samples had detectable levels of DNA but only 6 of these were suitable to be 
analyzed. One of the 6 gave a reliable result with aCGH which was concurrent with the nuclear 
DNA samples from the trophectoderm biopsy. The only other study investigating cell free DNA in 
spent media was by Xu et al (Xu et al., 2016). They completed the first clinical transfers of 
embryos to patients based on the spent media DNA analysis alone. They termed the method 
Non-Invasive Chromosome Screening or NICS. They carried out an initial study establishing 
concordance between biopsy results and NICS. To validate their results, 43 embryos were 
cultured from day 3 to day 5 and the spent media drops and biopsy samples were analyzed 
concurrently. 21 embryos diagnosed as euploid from the biopsy had a concurrent result from the 
NICS. 16 embryos diagnosed as aneuploid from the biopsy had an aneuploid result from the NICS 
(although only 6/16 had the exact same losses or gains). There were 2 false negative results 







where the NICS was euploid and the biopsy was aneuploid and 4 false positives where the NICS 
was aneuploid and the biopsy was euploid. 86% of the embryos therefore had a concurrent result 
between the biopsy and the NICS and 14% of embryos had a non-concurrent result overall. Their 
clinical application involved 7 patients and 9 embryo transfers replacing embryos solely 
diagnosed as euploid by NICS. The 9 transfers resulted in 6 live born allegedly chromosomally 
normal babies (authors stated that a karyotype had been performed). The DNA amplification 
method used in this study was the MALBAC (Multiple Annealing and Looping Based Amplification 
Cycles) WGA method, which amplifies the original DNA strands rather than amplifying copies of 
copies, and the products were analyzed on an Illumina HiSeq NGS platform. 
 
 
Cell free DNA is fragmented in segments of around 200bp in size(Fan et al., 2010). These DNA 
fragments are not as stable before amplification as nuclear DNA. The present study considered 
the length of time from sampling to the time of processing to achieve successful DNA 
amplification. Traditional amplification methods may not be as accurate in amplifying these 
smaller fragments and may be the cause of incongruous results between nuclear DNA and cell 
free DNA when using methods of amplification routinely used for nuclear DNA. An alternative 
modified MDA based amplification method is currently being investigated (here referred to as 
 “ŶŽǀĞůĂŵƉůŝĨŝĐĂƚŝŽŶŵĞƚŚŽĚ ?Žƌ “ED ? )ĂŶĚƚŚĞƌĞƐƵůƚĂƌĞƉƌĞƐĞŶƚĞĚŝŶƚŚŝƐĐŚĂƉƚĞƌ ? 







2.2.2.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
Patients who had consented to the use of leftover DNA as part of their IVF cycle with PGS for 
aneuploidy were included in the study. All embryos were created using ICSI as a method of 
fertilization which eliminates sperm contamination. 
Cell free DNA in 78 spent media samples from blastocyst culture were amplified utilizing three 
different whole genome amplification (WGA) strategies. Fresh Embryos were placed in individual 
3ul pre-equilibrated drops of Sage Blastocyst culture medium (Origio, US) with 10% HSA (Irvine, 
CA) under oil (Ovoil, Vitrolife), for culture from day 3 until day 5. On day 5, all embryos were 
examined for stage of growth. 
 
 
Embryos reaching the expanded blastocyst stage were allocated a number which was written by 
the drop under the dish. Biopsy drops were made using 37oC HEPES buffered media (Sage, Origio) 
with 5% HSA under oil. Each Blastocyst designated for biopsy was removed from its culture media 
drop in a minimal amount of fluid using a new stripper tip for each embryo and placed in its 
appropriately labelled biopsy drop. Each spent media drop was placed in a microfuge tube 
labelled with the embryo number again using a fresh stripper tip for each drop. The embryos 
were biopsied as usual and vitrified for future use. 







Vitrified embryos with known PGS results were warmed as per protocol and cultured for 24 hours 
before sampling spent media. Control media droplets (no embryo exposure) were collected to 
confirm an absence of DNA in the media itself. 
 
 
Tubing of samples was carried out with the tube rack on a cold pack and the tube rack was placed 
in a -20 freezer as soon as possible after tubing. Samples were amplified as soon as possible post 
sampling and this ranged from less than 12 hours to 28 days. Amplification in the genetic lab was 
in house and then amplified DNA was hand carried on cold gel packs as carry-on luggage from 




Samples were split into 3 groups for amplification: 1) Sureplex amplification (Illumina); 2) 
Multiple Displacement Amplification (MDA, Qiagen); 3) novel amplification method (NAM). 








Fourteen of 19 samples of spent media amplified with MDA had no reads (74%), 7 of 19 samples 
amplified with Sureplex had no reads (37%) independent of the amount of time the samples had 
been stored at -20oC. The novel amplification method (NAM) resulted in 2/40 (5%) no reads (1/30 







(3%) processed after 0.5 days post sampling, 1/10 (10%) processed after 17-28 days post 
sampling), therefore 95% had a spent media result. With the NAM 36 embryos had a result for 
both the biopsy and the spent media. Of those, the spent media and biopsy diagnosis of 
aneuploid or euploid was concurrent in 32/36 embryos (89%). Three of these samples were 
diagnosed with a concurrent euploid diagnosis but with the opposite gender. 5 of the samples 
gave inconcurrent results. (3 x aneuploid biopsy vs euploid spent media, 1 x euploid biopsy vs 
aneuploid media and 1 x euploid biopsy vs aneuploidy media but different genders). Three of 30 
media samples processed within a day of sampling had a complete discordance of the 
euploid/aneuploid diagnosis (10%) vs 2 of 10 (20%) of samples stored for 17-28 days. 
 
 
Results for the spent media incubated for 24 hours were more likely to have concurrent results 
with the original biopsy compared to 48 hours of incubation. Of the 25 frozen thawed samples 
using the NAM, only 2 gave a non-concurrent diagnosis and these 2 embryos had a mosaic only 
profile in their original biopsies. Of the 28 frozen thawed samples with all 3 amplification 
methods none had an opposite gender result but all 6 of the embryos with opposite genders in 
the spent media result to the biopsy were from fresh embryos. 3 embryos had a result for the 
spent media but a no read result for the biopsy. Amplification and analysis of the control media 
droplets confirmed absence of human DNA. 








Embryo state Fresh (48 hour culture) Frozen 
(24 hour culture) 
Total 
Time in -20oC prior to amp 28 days 17 days 0.5 day 0.5 day  
# embryos screened 4 6 5 25 40 
# results from spent media 3 6 4 25 (100%) 38 (95%) 
# with results for both 
media and biopsy 
3 6 3 25 37 
# concurrent ploidy results 
%/embryo with both 
results 




# non concurrent ploidy 
status 
1 1 1 2 5 
# concurrent ploidy status 
but non concurrent gender 
0 3 0 0 3 
# non concurrent ploidy 
status and gender 
0 0 1 0 1 
# no read bx but results 
from spent media 
0 0 1 0 1 








Embryo state Fresh (48 hour culture) Frozen 
(24 hour culture) 
Total 
Time in -20oC prior to amp 28 days 17 days 0.5 day 0.5 day  
# embryos screened 4 6 5 4 19 
# results from spent media 1 5 4 2 12(63%) 
# with results for both 
media and biopsy 
1 5 4 2 12 
# concurrent ploidy results 1 3 4 2 10/12 (83%) 
# non concurrent ploidy 
status 
0 0 0 0 0 
# concurrent ploidy status 
but non concurrent gender 
0 2 0 0 2 
# non concurrent ploidy 
status and gender 
0 0 0 0 0 
# no read bx or spent 
media 
0 0 1 0 1 
Table 11: spent media results of Sureplex amplification 









Embryo state Fresh (48 hour culture) Frozen 
(24 hour culture) 
Total 
Time in -20oC prior to amp 28 days 17 days 0.5 day 0.5 day  
# embryos screened 4 6 5 4 19 
# results from spent media 1 1 2 1 5(26%) 
# with results for both 
media and biopsy 
1 1 0 1 3 
# concurrent ploidy results 0 0 0 1 2/5 (40%) 
# non concurrent ploidy 
status 
1 1 0 0 2 
# concurrent ploidy status 
but non concurrent gender 
0 0 0 0 0 
# non concurrent ploidy 
status and gender 
0 0 0 0 0 
# no read bx but results 
from spent media 
0 0 2 0 2 







As aneuploidy is the main cause of implantation failure or miscarriage in human reproduction 
(Franasiak et al., 2014b; Harton et al., 2013; Kushnir and Frattarelli, 2009; Lathi and Milki, 2004; 
Munne et al., 2007a; Taylor et al., 2014a; Werner et al., 2012), establishing which pre- 
implantation embryos are euploid before transfer in a clinical setting has improved sustained 
implantation rates for patients undergoing IVF with PGS (Forman et al., 2013b; Schoolcraft et al., 
2010; Scott et al., 2012). Biopsy of embryos is currently the only reliable method of establishing 
ploidy status in pre-implantation embryos before transfer. 
 
 
Day 3 biopsy has been studied to assess the effects of single cell removal on embryo growth, 
implantation and effects on offspring. Bar-El et al (Bar-El et al., 2016) used Embryoscope time 







lapse incubators to compare growth patterns of 366 embryos biopsied for PGD with 385 embryos 
that had not been subjected to blastomere removal. They demonstrated that day 3 biopsied 




The removal of a portion of the trophectoderm layer (3-10 cells) for analysis seems to have little 
negative effect on the embryos ability post biopsy to give rise to viable offspring. Implantation 
rates of biopsied and non-biopsied day 3 and blastocyst stage embryos were compared in an 
elegant study by Scott et al (Scott et al., 2013b). This randomized controlled trial transferred 2 
embryos to each patient. Some patients were allocated to day 3 transfer and some patients were 
allocated to day 5 transfer according to the clinics standard protocol. Two embryos of equal 
morphological appearance were chosen for transfer and labelled as A or B before randomization. 
A and B were then randomized to either biopsy or control by way of sealed envelopes. One of 
the embryos was biopsied just before transfer and the other embryo remained intact. Ploidy 
status of the biopsied embryos was discovered several weeks post transfer. If a singleton 
pregnancy resulted the infant underwent DNA fingerprinting to establish which embryo it arose 
from. Day 3 embryo biopsy decreased sustained implantation rates significantly compared to 
non-biopsied day 3 embryos (30% biopsied vs 50% control). Blastocyst biopsied embryos showed 
no significant decrease in implantation rates compared to the non- biopsied blastocyst controls. 







BhCG levels of pregnancies resulting from biopsied euploid blastocyst stage embryos have been 
shown to be lower than from non- biopsied embryos. (Olcha et al.) This suggests that we are 
indeed altering the implantation process in some way by removing cells from the trophectoderm. 
 
 
Follow-up studies of offspring post embryo biopsy have only been carried out post day 3 biopsy. 
(Desmyttere et al., 2009; Liebaers et al., 2010; Sunkara et al., 2017) and the conclusions have 
been that there is no apparent evident negative effects seen in offspring. Outcome studies of 
offspring resulting specifically from embryos biopsied at the blastocyst stage have not been 
carried out to date. 
 
 
Each individual transferred euploid embryo biopsied at the blastocyst stage has a 60% chance of 
giving rise to a live baby independent of maternal age (own data). If the effects of the biopsy 
procedure were removed and embryos were diagnosed as euploid by analyzing spent media 




The potential for creating mosaic results during the biopsy procedure by the application of laser 
pulses to separate trophectoderm tissue for sampling has been hypothesized by Illkevitch et al 
(Illkevitch Y1, 2017). They developed a novel biopsy technique where the cells were removed by 
using the surface tension between the media droplet and the mineral oil overlay to pull cells from 
the trophectoderm layer. They stated that the cells were less sticky than after laser removal. 55 







embryos were biopsied using the novel method and 87 embryos were biopsied with a laser. There 
were no mosaic results for any of the embryos in either group. As the numbers were small they 
were unable to conclude that this was due to the novel biopsy technique. This is the first inkling 
that the biopsy process may have the potential to create errors in the sample itself. 
 
 
The potential for contamination with extra-embryonic DNA of the media drops to be tested is 
not an insignificant risk. DNA contamination can be from the culture media as human serum is 
used as a supplement, it can be from cumulus cells or sperm remaining on the zona pellucida, 
residual sperm stuck to the zona pellucida, or it could be from the operator handling the samples 
and loading the sample tubes. This study included analysis of control drops of media that had not 
come into contact with embryos. All of the controls came back with no DNA contamination. The 
embryos all underwent ICSI as part of their IVF cycle therefore reducing possible sperm 
contamination. All 8 embryos from the 3 groups that had the opposite gender in the spent media 
to the original biopsy sample, were from fresh embryos cultured for 48 hours. All of these spent 
media genders were female and the biopsies were male. It is possible that cumulus cell 
contamination remaining in the culture drop could have been responsible for the gender 
confusion. Frozen thawed embryos would have less cumulus cell contamination than fresh as 
they pass through many drops of media, from the biopsy drop to a holding drop, through 5 
vitrification solution drops, and then plunged into liquid nitrogen (LN2). During the warming 
procedure they are again  passed  through 4  drops of diluent  until they are  placed  in a culture 







media drop. Therefore during fresh culture, embryos would have to be extensively rinsed to 
remove all cumulus cells from the zona pellucidae. 
The length of time that embryos remain in the media drops before testing the media may be 
important. Results for the 24 hour period of culture were more concurrent than the fresh samples 
cultured for 48 hours. Cell free DNA degrades quickly compared to nuclear DNA, therefore if 
embryos remain in the same droplet for 48 hours, the cell free DNA from day 1 of micro drop 
culture may degrade and mix with the newly generated cell free DNA giving spurious results. A 




The cost of spent media sampling and handling would potentially cost less than the cost of the 
biopsy procedure. There would be no micromanipulation and therefore no holding or biopsy 
pipettes needed to purchase. However, the processing of the spent media is still very detailed 
and time consuming for the lab. When removing the embryo from the media drop, extreme care 
has to be taken to aspirate a minimal volume along with the embryo so as to leave behind enough 
for testing. Each 3ul drop of spent media still has to be carefully sampled and placed into 
individual tubes therefore the cost of sampling would not fall to zero. However the cost of the 
analysis of the spent media would remain the same as for an actual biopsy as each sample would 
be processed in the same way as a cellular biopsy. The embryos would still have to be vitrified to 
allow for results of the spent media analysis to be concluded. Therefore the only time saving over 
biopsy would be on average 15 minutes per case depending on the number of available embryos. 







Three of the results in this study had a no read result for the biopsy sample but did have a result 
for the spent media. When biopsying an embryo, there is a chance of obtaining a no read or 
chaotic result in 2-3% of biopsied blastocysts. This means that, either the cells were degenerating, 
the sample was too small or the sample was not placed in the testing tube. If needed, we thaw, 
re-biopsy and refreeze the embryo in order to get a definitive result. Taylor et al (Taylor et al., 
2014b) showed that thawing non screened embryos for PGS and then refreezing, had a negative 
effect on subsequent survival of the embryos (87% for twice frozen/thawed vs 98% for once 
frozen thawed) but once they had survived the twice frozen group resulted in pregnancies with 
the same rate as their once frozen thawed counterparts. There is little data on the effect of 
biopsying blastocysts twice in addition to multiple freeze/ thaw events. 
 
 
It is possible if we can reach a stage of confidence with analyzing spent media that we could use 
the spent media as a secondary result and reduce the need for re-biopsy of no read result 
embryos. The other practical use for this methodology may be that we could use spent media 
analysis for a previous no read biopsy result and just culture the embryo overnight rather than 




Further studies are needed to assess the potential for non-invasive PGS in fresh cycles as a 
replacement for biopsy. The protocol needs to be optimized to decide the following: length of 







time in culture before sampling, temperature to store the samples before amplification, time 
from sampling to amplification and fine tuning of processes to minimize cumulus contamination. 
 
 
Noninvasive PGS would be revolutionary by reducing potential risks to the embryo. As the basic 
tenet of any good embryology lab is to keep the process as simple and as near to physiologically 
normal as possible then to reduce micromanipulation to the embryo can only be a good thing. It 
may in fact give rise to more accurate representation of the embryo proper if cells are being 
damaged during the biopsy process. A further trial is planned to optimize the process and to 
further correlate biopsy and spent media samples in the initial embryo creation cycle. 







2.3 Specific aim 2 
 
To determine if the technique of ICSI creates embryonic aneuploidy 
 
dŚŝƐ ŝƐ ĂĚĚƌĞƐƐĞĚ ŝŶ ƚŚĞ ƉĂƉĞƌ ĞŶƚŝƚůĞĚ  ? dŚĞ ƵƐĞ ŽĨƐƵďŽƉƚŝŵĂů ƐƉĞƌŵ ŝŶĐƌĞĂƐĞƐ ƚŚĞ ƌŝƐŬ ŽĨ
ĂŶĞƵƉůŽŝĚǇŽĨƚŚĞƐĞǆĐŚƌŽŵŽƐŽŵĞƐŝŶƉƌĞŝŵƉůĂŶƚĂƚŝŽŶďůĂƐƚŽĐǇƐƚĞŵďƌǇŽƐ ?tƌŝƚƚĞŶďǇůŝƐŽŶ
Coates, John Hesla, Amanda Hurliman, Breanne Coate, Elizabeth Holmes, Rebecca Matthews, 
Emily Mounts, Kara Turner, Alan Thornhill and Darren K Griffin . Published in Fertility and Sterility 
(Coates et al., 2015) 
 
 
2.3.1 My Personal Contribution to the Work 
 
I biopsied some of the embryos, retrospectively analyzed the data generated during clinical IVF 
cases and I wrote and edited the paper. 
 
 
2.3.2 Chapter Summary 
 
This chapter discusses the hypothesis that the ICSI procedure may contribute to embryonic 
aneuploidy. Patients undergoing IVF with normal semen parameters were advised to have 
standard insemination or ICSI to achieve optimal fertilization rates based on the following 
criteria: 
x Standard insemination: Couples using fresh sperm where the male partner had had 
previous naturally occurring pregnancies. 







x ICSI: Patients using frozen sperm or fresh sperm from male patients without a history of 
natural conception. 
568 patient cycles were into 2 main groups: Patients less than 40 years of age using their own 
oocytes and patients using young donor oocytes. Within these groups, aneuploidy rates with and 
without ICSI were considered. Aneuploidy rates were similar for patients using ICSI or standard 






Intra-Cytoplasmic Sperm Injection (ICSI) is used routinely during the IVF cycle to achieve 
fertilization. Originally used for male factor infertility it is increasingly used for patients with 
normal semen parameters for example if the sperm is frozen, which allows analysis of data from 
ICSI created embryos that have not been created with sub-optimal sperm . As there is evidence 
that sperm from patients with male factor infertility have higher rates of aneuploidy than patients 
with normal parameters (Bernardini et al., 2005; Tempest and Griffin, 2004) the assumption 
remains that this could translate into a higher rate of aneuploidy in resulting embryos. Removing 
this population from the data analysis therefore refines the parameters and only considers the 
ICSI technique alone as a possible mechanism or not for increasing rates of aneuploidy. 
 
 
As the technique itself is invasive , it has been suggested that it may have the potential to be 
detrimental to embryo development in several ways (Griffin et al., 2003). ICSI has been shown to 







compromise sperm nuclear de-condensation, possibly leading to aneuploidy in the embryo 
(Terada Y1, 2000). The ICSI process has the potential to disrupt the oocyte spindle apparatus 
when the ICSI needle passes through the oolemma into the center of the oocyte, possibly leading 
to abnormal patterns of chromosome segregation (Van Der Westerlaken et al., 1999). Finally, the 
oocyte may be handled outside of the incubator for a longer period of time during ICSI as 
compared to standard insemination, during cumulus cell removal with hyaluronidase, and 
injection of sperm. Slight temperature and pH changes during micromanipulation may increase 
the possibility of stress-induced aneuploidy (Dumoulin et al., 1999; Munne et al., 1997; Swain et 
al., 2016). All of these interventions associated with the ICSI technique have the potential to 
impair chromosome segregation in the oocyte and subsequently the cleaving embryo. 
 
 
If the ICSI process itself induces aneuploidy, one would expect that all ICSI treatments would 
show an increase in embryo aneuploidy as compared to standard insemination cycles, regardless 
of sperm quality. To date there has not been a published study definitively establishing whether 
the ICSI process itself creates aneuploidy in pre-implantation embryos. ICSI conceived products 
of conception (POC) have been analyzed and compared to naturally conceived and IVF conceived 
POCs. (Lathi and Milki, 2004) (Wu et al., 2016) (Bingol et al., 2012) and showed no increase in 
overall aneuploidy rates between the two groups. 
 
 
Testing the ploidy status of pre-implantation embryos via trophectoderm biopsy and 
preimplantation genetic screening (PGS) is now a routine practice in many IVF centers throughout 







the world. The objective of this study was to test the hypothesis that aneuploidy frequency (sex 




2.3.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
Between August 2010 and March 2015, 586 couples underwent IVF using either ICSI or standard 
insemination with normal semen parameters. A total of 3683 embryos resulting from these cycles 
were tested for aneuploidy by trophectoderm (TE) biopsy followed by preimplantation genetic 




All male patients underwent semen analysis before the IVF cycle commenced and again on the 
day of the oocyte retrieval to determine whether ICSI or standard insemination would be 
employed to achieve fertilization. Parameters measured included sperm density/mL, forward 
progression, speed of progression, percent normal forms (WHO 4th edition), and anti-sperm 
antibody binding. (WHO, 2010) Patient history was also taken into account when deciding which 
method of insemination was to be used on the retrieval day. Only patients with normal semen 
parameters were included in this analysis and the reason for performing ICSI with normal semen 







parameters were: the use of frozen sperm, many years of unexplained infertility without a 
pregnancy, or previous poor fertilization using standard insemination in an earlier IVF cycle. 
For standard Insemination, 15,000 sperm were placed with each cumulus-oocyte complex on the 
day of oocyte retrieval. The ICSI procedure was performed on all mature oocytes as described 
elsewhere (Van Der Westerlaken et al., 1999). 
 
 
Any possible effect of the ICSI procedure itself was controlled for by comparing rates of 
aneuploidy in embryos derived from the control group involving standard insemination with 
normal sperm and ICSI with normal sperm. Finally, in order to control for maternal age, the 
groups were further sub-ĚŝǀŝĚĞĚ ŝŶƚŽ  “ŽǁŶ ŽŽĐǇƚĞƐ ? ĂŶĚ  “ĚŽŶŽƌ ŽŽĐǇƚĞƐ ? ǁŝƚŚ ƚŚĞ mean 
maternal age near identical in both cases (35.3- ? ? ? ?ĨŽƌ “ŽǁŶŽŽĐǇƚĞƐ ?ĂŶĚ ? ? ? ?- ? ? ? ?ĨŽƌ “ĚŽŶŽƌ
ŽŽĐǇƚĞƐ ? ) ? Thus, four groups were examined in total and differences in aneuploidy rates for each 
chromosome pair evaluated by Fishers exact test (significance set at p=<0.05). 
 
 
Institutional review board approval was obtained for review of patient charts and laboratory data 
for this study. The study was also approved by the University of Kent Local Research and Ethics 
Committee. 









Our results are summarized in table 13. Each chromosome pair is considered individually and the 
data set broken down into couples in which their own oocytes were used and in which donor 
oocytes were used. In both groups, standard IVF (first column) is compared to ICSI with normal 
ƐĞŵĞŶ ƉĂƌĂŵĞƚĞƌƐ  ?ƐĞĐŽŶĚ ĐŽůƵŵŶ ) ? &Žƌ ďŽƚŚ  “ŽǁŶ ŽŽĐǇƚĞƐ ? ĂŶĚ  “ĚŽŶŽƌ ŽŽĐǇƚĞƐ ? ƚŚĞ ŵĞĂŶ
maternal age was near identical within the three groups i.e. 35.5 and 35.3 respectively for the 
 “ŽǁŶ ŽŽĐǇƚĞƐ ? group, and 24.9, 25.0 for the  “ĚŽŶŽƌ ŽŽĐǇƚĞ ? group. The greatest number of cycles 
involved ICSI with normal sperm (262 and 222 respectively). When standard insemination was 
compared to ICSI with normal sperm, no significant difference was seen, either when considering 
overall aneuploidy, overall autosomal aneuploidy, sex chromosome aneuploidy or aneuploidy of 
any individual chromosome. 







 Group 1 own oocytes <40 P value Group 2 donor oocytes P value 
 std insem ICSI normal sperm  Std insem ICSI normal sperm  
Ave age 35.5 35.3  24.9 25  
# cycles 77 262  25 222  















































XO x 12,OY 
XXYY,XXX x4 






XO x20,OY x2 
XYY x2,XXY x9 
XXX x2 
>0.05 
1 2.3 1.5  1.4 1.4  
2 2 1.7 1.4 1.5 
3 1.6 1.5 1.4 1 
4 1 1.9 1.4 1.4 
5 2 1.6 1.4 1.4 
6 2.6 2.8 2.4 1.8 
7 2.6 2.8 2.4 1.8 
8 2.9 1.5 1.4 1.8 
9 1.8 1.7 1 1.2 
10 2.6 1.4 1 1.3 
11 0.8 1.8 1.4 1.1 
12 0.8 1.1 1.4 0.9 
13 3.1 2.4 0.5 1.5 
14 1.3 2.6 0 1.4 
15 4.9 3.9 1.9 1.4 
16 7.5 7 2.4 3.4 
17 1.6 1.2 1.4 0.5 
18 3.6 2.3 1 1.3 
19 4.7 2.6 1.4 1.3 
20 2.9 1.8 0 1 
21 6.2 5.5 1.4 1.5 
22 3.9 5.8 1.4 1.6 
Table 13: Comparing embryonic aneuploidy rates for ICSI vs sta>0ndard insemination with normal sperm 









Since the implementation of ICSI over 20 years ago, IVF babies born using both ICSI and standard 
insemination techniques have been followed closely to assess rates of major birth defects as 
compared to spontaneously conceived babies. There appears to be an equal, modest increase in 
major birth defects with IVF-derived offspring as compared to naturally conceived offspring, 
whether ICSI or standard insemination are used to achieve fertilization in-vitro (Wen et al., 2012). 
This suggests that the complex IVF process as a whole, or an intrinsic aberration in the infertile 
population, is responsible for this increase, rather than the insemination method used. Indeed, 
follow-up of babies conceived via ICSI and standard insemination thus far have been relatively 
reassuring in that there appears to be no difference in cognitive or motor development, pubertal 
development, or major birth defects between standard insemination and ICSI-derived offspring 




Aneuploidy frequency in spontaneously aborted conceptuses conceived via ICSI compared to 
standard insemination has been examined with varying conclusions. Bonduelle et al reported 
increase in sex chromosome abnormalities and de novo chromosomal aberrations in pregnancies 
derived from ICSI with suboptimal sperm parameters as compared to standard insemination- 
conceived pregnancies (Bonduelle et al., 2002). Lathi et al also observed a marked increase in 
overall aneuploidy frequency in products of conception (POC) from ICSI patients compared to 
those derived from standard insemination (76% ICSI vs 41% IVF, P<0.01). 







Kushnir et al. observed similar overall rates of aneuploidy in POC between standard insemination 
and ICSI, although a small increase in sex chromosome abnormalities in the ICSI group was found 
(Kushnir and Frattarelli, 2009; Lathi and Milki, 2004). Again these studies did not consider sperm 
quality in their analysis. In one of the few studies analyzing aneuploidy rates of ICSI vs. standard 
insemination-derived embryos, Munné et al. found that ICSI embryos did not show an increase 
in aneuploidy rates compared to embryos created using standard insemination, unless the 
parents had a balanced chromosomal abnormality (Munne et al., 1998c). However, in that report, 
embryos were biopsied on day 3 and analyzed using FISH for chromosomes X, Y, 13, 16, 18, and 
21. Only a subset of the karyotype was therefore analyzed and the use of FISH for determining 
aneuploidy in human embryos has come under considerable scrutiny due to its limitations for 
chromosomal screening of pre-implantation embryos. 
 
 
In the results presented here, we controlled for any effect that the ICSI process might have on 
aneuploidy frequency by separately analyzing data of embryos created from normal sperm using 
ICSI and standard insemination techniques. Our study also suggests that, at least in terms of the 
risk of aneuploidy, the ICSI procedure using sperm with normal parameters is no more risky in 
creating aneuploid embryos than standard insemination. With the current findings and past 
studies in mind, patients undergoing ICSI as part of their IVF cycle with normal semen parameters, 
need not be counselled for increased embryonic aneuploidy rates based on the use of ICSI alone. 







2.4 Specific aim 3 
 
To establish novel patient populations that may benefit from the use of pre- 
implantation screening 
PGS is most commonly applied to patients of advanced maternal age and patients who have had 
repeated miscarriages, as they have a high risk of aneuploidy occurring in each embryo created 
(Harton et al., 2013; Shahine et al., 2016). Other categories of patient may also benefit from PGS 
and two novel patient populations are discussed in this chapter. 
 
 
2.4.1 Population number 1: Male factor infertility patients 
 
dŚŝƐ ŝƐ ĂĚĚƌĞƐƐĞĚ ŝŶ ƚŚĞ ƉĂƉĞƌ ĞŶƚŝƚůĞĚ  ? dŚĞ ƵƐĞ ŽĨƐƵďŽƉƚŝŵĂů ƐƉĞƌŵ ŝŶĐƌĞĂƐĞƐ ƚŚĞ ƌŝƐŬ ŽĨ
ĂŶĞƵƉůŽŝĚǇŽĨƚŚĞƐĞǆĐŚƌŽŵŽƐŽŵĞƐŝŶƉƌĞŝŵƉůĂŶƚĂƚŝŽŶďůĂƐƚŽĐǇƐƚĞŵďƌǇŽƐ ?tƌŝƚƚĞŶďǇůŝƐŽŶ
Coates, John Hesla, Amanda Hurliman, Breanne Coate, Elizabeth Holmes, Rebecca Matthews, 
Emily Mounts, Kara Turner, Alan Thornhill and Darren K Griffin. Published in Fertility and Sterility 
(Coates et al., 2015). 
 
 
This manuscript answers the question: do male factor infertility patients warrant counselling to 
consider utilizing PGS during the IVF cycle? The study design is described in the previous chapter 
addressing if the ICSI technique itself creates aneuploidy. 







2.4.1.1 My Personal contribution to the work 
 
I biopsied and cultured some of the embryos, retrospectively analyzed data generated as part of 
regular IVF cycles and I wrote and edited the paper. 
 
 
2.4.1.2 Chapter summary 
 
Aneuploidy rates of 3,242 ICSI generated blastocysts, created with oligozoospermic and 
normozoospermic semen samples were compared between July 2010 and December 2013. 
Overall aneuploidy rates between the 2 groups were similar however there was a significant 
increase in sex chromosome aneuploidy in embryos generated from males with oligozoospermia 
(6.6%) compared to embryos from normozoospermic males (3.3%). Data from January 2014 to 
December 2015 from a further 2127 donor egg generated embryos were subsequently added to 
the dataset post publication of the manuscript. Patients presenting with male factor infertility 
should be aware that the rates of sex chromosome aneuploidy when using suboptimal semen 





Studies have shown evidence of a significantly higher proportion of aneuploid sperm in the 
ejaculates of men with male factor infertility when compared to normal controls (Bernardini et 
al., 2005; Mehdi M1, 2012; Vegetti W1, 2000). A review of the literature by Tempest et al, 
demonstrated a clear association between suboptimal semen parameters, principally 
oligozoospermia,  and  increased  sperm  aneuploidy  rates  for  most  chromosomes  examined, 







although it was noted that patient parameters were not always clearly defined (Tempest and 
Griffin, 2004). Sperm of poor quality are frequently unable to penetrate an oocyte, either in-vivo 
or through standard insemination techniques in-vitro, possibly leading to failure of fertilization. 
To overcome this barrier to conception, intra-cytoplasmic sperm injection (ICSI) was developed 
and has found widespread, worldwide use as the treatment of choice for male factor infertility 
(Palermo et al., 1992; Van Steirteghem et al., 1993). Partly because of the increase in sperm 
aneuploidy associated with some infertile men, the rates of aneuploidy in the products of 
conception of nonviable pregnancies and the prevalence of birth defects and achievement of 
developmental milestones in children conceived through assisted reproduction have been 
studied. This has enabled the comparison of the outcomes of standard IVF, ICSI and natural 
conception and results have been relatively reassuring (Bonduelle et al., 2005; Kushnir and 
Frattarelli, 2009; Lathi and Milki, 2004; Sazonova et al., 2011). 
 
 
If the genetic component of sperm is the predominant risk factor for aneuploidy in the blastocyst 
embryo, one may expect that aneuploidy would be the most prevalent in embryos derived from 
the sperm of more severely oligozoospermic males (as the potential for sperm aneuploidy 
appears to be directly correlated with the severity of abnormalities in semen parameters). 







2.4.1.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
For the purposes of testing the hypothesis that it is the effect of compromised semen parameters 
that increase embryonic aneuploidy rate, patients were divided into 2 treatment groups: The first 
underwent ICSI with normal semen parameters (>19 x 106/ml, >30% gross normal morphology, 
>30% motility, WHO 4th edition). The second underwent ICSI but male patients were diagnosed 





In both the original published data and the updated dataset the sex chromosome aneuploidy rate 
was significantly greater in the oligospermic patient group than the group with normal sperm. In 
the original dataset, it was 6.1% in the oligozoopsermic group compared to 1.6% in the normal 
ƐĞŵĞŶĐĂƚĞŐŽƌǇ ?ƉA? ? ? ? ? ? )ĨŽƌƚŚĞ “ŽǁŶŽŽĐǇƚĞ ?ŐƌŽƵƉ ?ĂŶĚ ? ? ?A?ŝŶƚŚĞŽůŝŐŽǌŽŽƉƐĞƌŵŝĐŐƌŽƵƉ
compareĚƚŽ ? ? ?A?ŝŶƚŚĞŶŽƌŵĂůƐĞŵĞŶĐĂƚĞŐŽƌǇ ?ƉA? ? ? ? ? )ĨŽƌƚŚĞ “Ě ŶŽƌŽŽĐǇƚĞ ?ŐƌŽƵƉ ?/ŶƚŚĞ
reanalysis of newer data using donor oocyte only to minimize the maternal age variable, overall 
aneuploidy was similar in both the ICSI with normal sperm and ICSI with oligozoospermic sperm, 
but the original findings were reconfirmed in that the oligozoospermic group had a statistically 
significantly higher rate of sex chromosome aneuploidy at 5.5% of embryos biopsied compared 
to 3.3% in the embryos created with sperm with normal sperm parameters (p=0.03). 







There was no significant increase in overall aneuploidy as a result of ICSI with oligozoospermic 
males, nor in the overall rate of autosomal aneuploidy. In the original dataset, three individual 
autosomes however did show significantly increased levels of aneuploidy in the oligozoospermic 
group, namely chromosomes 1 and,2, (own oocytes) and chromosome 18 (donor oocytes). 
 
 
For each of these chromosomes in turn, the aneuploidy levels in the oligozoospermic samples 
were: Chromosome 1 - 7% (compared to 2.3 and 1.5% - p=0.01); Chromosome 2  W 6.0% compared 
to 2.0 and 1.7% - p=0.006; Chromosome 18  W 4.7% (compared to 1.0 and 1.3% - p=0.02). Other 
autosomes showed greater aneuploidy levels in oligozoospermic males but not at the level of 
statistical significance (threshold p<0.05). 
 
 
More data has been analyzed since the publication of the paper. This extended data set shown 
in table 15, using only donor oocytes to control for maternal age, confirms the previous finding 
at the time of publication of an increase in sex chromosome aneuploidies in embryos created 
from oligozoospermic samples vs normal semen parameters. In this larger data set than the 
original data there showed no increase in aneuploidies for any of the autosomal chromosomes. 







  Group 1 own oocytes P value Group 2 donor oocytes P value 
  ICSI  normal 
sperm 
ICSI   oligo 
sperm 





 Ave age 35.3 35.3  25 25  
 # cycles 262 31  222 12  
 # embryos 1300 114  1743 85  
 
Ave # embryos 
for biopsy 












































XO x 12, 
OY,XXYY, 
XXX x4 











OY x2,XYY x2 








 1 1.5 7 p=0.001 1.4 2.3  
2 1.7 6 p=0.007 1.5 0 
3 1.5 0.9  1 1.2 
4 1.9 4.4 1.4 3.5 
5 1.6 1.8 1.4 3.5 
6 2.8 2.6 1.8 1.2 
7 2.8 2.6 1.8 3.5 
8 1.5 2.6 1.8 2.3 
9 1.7 2.6 1.2 1.2 
10 1.4 1.8 1.3 2.3 
11 1.8 4.4 1.1 0 
12 1.1 0 0.9 3.5 
13 2.4 2.6 1.5 1.2 
14 2.6 0.9 1.4 2.3 
15 3.9 2.6 1.4 2.3 
16 7 5.3 3.4 5.9 
17 1.2 1.8 0.5 3.5 
18 2.3 0.9 1.3 4.7 p=0.03 
19 2.6 1.8 1.3 0  
20 1.8 1.8 1 1.2 
21 5.5 3.5 1.5 1.2 
22 5.8 7 1.6 2.3 
Table14: Embryonic Aneuploidy rates and chromosomes affected according to sperm quality 
(original data from the published manuscript) 







  ICSI normal sperm ICSI oligo sperm P value 
 Ave age 25 25  
 # embryos 3590 365  












OY x2, XO x 55, XYY x 23, 
XXY x 29, XXX x 8 
20 
5.5% 
XO x 13, XYY x 5, XXY x 2 
 
p=0.03 
 1 1.9 1.6  
2 2.1 3.6 
3 1.8 2.2 
4 2.0 2.5 
5 1.7 2.8 
6 2.0 1.6 
7 1.9 2.7 
8 2.2 1.6 
9 2.2 2.2 
10 1.3 1.0 
11 1.6 1.4 
12 1.4 1.9 
13 2.0 2.5 
14 2.1 1.4 
15 1.9 3.0 
16 3.6 3.0 
17 0.8 1.6 
18 1.5 2.7 
19 1.5 0.8 
20 1.6 2.7 
21 2.0 2.2 
22 2.3 3.6 
Table 15: Embryonic Aneuploidy rates and chromosomes affected (donor egg derived embryos 
only), according to sperm quality subsequent data analysis post publication of the manuscript to 
further support the differences between sex chromosome defects seen in the original dataset. 









The frequency of occurrence of sex chromosome abnormalities in live born offspring varies with 
the type of aneuploidy. Males with Klinefelter syndrome (47,XXY) occur 1 in 500 (0.2%) of live 
births (Visootsak and Graham, 2006) compared to 5 in 365 (1.4%) blastocyst embryos derived 
from oligozoospermic sperm in the extended dataset in this study. The prevalence of newborns 
with Turner syndrome is 32/10,000 (0.03%) and 176/100000 for fetuses at amniocentesis (0.18%) 
(Gravholt et al., 1996). In the extended dataset from the present study the rate of blastocyst 
embryos with monosomy X from the oligozoospermic group was 13/365 (3.6%). 
 
 
In humans, the majority of aneuploidies are maternal in origin. In the sex chromosomes however, 
while 47,XXX is 5% paternal in origin; 47,XXY is 50% paternal in origin and 100% of 47,XYY cases 
are paternally derived. For 45,XO, 75% of cases indicate that the remaining sex chromosome is 
maternal in origin, suggesting that the error arose on paternal meiosis (Griffin, 1996; Hassold T, 
1996). If increased sperm aneuploidy is indeed the underlying cause of our observations than we 
would therefore expect the effect to be seen predominantly in the sex chromosomes, rather than 
the autosomes and to observe proportionally fewer 47,XXX and 45,OY conceptuses. In our 
updated amended results (table 15), there were zero 47,XXX and zero 45 OY aneuploidies in the 
male factor group but these anomalies were present in the normal sperm group. 
 
 
In the original dataset, some autosomes showed a significant increase in the oligozoospermic 
group compared to the normal sperm group. Chromosomes affected were 1, and 2 in the  “ŽǁŶ 







ŽŽĐǇƚĞƐ ? group. Among spontaneous abortions, the larger chromosomes (up to chromosome 12) 
have greater paternal contributions to trisomy (Griffin, 1996; Hassold T, 1996) and it is 
noteworthy that all these autosomes fall into these category (including three of the largest four). 
In the  “ĚŽŶŽƌ ŽŽĐǇƚĞ ? group none of the autosomes apart from chromosome 18 showed elevated 
levels of aneuploidy for the oligozoospermic males. As a smaller chromosome, 18 is 
predominantly (96%) maternally derived (Griffin, 1996; Hassold T, 1996) so increased sperm 
disomy is unlikely to be the cause. The result may of course be a statistical anomaly and 
autosomal aneuploidy was not increased significantly in the latest dataset. One possible 
explanation if the dataset was representative is that trisomy 18 is the only autosomal aneuploidy 
of which we are aware that arises predominantly in maternal meiosis II. Human oocytes only 
complete meiosis II post-fertilization so perhaps a (genetically) sub-optimal sperm may impair 
subsequent segregation of maternal chromosome 18 more than any other. Some of these 
questions could be addressed in future studies by a molecular analysis of the phase and parent 
of origin of the aneuploidy, the ability to do this has recently been reported using SNP 
microarrays (Gabriel AS, 2011; Handyside et al., 2010). Such an approach is not trivial however 
as it would require taking and sampling parental DNA. This is not currently routine for ethical, 
logistical and cost reasons however if new approaches such as Karyomapping were implemented 
(Natesan S, 2014; Thornhill AR, 2015), it might become so in the future. 
 
 
Since studies have shown that oligozoospermic sperm samples have an elevated proportion of 
aneuploid sperm, one suggested clinical solution has been to screen the sperm of these patients 







using FISH to determine aneuploidy frequency prior to ICSI. One of the limitations of the present 
study was that only one semen parameter (sperm concentration) was considered for analysis. 
Further studies might involve asking whether any other specific semen parameters (apart from 
oligozoospermia) impact on blastocyst aneuploidy. Indeed, for the most part, studies have 
focused on oligozoospermia and Tempest et al (Tempest and Griffin, 2004) suggested that the 
sperm concentration was most likely to be correlated to the levels of sperm disomy than motility 
or morphology. A more recent study showed that men with poor sperm morphology that had 
repeated pregnancy loss had a higher occurrence of sex chromosome and autosome aneuploidy 
in their sperm than those with normal morphology (Ramasamy et al., 2015). These men also 
showed a higher rate of sperm aneuploidy with chromosome 18, 13 and 21. The clinical value of 
testing sperm samples with FISH to assess the proportion of aneuploid sperm may only be useful 
in helping to direct patients towards PGS testing of embryos if they had otherwise not been 
inclined to do so. 
 
 
In any event it is very unlikely that patients or clinicians (the groups that this data will affect 
most) will pay a great deal of attention to whether or not the abnormalities are paternally 
derived. Moreover, when we presented these preliminary results to the Pacific Coast 
Reproductive Society recently and 62% of 700 participants said that they would change their 
practice as a consequence of our findings. A further consideration is that we have only sampled 
a few cells from the trophectoderm, assuming the ploidy status to be representative of the rest 
of the embryo. Confined placental mosaicism (where cell derived from the trophectoderm differ 







in ploidy status to those derived from the inner cell mass) is nonetheless a well-described 
phenomenon (Griffin, 1996; Kalousek DK, 1992) with the errors of meiotic origin most likely 
leading to adverse clinical outcomes. Implementation of an approach that can not only 
distinguish parent, but also phase, of origin of the aneuploidy (Gabriel AS, 2011; Handyside et al., 
2010) would ultimately allow us to select against those embryos that arose as a result of 
fertilization with an aneuploid sperm. 
 
 
Given that ƐĞǆ ĐŚƌŽŵŽƐŽŵĞ ĂŶĞƵƉůŽŝĚǇ ǁĂƐ ƐŝŐŶŝĨŝĐĂŶƚůǇ ĞůĞǀĂƚĞĚ ŝŶ ďŽƚŚ  “ŽǁŶ ŽŽĐǇƚĞ ? ĂŶĚ
 “ĚŽŶŽƌ ŽŽĐǇƚĞ ? ƉŽƉƵůĂƚŝŽŶƐ ǁĞ ƉƌŽǀŝĚĞ ĞǀŝĚĞŶĐĞ ƚŚĂƚ ƚŚĞ ŽďƐĞƌǀĞĚ ĞĨĨĞĐƚ ŝƐ ŝŶĚĞƉĞŶĚĞŶƚ ŽĨ
maternal age. Moreover, as no significant increase was seen for any of the chromosomes in either 
of the  “/^/ with normal ƐƉĞƌŵ ? groups, the most plausible explanation for our observations was 
sub-optimal genetic quality of the sperm (probably increased sperm aneuploidy), rather than any 
effect of the procedure itself. Our study advances the current knowledge base in providing strong 
evidence that it is the quality of the sperm that may be the underlying cause that could lead to 
the slight increase in rates of anomalies associated with ICSI (specifically sex chromosomal 
aneuploidy) and not the consequence of the ICSI procedure itself. 
With the additional data as further confirmation of our original findings, we feel that this provides 
sufficiently compelling evidence that it is the presence of compromised semen parameters that 
led to the increase in the rate of sex chromosome aneuploidy in this patient group. Patients 
should be counselled accordingly and PGS should be offered as an adjunct to IVF treatment for 
male factor infertility. 







2.4.2 Population number 2: Young oocyte donors 
 
Paper entitled: Differences in pregnancy outcomes in donor oocyte frozen embryo transfer (FET) 
cycles following Preimplantation Genetic Screening (PGS): A single center retrospective study. 
Published in November 2016 in the Journal of Assisted Reproduction and Genetics. 
Authors: Alison Coates, Brandon Bankowski, Allen Kung, Darren Griffin and Santiago Munne 
(Coates et al., 2016a) 
 
 
2.4.2.1 My Personal Contribution to the Work 
 




2.4.2.2 Chapter Summary 
 
The data used for this retrospective analysis was from patients undergoing frozen thawed 
embryo transfers only. Fresh non tested embryo transfers were not included in this study. The 
goal of this paper was to discuss the merits of PGS on donor oocyte derived embryos prior to 
cryopreservation. Many patients using donor oocytes in our own program need to use a 
gestational carrier (GC) to carry the pregnancy. Often the oocyte donor is ready to cycle before 
the GC is even recruited by the patient therefore embryos have to be frozen to await the GC. 
Patients using their own uterus also may wish to postpone a transfer for social or economic 
reasons and also may need to cryopreserve embryos. Both groups of patient (own uterus and GC 
uterus) were considered separately due to the intrinsically better pregnancy outcomes when 








experienced many years of infertility and may have never carried a baby to term. 
 
 
To maximize live birth rates per embryo post thaw is the goal and this paper analyzed data from 
frozen thawed embryos with and without PGS to assess live births per embryo to establish if 
screening prior to freezing increased live birth outcomes. The own uterus group showed a highly 
significant difference in favor of PGS (59% PGS vs 36% no PGS P= 0.0005) and the GC uterus group 
showed a 10% difference in favor of PGS which almost reached significance (68% PGS vs 58% no 
PGS P= 0.07). 
 
 
/Ŷ ŽƵƌ ŽǁŶ ĚĂƚĂ ƐĞƚ ?W'^ ďĞĨŽƌĞ ĐƌǇŽƉƌĞƐĞƌǀĂƚŝŽŶ ŝŶĐƌĞĂƐĞƐ ůŝǀĞďŝƌƚŚ ƌĂƚĞƐ ŝŶ ƉĂƚŝĞŶƚ ?ƐƵƐŝŶŐ





Approximately 12% of all IVF cycles in the US are completed using donor oocytes from young 
anonymous oocyte donors, which equated to over 20,000 cycles in 2013 (SART, 2013). Reasons 
for using donor oocytes from young women rather than autologous oocytes during cycles of IVF 
are varied. They include: advanced maternal age, premature ovarian failure, diminished ovarian 
reserve, multiple failed IVF cycles using own oocytes, oophorectomy, same sex male couples, 
maternal single gene defects and cancer treatment in the female patient. 







As aneuploidy frequency in human pre-implantation embryos increases with maternal age 
(Franasiak et al., 2014b; Munne et al., 2007a), implantation and live birth rates decrease (SART, 
2013) because most aneuploid embryos either fail to implant (Munne et al., 2004) or miscarry 
and, rarely, are compatible with life (Kim et al., 2010; Werner et al., 2012). National IVF live birth 
rates for embryo transfers (ET) using fresh embryos compiled by the Centre for Disease Control 
in 2013 from patients younger than 35 were 48% per ET compared to patients aged 41-42 with a 
live birth rate of only 16% per ET (SART, 2013). While fresh embryo transfers using donor oocytes 
have resulted in high live birth rates without PGS (live birth rate 77%/ET 2012 SART published 
Oregon Reproductive Medicine (ORM) data (SART, 2012)), frozen ET live birth rates in this group 
have been lower. Improvements in freezing techniques over the last ten years have led to better 
survival of embryos and therefore higher pregnancy rates. National US data (SART, 2013) 
comparing fresh vs frozen ETs in the donor oocyte recipient group showed that in 2003 fresh live 
birth rate/ET was 51% compared to frozen ET at 30%. In 2013 the national fresh live birth rate/ET 
rate was 56% compared to 40.5% with frozen ET. The gap between fresh and frozen embryo 
transfers has thus become less over this time period from a 21% difference in 2003 to a 14.5% 
difference in 2013, partly attributable to improved freezing methods. In all of the above 
comparisons it has to be noted that the CDC data does not break down the data into day 3 vs 
blastocyst stage transfer. However, in data from our own lab comparing slow freezing vs 
vitrification, using donor egg derived blastocyst stage embryos, 53 transfers of slow frozen 
balstocysts resulted in 22 live births (40%) compared to 1110 transfers of vitrified blastocysts 
resulting in 698 live births (63%) (p= 0.009, Fishers exact test). 







PGS of blastocysts before transfer, it has been suggested, can reduce the maternal age effect on 
implantation (Harton et al., 2013), significantly increase live birth rates, and reduce miscarriage 
risk in IVF cycles when using autologous oocytes (Dahdouh et al., 2015a; Forman et al., 2012a; 
Hodes-Wertz et al., 2012; Lee et al., 2015; Schoolcraft et al., 2010; Schoolcraft and Katz-Jaffe, 
2013; Scott et al., 2013a; Yang et al., 2012). This area is perhaps among the most contentious in 
reproductive medicine however with significant proponents and opponents on both sides.(Chen 
et al., 2015; Verpoest et al., 2009) Meta-analyses and randomized controlled clinical trials have 
demonstrated the benefits of PGS for high-risk groups (e.g. advanced maternal age, recurrent 
implantation failure) however analyses and conclusions still attract criticism (Dahdouh et al., 
2015b; Sahin et al., 2014). At the time of writing, the community awaits the results of the Illumina 
STAR trial for PGS. (Trial registration number: (NCT02268786) 
To date, most attention has been on the high-risk referral categories, however many IVF/PGD 
practitioners have proposed that all IVF embryos should be screened for aneuploidy prior to 
transfer, including those from younger patients (Munne et al., 2006a). Although the percentage 
of aneuploid blastocysts from young donors is low compared to older patients (25% for donor 
oocytes vs 60% for 41-43 year old women, ORM unpublished data) it is nonetheless a concern 
since most aneuploidies arise from maternal meiotic errors in the oocytes of younger women 
(Ata et al., 2012). Sills et al determined, using SNP technology, the parental origin of aneuploidy 
using donor oocytes (Sills et al., 2014), finding that 88% of all the aneuploidies were attributable 
to maternal errors. Despite this, oocyte donor cycles have historically been the least likely group 
to be offered this screening. 









To the best of our knowledge there has only been one study examining the use of PGS in frozen 
thawed donor oocyte derived embryos (Haddad et al., 2015). Their conclusion was that, although 
their dataset was small, there was an increase (not significant) in implantation rates and 
pregnancy rates in the PGS group compared to the non-tested group. In the absence of any 
statistical significance however, results remain unconvincing. A larger study is thus needed, as is 
ƐƚƌĂƚŝĨǇŝŶŐ ƉĂƚŝĞŶƚƐ ŝŶƚŽ  “ŽǁŶ ? ĂŶĚ  “ŐĞƐƚĂƚŝŽŶĂů ĐĂƌƌŝĞƌ ? ƵƚĞƌƵƐ ĂƐ ǁĞůů ĂƐ ĚŽƵďůĞ ǀƐ ? ƐŝŶŐůĞ
embryo transfers. In this study we thus tested the hypothesis that ongoing pregnancy and 
implantation rates in frozen embryo transfer (FET) cycles are significantly different in FET cycles 
utilizing PGS compared to FET cycles not utilizing PGS in a single center. 
 
 
2.4.2.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
 
 
2.4.2.4.1 Ethical statement 
 
All patients were consented for all procedures as part of routine care. Oocyte donors were all 
anonymous. Institutional review board approval was obtained for review of patient charts and 
laboratory data for this study. The University of Kent Research and Ethics Committee also 
approved this study. 









Blastocysts resulting from donor oocyte IVF cycles at the Oregon Reproductive Medicine (ORM) 
clinic between January 2013 and December 2015 either elected to be tested for aneuploidy by 
trophectoderm (TE) biopsy followed by PGS using aCGH (Gutierrez-Mateo et al., 2011) or NGS 
(Wells et al., 2014) before cryopreservation; otherwise, their embryos were cryopreserved 
without testing depending on patient preference. Post publication of the manuscript a further 89 
FET cycles were analyzed and added to the original data. All blastocysts subsequently transferred 
in this retrospective observational study were at the day 5 stage when biopsied and vitrified. Only 
embryos vitrified with DMSO as a cryprotectant were included in the data analysis. 
 
 
2.4.2.4.3 Recipient population and study design 
 
Patients using donor oocytes from Caucasian donors to create embryos for their IVF cycle were 
included in this retrospective analysis. The patients were divided into 2 main groups: those using 
their own uterus and those using a gestational carrier (GC) uterus for the embryo transfer. These 
groups were further divided into those transferring a single embryo (SET) and those transferring 
2 embryos (Double embryo transfer, DET). The groups were then finally divided into those 
transferring apparently euploid embryos screened by PGS (study group) and those transferring 
non-screened embryos (control group). 







2.4.2.4.4 Uterine preparation and blastocyst warming protocol for embryo transfer 
Embryo transfers of previously vitrified blastocyst stage embryos were carried out in a medicated 
uterine preparation cycle as described previously (Roque et al., 2015). Embryos were warmed 
using Irvine warming kits (Irvine Scientific, Irvine, CA) on the morning of the scheduled embryo 
transfer and allowed to re-expand in equilibrated drops of Embryogluetm (Vitrolife) under Ovoiltm 
(Vitrolife) until the time of transfer. Embryo transfer was carried out using a Wallace Sureview 
Embryo transfer catheter (Cooper surgical) under ultrasound guidance. Patients rested for 45 
minutes post transfer. 
2.4.2.4.5 Measured outcomes and statistical analysis 
 
Measured outcomes were live birth rate per cycle and live birth implantation rate (number of 
babies born per embryo transferred). Any statistical differences in each of these parameters for 
each group were established using Fishers exact test and Mann Whitney test on ranks where 
appropriate. Statistical significance was determined at P<0.05 at the 95% confidence level. The 
tested and non-tested groups had near identical average oocyte donor age and the numbers of 
embryos biopsied in each group was not statistically significantly different (table 1). During the 
study period personnel in the laboratory all remained constant and there were no major changes 
to protocols during the time period of the study. 









A total of 398 thaw cycles were included in the original analysis. One thaw cycle resulted in no 
transfer due to failure to survive of the one available embryo. 397 frozen embryo transfers (FET) 
were performed using blastocyst stage embryos generated from oocytes from anonymous 
donors. All embryos were classed as of good morphological appearance (AA grade, Gardner scale) 
(Gardner DK, 1999) prior to cryopreservation. In the test (PGS) group, 435 known euploid 
embryos were transferred in 294 frozen ET cycles. In the control (no PGS) group 103 embryos of 
unknown ploidy status were transferred in 162 frozen ET cycles. 
 
 
There was no difference in survival of embryos post thaw in both the PGS and control groups 
(96% in the PGS group and 97% in the control group, p=1.0 NS). No patients using donor oocytes 
during the time period of the study had a cycle with all aneuploid embryos. 
Published results are summarized in table 16. 







 Gestational carrier uterus Own recipient uterus 

















# Thaw cycles 95 20 100 26 58 25 41 33 
# FET 95 19 100 26 58 25 41 33 
# embryos 
transferred 




















P value: 1.0 NS 0.2 NS 0.06 0.04 































P value:   0.07   0.1 NS 




Data from the original dataset show that live birth implantation rates (number of babies born per 
embryo transferred) were significantly higher in the PGS group in both the GC and own uterus 
groups, but only after double embryo transfer (DET); (72% vs 56% GC, 60% vs 36% own uterus, P 
values: 0.03 and 0.005 respectively). The live birth rate per transfer cycle in the DET groups were 
nominally higher in the PGS group compared to control group but not significantly so (87% vs 
77% GC, 76% vs 55% own uterus, P values: 0.2 and 0.08 respectively). Live birth implantation 
rates and live births per cycle in the GC SET group were the same in the PGS and own uterus 
group but the control group was small including only 20 cycles. Live birth implantation rates (58% 
vs 36% p=0.09) and live births per cycle (58% vs 36%, p=0.09) were nominally higher with PGS vs 
control in the SET own uterus group but not significantly. 







Combining SET and DET in a further data analysis post publication of the paper to analyze live 
birth rates for each embryo transferred is shown in table 17. The own uterus group showed a 
highly significant difference in favor of PGS (59% vs 36% P= 0.0005) and the GC uterus group 
showed a 10% difference in favor of PGS which almost reached significance (68% vs 58% p= 0.07). 









# FET 250 52 117 67 
# embryos 
transferred 
375 85 165 107 











P value 0.07 0.0005 
Table 17: Frozen embryo transfer outcome data comparing PGS vs non PGS donor egg derived embryos. 
Further data analysis post publication of the paper of live birth rates per embryo transferred. 
 
Finally, live birth twinning rates were nominally higher following PGS for DET cases (67% vs. 45% 
for GC uterus, p= 0.07 and 58% vs 33%, for recipient own uterus p=0.1 in test and control groups 
respectively) compared to zero monozygotic twinning following SET in either the test or control 
group. 
Table 18 illustrates that 25% of all donor oocyte derived trophectoderm samples tested were 
aneuploid, 19% with a single aneuploidy and 5.7% with more than one chromosome involved. 







Biopsied Donor oocyte blastocyst embryos 
# embryos biopsied 3393  
















  Single aneuploidy only:  
Chromosome affected: # embryos with monosomy # embryos with trisomy 
1 18 8 
2 19 10 
3 7 9 
4 17 8 
5 13 14 
6 16 11 
7 21 6 
8 17 12 
9 10 17 
10 11 9 
11 16 8 
12 5 11 
13 19 6 (0.2%)* 
14 13 6 
15 22 16 (0.5%)* 
16 38 37 (1.1%)* 
17 6 3 
18 9 4 (0.1%)* 
19 11 10 
20 4 9 
21 13 11 (0.3%)* 
22 24 15 (0.4%)* 
Sex chromosomes 35 (XO) (1%)* 32 (0.9%)* 
Total # of embryos with most 
common aneuploidies * 
associated with implantation 
and  subsequent  miscarriage or 




Table 18: Errors per chromosome for donor egg derived embryos. 4.6% of embryos resulting in a chromosomal 
aneuploidy commonly associated with miscarriage or abnormal offspring (i.e. ƚƌŝƐŽŵǇ ?Ɛ 13, 15, 16, 18, 21, 22, XY and 
monosomy X). aCGH and NGS methodologies resulted in similar overall aneuploidy rates per embryo (24% for aCGH 
ǀƐ  ? ?й ĨŽƌ E'^ ƌĞƐƉĞĐƚŝǀĞůǇ Wх ? ? ? ? ŶŽƚ ƐŝŐŶŝĨŝĐĂŶƚ ? ? DŽŶŽƐŽŵŝĞƐ ĂŶĚ ƚƌŝƐŽŵǇ ?Ɛ ŽĐĐƵƌƌĞĚ Ăƚ ƐŝŵŝůĂƌ ĨƌĞƋƵĞŶĐŝĞƐ
(overall and per-chromosome) with chromosome 16 and the sex chromosomes most commonly aneuploid. 









Donor oocyte IVF cycles have many variants: If the female donor oocyte recipient is able to carry 
the pregnancy herself the embryos are transferred to her uterus. If however she has an abnormal 
uterus or no uterus at all the recipient may engage a gestational carrier to gestate the pregnancy. 
Same sex male couples or single men can fertilize donor oocytes with their own sperm and 
transfer resulting embryos to a gestational carrier. While the live birth rate of fresh donor oocyte 
embryos is high overall, if the cases which used a gestational carrier are separated out from the 
recipients who used their own uterus, we find an even higher pregnancy rate in the donor oocyte 
gestational carrier patients than when using a donor oocyte recipient uterus from an infertile 
patient. This even higher pregnancy rate when using a gestational carrier who has successfully 
previously carried a baby to term, could be attributable to the elimination of unknown uterine 
factors that may contribute to failure to achieve a successful pregnancy in patients who have 
been infertile for long periods of time. 
 
 
In this study, patients elected whether or not to test their embryos by PGS before 
cryopreservation. The people who elected not to test had the same prognosis as the patients 
who did elect to test i.e. all patients presenting in our anonymous oocyte donor program had a 
high chance of conceiving and had access to the same pool of young oocyte donors. Patients 
committed to the testing process before the cycle started and patients did not change their mind 
depending on how many blastocysts developed. The reasons patients elected not to test were 











Oocyte donor cycles have historically culminated in a transfer of fresh, untested embryos to a 
recipient or gestational carrier uterus or a freeze all cycle for future use. With an average of 7 
good quality blastocysts produced each donor oocyte cycle, even if a fresh transfer is undertaken, 
there are usually surplus embryos remaining to be cryopreserved for future use (Doherty et al., 
2014). Often an oocyte donor cycle cannot be synchronized for a fresh embryo transfer with a 
recipient or gestational carrier uterus for social or medical reasons and cryopreservation of the 
ǁŚŽůĞ ĞŵďƌǇŽ ĐŽŚŽƌƚ  ? “ĨƌĞĞǌĞ Ăůů ? ) ďĞĐŽŵĞƐ ŶĞĐĞƐƐĂƌǇ ?DĐ>ĞƌŶŽŶet al., 2016; Zenke and 
Chetkowski, 2004). The findings of this study indicate that there are possible benefits in 
implantation and ongoing pregnancy rates through the use of PGS in FET donor oocyte cycles. 
The question of whether FET cycles derived from donor oocytes need to include PGS in future 
should thus now be subject of larger and ultimately randomized studies. 
 
 
Single center retrospective cohort studies such as this one provide supportive evidence to justify 
future prospective cohort studies, multi-center meta-analyses and ultimately randomized 
controlled clinical trials (RCTs). For evidence-based reproductive medicine, each has their value. 
RCTs remain the gold standard but, in a field where individual operator skills can have such a 
profound effect on IVF outcome, larger studies can mask effect of good (or bad) practice of  
individual groups or centers. In this context, smaller single center trials have considerable value 







and may point to genuine efficacy of clinical interventions. On the other hand, the absence of 
randomization leaves an open question of whether any significant differences observed 
represent selection bias, inadvertent or otherwise. Moreover, different sizes of test and control 
groups (in this case control groups are much smaller than test groups) mean that statistical 
analyses need to be viewed with a degree of caution. RCTs are however expensive, time 
consuming and cannot be justified without sufficient published datasets from retrospective 
analyses. In our opinion, the current study justifies further work in this area, particularly with the 
increased interest in IVF and PGS. 
 
 
With all the above caveats in mind, the current study is nonetheless the first to show significant 
differences as a result of the use of PGS in patients who elected to have it as part of their FET 
donor oocyte treatment cycle. Apparent improvements were seen after double embryo transfer 
(DET), raising the question of whether differences are only likely to be seen in this context. 
Equally, as the IVF world in most countries moves more in the direction of single embryo transfers 
(SET)(Forman et al., 2014; Styer et al., 2016; Ubaldi et al., 2015), attention will inevitably turn to 
means through which the chances of implantation of that single embryo can be maximized. In 
our SET GC group, there was no difference in live births per cycle nor live birth implantation rates 
per embryo between the PGS and no PGS embryos, and in the SET group using a recipient uterus 
there was a nominal increase in those parameters when using PGS but not significantly. 







Taking gestational carrier and own uterus cycles together, all measures favored the PGS cycles 
but, in the absence of statistical significance, the question remains open about whether this 
represented a genuine difference. The DET results suggest that, had sufficient numbers been 
analyzed, the numbers might have reached statistical significance for SET also, however this 
needs to be confirmed by further studies. Elective single embryo transfer (eSET) to reduce 
multiple pregnancy rates in IVF cycles is a primary goal of the reproductive medicine community 
(Forman et al., 2014). SETs however result in lower pregnancy rates per transfer, and higher rates 
of complete pregnancy loss (post positive pregnancy test) compared to double embryo transfer 
(DET). The benefit of transferring a single embryo is the reduction in the number of twin 
pregnancies because of the obstetric complications associated with multiple births. In future 
studies therefore we would look closely to ask whether the nominal differences seen for SET in 
this study reach statistical significance in larger data sets. 
 
 
Without randomization, the question also arises about whether the statistical differences that 
were observed reflect patient cohorts that inherently had differing aneuploidy rates. Of course 
we cannot completely rule this out. In these particular patient groups however, patients had near 
identical oocyte donor ages, the best known correlate for different aneuploidy rates (Franasiak 
et al., 2014b; Harton et al., 2013; Munne et al., 2007a). Equally the couples who elected not to 
test had the same prognosis as the patients who did elect to have PGS i.e. all patients presenting 
in our anonymous oocyte donor program had a high chance of conceiving and had access to the 
same pool of young oocyte donors. Patients committed to the testing process before the cycle 







started and patients did not change their mind depending on how many blastocysts developed. 
The reasons patients elected not to test were financial, uncertainty about the biopsy process and 
a wish to leave the choosing of embryos up to chance. Whether these are confounding factors 
that might predispose to increased aneuploidy or reduced pregnancy is questionable. In a study 
of 23 US clinics sending biopsies to a single reference lab (Reprogenetics, a Cooper Surgical 
Company) Munne et al showed that aneuploidy rates in donor oocyte derived embryos screened 
with aCGH, vary between IVF clinics (Munne S, 2015). Embryos were not reported as a mosaic 
result from this reference clinic when using aCGH. They were reported as euploid or aneuploid 
depending on the percentage of cells affected with a loss or gain. The percent of aneuploid donor 
oocyte embryos per clinic ranged from 20% to 58% with an average rate of 35%. One possible 
explanation for this is geographical variation in aneuploidy rates however there is scant data 
supporting this hypothesis. A more likely explanation is subtle differences in ovarian stimulation 
and lab protocols might lead to marked differences in aneuploidy levels between centers. Such 
questions are beyond the scope of this study and are not entirely relevant in this case as this is a 
single center study in which personnel did not change and identical standard operating practices 
were performed. Indeed, in our own experience, donor oocyte aneuploidy rates are lower than 
the average shown in the Munne study (Munne S, 2015). Nonetheless we cannot rule out 
inadvertent, subtle differences between treatments of test vs. control groups, however unlikely 
we believe it to be. It is perhaps not unreasonable to suggest however that the centers with 
higher aneuploidy rates in embryos derived from donor oocytes might be the ones that benefit 
most from PGS, should it ultimately prove effective for this application. 









Aneuploidy rates between Oocyte donor cycles within clinics are also variable and can be patient 
(donor) specific, which is another reason why PGS can be helpful in this patient group. 
The reports below illustrate the variability of oocyte donor cycles within our own clinic. The 
stimulation protocols and lab conditions were the same for each donor cycle. 
 
 
Donor oocyte pregnancies, although at lower risk for miscarriage or offspring with chromosomal 
defects than pregnancies from patients of advanced maternal age, are still at risk from adverse 
pregnancy outcomes. The most common single aneuploidies associated with miscarriage or 
congenitally affected live births are ƚƌŝƐŽŵǇ ?Ɛ 13, 15, 16, 18, 21, 22, XY and monosomy X (Hook et 
al., 1983; Jenderny, 2014). In this retrospective analysis, 4.6% of blastocysts fall into this category 
(Table 18). Given that monosomies (other than monosomy X) are rarely, if ever, seen among 
spontaneous abortions we might expect thesĞĂŶĚŽƚŚĞƌƚƌŝƐŽŵǇ ?Ɛ ?Ğ ?Ő ?ƚƌŝƐŽŵǇ ?Ɛ ?ĂŶĚ ? ? )ŶŽƚ
to reach the stage of a clinically recognized pregnancy, perhaps through failed implantation. 
KƚŚĞƌƐ ŚŽǁĞǀĞƌ ? ƐƵĐŚ ĂƐ ƚŚĞ ŵŽƌĞ ĐŽŵŵŽŶ ƚƌŝƐŽŵǇ ?Ɛ ĂďŽǀĞ ƌĞŵĂŝŶ Ă ƐŝŐŶŝĨŝĐĂŶƚ ĐŽŶĐĞƌŶ ĨŽƌ
donor oocyte recipients when using unscreened embryos for transfer, especially since prenatal 
diagnosis is not routinely recommended for this group. Other features also noteworthy from 
table 18 include: Monosomies and ƚƌŝƐŽŵǇ ?Ɛ occur with equal frequency indicating that embryos 
are equally likely to survive to the blastocyst stage whether they arise from a nullisomic or 
disomic gamete. Moreover the most common aneuploidies seen in spontaneous abortions 
(monosomy X and trisomy 16)(Shen et al., 2016) are the most common in this dataset, suggesting 











PGS costs around $4500 (including biopsy procedure plus testing process) per cycle in addition 
to the IVF cycle costs. The cost including medication of one FET cycle is also around $4500. As 
52% of non PGS frozen embryos fail to implant and result in a pregnancy compared to 35% of 
PGS embryos, it is more likely that a second or maybe third frozen embryo transfer may be 
needed to achieve a successful outcome when using untested embryos therefore offsetting the 
initial cost of embryo screening. 
 
 
Aneuploidy is a condition that affects all age groups, even women in their twenties (Franasiak et 
al., 2014b). While it has been suggested that PGS is a valuable tool for improving outcome in 
patients of advanced maternal age (Harton et al., 2013), in the current study we provide 
preliminary evidence that the application of PGS may improve IVF outcomes using younger 
oocytes from an oocyte donation cycle. This research provides sufficient evidence for increased 




This study only examined the outcome of frozen donor oocyte derived embryo transfer cycles 
with PGS and non PGS embryos. Fresh embryo transfer is also a consideration for this patient 
group. In the next chapter I attempt to answer the question whether fresh or frozen transfer of 







euploid embryos results in higher live birth rates but only in patients using their own eggs. As the 
live birth rates for patients using fresh donor egg derived embryos without screening is already 
high with 63% of embryos transferred resulting in a baby, the possibility of biopsying these 
embryos on day 5 and rush testing overnight for a day 6 transfer into a non-stimulated recipient 
uterus may result in even higher live birth rates per embryo. 
 
 
The issue of asynchrony between the uterus and the embryo when transferring autologous 
oocyte fresh embryos on day 6 in the same cycle as the oocyte retrieval as described in the next 
chapter is removed when using a recipient uterus. Further studies should be completed to 
investigate if implantation rates can be improved further using fresh euploid donor oocyte 
derived embryos. 







2.5 Specific aim 4 
 
To establish the optimal transfer strategy (fresh vs frozen) for euploid embryos in 
patients using their own oocytes 
 
This was a randomized controlled trial (RCT) comparing the two commonly utilized transfer 
protocols for euploid embryos, fresh vs frozen. The data was presented as an oral abstract at 
ASRM 2016 in Salt Lake City and won the SART prize paper award. Paper entitled: ͞Optimal 
euploid embryo transfer strategy, fresh vs frozen, following PGS with NGS. A randomized 
ĐŽŶƚƌŽůůĞĚ ƚƌŝĂů ? ? ƵƚŚŽƌƐ P ůŝƐon Coates, Allen Kung, Emily Mounts, John Hesla, Brandon 
Bankowski, Elizabeth Barbieri, Baris Ata, Jacques Cohen and Santiago Munne (Coates et al., 
2017). Comment in Fertility and Sterility (Kort et al.) 
 
 
2.5.1 Personal contribution to the work 
 
I designed the study, developed the protocol, oversaw the recruitment and randomization of 
patients, analyzed the data, wrote the paper and responded to the reviewers comments before 
final acceptance for publication. 
 
 
2.5.2 Chapter Summary 
 
This RCT was developed to determine the optimal transfer strategy using PGS for patients using 
their own oocytes and uterus. In order to screen embryos for aneuploidy, a biopsy is taken from 







the trophectoderm on day 5 or 6 of in-vitro development. If ploidy determination is carried out 
using NGS or aCGH, there is an 18-20 hour turnaround time to obtain results. Because of the 
length of time needed to get results, the transfer in the embryo creation cycle of a fresh embryo 
can only occur if a day 5 ready blastocyst is shown to be euploid by day 6. The other option for 
transferring euploid embryos is to freeze all embryos post biopsy and transfer in a subsequent 
cycle. These 2 options are routinely used in IVF clinics. The fresh day 6 option is stressful for the 
patient and the clinic but is perceived to be better for cycle outcome than freezing all embryos. 
The freeze all option allows for consideration of all embryos in the cohort (day 5 and day 6) for 
transfer. The results of this RCT showed that live birth rates were superior using frozen compared 
to fresh euploid embryos (77% frozen vs 59% fresh p= 0.04). The conclusion of this RCT was that 






Embryo aneuploidy is likely the leading cause of implantation failure in in-vitro fertilization (IVF) 
cycles. There is well documented evidence of increasing maternal age directly correlating with 
an increase in embryonic aneuploidy rates (Ata et al., 2012; Franasiak et al., 2014a; Hassold et 
al., 1980; Munne et al., 2007a). With recent advances in IVF (extended embryo culture, 
trophectoderm biopsy and vitrification) along with the combination of new and advanced 
technology in pre-implantation genetic screening (PGS) (the use of array-comparative genomic 
hybridization  (aCGH),  quantitative  polymerase  chain  reaction  (qPCR)  and  next  generation 







sequencing (NGS) to determine all chromosome copy number), ongoing pregnancy rates have 
improved with the selective transfer of euploid blastocysts (Forman et al., 2012a; Forman et al., 
2012b; Lee et al., 2015; Schoolcraft and Katz-Jaffe, 2013). Preimplantation genetic screening 
(PGS) is routine in some clinical IVF practices in the USA (Schoolcraft and Katz-Jaffe, 2013; Scott 
et al., 2013a). However, despite ongoing advances in reducing error rates (Capalbo et al., 2016a) 
and increasing implantation (Chen et al., 2015; Dahdouh et al., 2015b), the optimal embryo 
transfer strategy for euploid embryos still needs to be determined. 
 
 
The two transfer strategies for euploid embryos currently in clinical practice are to utilize 
ǀŝƚƌŝĨŝĞĚ ?ǁĂƌŵĞĚ  ? “ĨƌĞĞǌĞ-Ăůů ? ) Žƌ ĨƌĞƐŚ ĞŵďƌǇŽƐ ĨŽƌ ƚŚĞ ĨŝƌƐƚ ĞŵďƌǇŽ ƚƌĂŶƐĨĞƌ ? dŚĞ ĨƌĞĞǌĞ-all 
strategy involves cryopreservation of all embryos post-biopsy, and then waiting for the PGS 
results of the whole cohort (day 5 and day 6 embryos) in preparation for a frozen embryo transfer 
(FET). The fresh strategy involves biopsy of expanded blastocysts before 10 am on day 5 and 
culture overnight to await PGS results for a fresh embryo transfer of euploid embryos before 12 
midday on day 6. In this scenario, slower-growing embryos may be biopsied on day 6 and frozen 
for later use. 
 
 
There are benefits and challenges to each approach. There is evidence that implantation and 
clinical ongoing pregnancy rates may be higher when transferring vitrified/warmed embryos in a 
non-stimulated cycle compared to fresh transfer in a stimulated cycle (Bhattacharya, 2016) . The 
incidence of low birth weight babies and pre-term delivery has also been shown to be lower in 







pregnancies resulting from frozen transfers compared to fresh transfers (Maheshwari and 




survival rates. Even with the latest methods, an embryo still has about a 3% chance of being 
damaged by either the vitrification or warming processes (Darwish and Magdi, 2016). 
 
 
Although there are an increasing number of studies supporting improved clinical outcomes after 
FET (Evans et al., 2014; Ozgur et al., 2015; Roque et al., 2015; Shapiro et al., 2014), fresh transfer 
protocols are typically more affordable, require little to no additional medications, and 
potentially allow the patients immediate transfer. However, a successful fresh day 6 transfer 
approach necessitates not only that expanded blastocysts be available on the morning of day 5, 




The main aim of the present clinical trial was to identify which embryo transfer strategy after PGS 
by NGS, freeze-all or fresh, would improve implantation and live birth rates or if the strategies 
were equally successful. 







2.5.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
 
 
2.5.4.1 Patient Population 
 
Participants were recruited at the Oregon Reproductive Medicine Center between December 
2013 and August 2015. Patients between the age of 18 and 42, while undergoing IVF and PGS 
using their own oocytes were eligible to participate in the trial. The exclusion criteria included 
the following: the need to use surgically retrieved sperm (microsurgical epididymal sperm 
aspiration (MESA) or testicular sperm aspiration (TESA)), patients utilizing preimplantation 
genetic diagnosis for a single-gene or chromosomal disorder, oocyte donor cycles, gender 
selection cycles, decreased ovarian reserve indicated by early follicular phase serum FSH level 
>10 IU/L or random serum AMH level <1 ng/ml, and any medical reasons occurring prior to 
recruitment which would not allow a patient to undergo a fresh embryo transfer such as the need 
for uterine surgery prior to transfer. Patients were excluded post recruitment prior to 
randomization if they were unable to undergo a fresh transfer for medical reasons such as OHSS 





At the time of hCG administration, patients were randomized to either a freeze-all cycle or a fresh 
day 6 embryo transfer during the stimulated cycle. The stratified block randomization sequence 







was prepared by a professional third party (sealedenvelope.com). The allocation sequence was 
stratified for female age (<35, 35  W 37, 38  W 40, and 41  W 42 years) and number of prior ART cycles 
(<2 or >3). Women were randomized in a 1:1 ratio in blocks of 10, i.e. of every ten women in each 
stratum five were allocated to fresh and five to frozen transfer in a random order. Principal 
investigator registered each participant in the designated trial website, and allocation 
information was disclosed after confirmation of the eligibility criteria. 
 
 
2.5.4.3 Frozen embryo transfer (FET) cycle uterine preparation 
 
FETs were performed in an artificial cycle. A combined oral contraceptive containing 30 mcg 
ethinyl estradiol/0.15 desogestrel (Apri, Teva) was administered for 15-21 days starting from the 
third day of menstrual cycle. 
 
 
Estradiol valerate 4mg/day (Delestrogen, JHP pharmaceuticals) via IM injection was commenced 
5-7 Days after the last contraceptive pill, increasing by 1mg each injection until dosage of 6mg 
twice weekly was reached and the endometrium measured a minimum of 7.5 mm thickness and 
had a tri-laminar pattern visualized on ultrasound using a GE S6 device . Then progesterone in oil 
(Watson) was commenced at a dose of 50 mg/day intra muscularly for the initial two days and 
increased to 100 mg/daily thereafter. Frozen thawed embryo transfer was performed on the 7th 
day of progesterone injections. Patients who had a positive pregnancy test were also given 
100mg Endometrin®(Ferring) administered vaginally three times a day. A weaning schedule for 







estradiol and progesterone in oil was followed until discontinuation of the medication at 11- 12 
weeks of pregnancy. 
 
 
2.5.4.4 Fresh embryo transfer (Fresh ET) cycle uterine preparation 
 
Fresh ETs were carried out during the original oocyte retrieval cycle. On day 2 post Wretrieval, 
supplementary progesterone (Endometrintm, Ferring), was administered vaginally once/day 
along with 2mg oral estrogen supplementation (Estrace, Teva) twice a day. Day 3 post-retrieval 
progesterone increased to twice a day. The transfer occurred on the morning of day 6 of embryo 




2.5.4.5 Statistical and Ethical Considerations 
 
The primary outcome measure was the live birth rate. Live birth was defined as the delivery of a 
viable fetus. Ongoing pregnancy was defined as viable pregnancy progressing beyond the 8th 
week of gestation. Embryo implantation rate was calculated as the number of gestational sacs 
divided by the number of embryos transferred per group. 
 
 
Continuous variables were defined with mean (standard deviation) or median (25th  W 75th 
percentile) and compared between the groups with t-test for independent variables or Mann- 
Whitney U test, depending on distribution characteristics. Categorical variables were defined as 
numbers  and percentages  and  compared  between  the  groups  by  the  chi-square  test  or its 







derivatives as appropriate. Significance was defined as a p value of <0.05. A logistic regression 
analysis involving live birth as the dependent variable and female age, number of metaphase two 
oocytes, and embryo transfer cycle (fresh transfer as the reference) was conducted to adjust for 
possible differences in baseline characteristics in the per protocol analysis including all women 
who eventually underwent a fresh or frozen embryo transfer regardless of initial allocation. 
 
 
For reference, the study center had a 63% ongoing FET pregnancy rate with euploid embryos for 
patients who were younger than 42 years using their own oocytes the year before commencing 
the study. Seventy-four patients would be required to detect an absolute increase of 20% from 
63% with an alpha error level of 0.05 and a beta error level of 0.2. In order to account for possible 
drop-outs the aim was to recruit up to 186 participants during the study period. Offspring or 
products of conception were not routinely karyotyped for concurrence with the embryo biopsy 
results. The protocol was Institutional Review Board approved and registered with 
clinicaltrials.gov (NCT02000349). All patients that met inclusion criteria and expressed the desire 
to participate in the study were consented before ovarian stimulation. 









183 patients were consented to the study. Four patients were cancelled due to poor response 
before hCG administration. A total of 179 patients received hCG for oocyte retrieval and were 
randomized; 88 patients were allocated to the fresh transfer group and 91 to the frozen transfer 
group. Patients had either 1 or 2 embryos transferred depending on availability of euploid 







Average Age (range) 36.6 (25  W 42) 36.7 (27  W 42) 0.7 
Average AMH (range) 3.6 (1.5  W 4.5) 3.3 (1.4-4.7) 0.7 
Average FSH (range) 7.4 (0.5-21) 7.9 (1.8-15) 0.2 
Oocytes collected 
(range) 
14 (0-41) 17 (4-44) 0.1 
Average # Metaphase 
II oocytes 
11.5 13.3 0.3 
2pn Fertilization 
rate/mature egg 
78% 77% 0.6 
% aneuploidy 
rate/embryo 
37% 40% 0.4 
Infertility diagnosis: 
Unexplained 23.6% 29.7% 0.4 
Female factors 31.4% 30.7% 1.0 
Male factor 12.4% 7.7% 0.3 
DA䠃? ? 11.2% 16.5% 0.4 
RPL 3.4% 2.2% 0.6 
>1 factor 19.1% 13.2% 0.3 
Table 19: Baseline and IVF cycle characteristics of patients randomized to each treatment group 







2.5.5.1 Outcome of patients in the intention to treat analysis 
 
The intention to treat analysis considered all randomized patients in their original group of 
allocation regardless of achieving an embryo transfer, fresh or frozen. 14 of the fresh group 
allocation failed to achieve a fresh day 6 transfer (9 had only day 6 euploid embryos, 2 had to re- 
biopsy day 5 embryos and freeze, 1 had OHSS, 1 NGS equipment failure, 1 had pulmonary 
embolism so could not transfer) but did have euploid embryos available which were transferred 
in a subsequent FET cycle. These 14 cycles, even though they had their embryos transferred in 
an FET cycle, were still included in the fresh transfer group according to intention to treat 
protocol, as this was their original randomization allocation. One patient dropped out of the 
study post randomization and had a day 3 transfer of untested embryos. 8 patients in the freeze 
all group did not have embryos available to biopsy on day 5 but had day 6 euploid embryos 
available and these were transferred in their primary FET cycle. Ongoing pregnancy rates (40.9% 
vs 62.2% p=<0.01) and live birth rates (39.8 vs 61.5% p= <0.01) per intended treatment was 
significantly higher for the freeze all group compared to the fresh. 
 Fresh (n=88) Frozen (n=91) p 




















Implantation rate (total number of sacs/total 






Table 20: Outcome in the Intention to Treat Population (Values are number (percentage) or amean 
(standard deviation). 







2.5.5.2 Outcome of patients receiving the intended transfer protocol 
 
Only patients who had at least 1 expanded blastocyst to biopsy on day 5 were included in this 
analysis. A total of 46/88 (52.27%) patients underwent a fresh euploid blastocyst transfer and 
61/91 (67.03%) patients underwent a frozen thawed euploid blastocyst transfer. 
 
 
The mean number of embryos transferred was similar in both fresh and frozen transfer groups 
(1.4 and 1.5 respectively, p = 0.3). The implantation rate (sac formation/embryo transferred) was 
higher in the frozen group (75%) compared to the fresh (67%) but this difference was not 
significant (Table 21). The ongoing pregnancy and live birth rates were significantly higher for the 
frozen group compared to the fresh (ongoing: 80% frozen vs 61% fresh, p value=0.03, live births: 
77% frozen vs 59% fresh, p value=0.04). 
 Fresh (n=46) Frozen (n=61) P value 







Average number of 
embryos transferred 
1.4 1.5 0.3 












Live birth rate(babies 















Table 21: Outcomes for each transfer strategy (only includes patients who had at least 1 day 5 embryo 
to biopsy) 







The analysis was further broken down into single embryo transfers (SET) and double embryo 
transfers (DET)(table 22). In the SET subset, ongoing pregnancy (52% fresh vs 64% frozen p=0.5), 
implantation rates (68% fresh vs 73% frozen p=0.7) and live birth rates (52% fresh vs 64% frozen 
p=0.7) were all trending higher in the frozen group than in the fresh group, but not significantly. 
In the DET subset, implantation rates (67% fresh vs 73% frozen p=0.5) and live birth rates (67% 
fresh vs 86% frozen p=0.1) were trending higher but not significantly, however the ongoing 
pregnancy rate (71% fresh vs 91% frozen p=0.04) was significantly higher in the frozen group 
compared to the fresh. Despite a strong trend toward improved live birth rates with frozen 
transfer, embryo transfer strategy did not have a statistically significant effect on the likelihood 
of achieving a live birth when adjusted for female age and number of metaphase two oocytes in 
the logistic regression model. Odds of a live birth was 2.1 (95% confidence interval 0.95  W 4.68), 
(p = 0.68) with a FET as compared to a fresh ET. 
 SET DET 
 Fresh Frozen Fresh Frozen 
# ET 25 25 21 36 










P value: 0.4 0.04 










P value: 0.5 0.1 
# twins 0/13 1/15 8/13 15/30 











P value 0.7 0.5 
Table 22: Further breakdown of analysis into Single (SET) vs double (DET) embryo transfer 
between the 2 transfer strategies 







2.5.5.3 Comparison between fresh ET and Frozen ET of only day 5-biopsied euploid 
blastocysts 
When comparing the use of only day 5 blastocysts, 46 patients underwent a fresh ET, and 37 
patients underwent an FET. The average number of embryos transferred in each group was the 
same at 1.5 (p=0.3). Live birth, ongoing pregnancy and implantation rates were higher in the 
frozen transfer group but did not reach statistical significance (table 23). 
 
 
 Fresh ET (n=46) Frozen ET(n=37) P value 
Average number of 
embryos transferred 
1.5 1.5 0.3 


























2.5.5.4 Comparison between only FET of euploid blastocysts that were biopsied on post 
retrieval day 5 or day 6 
While 37 patients in the freeze-all group exclusively transferred day 5 biopsied euploid 
blastocysts, 20 patients in the freeze-all group exclusively transferred day 6 biopsied euploid 
blastocysts. Euploidy rates between day 5 and 6 biopsied blastocysts in the study were similar at 
56.5%/embryo for day 5 and 53%/embryo for day 6 (p = 0.54). The average number of embryos 







transferred in each group was significantly different at 1.5 for day 5 and 1.2 for day 6 (p=0.009). 
Despite this, the positive pregnancy, ongoing pregnancy and implantation rates for each group 
were nearly identical (table 24). 
 Frozen day 5 (n=37) Frozen day 6 (n=20) P value 







Average number of 
embryos transferred 
1.5 1.2 0.009 




















Table 24: Comparison of outcome within the frozen transfer strategy group between transferring day 5 
vs day 6 biopsied embryos 
 
 
2.5.5.5 Cycle management of patients undergoing fresh transfer 
 
2.5.5.5.1 Progesterone (P4) monitoring at hCG administration 
 
Progesterone levels in the present study were monitored at hCG administration to capture 
premature luteinization and therefore possible cancellation of a fresh transfer in the stimulated 
cycle. P4 levels of >1.5 have been reported to have a deleterious effect on implantation (Bosch et 
al., 2010). Three patients in the fresh arm of the study, exhibited a rise before hCG and had 
borderline high p4 values of 1.7, 2.2 and 2.4. They were not cancelled because of this premature 
rise and the patients with levels of 2.2 and 2.4 both had a live birth from the fresh cycle. The 
patient with a level of 1.7 had a negative pregnancy test. The other patients in the fresh transfer 
group had a range of P4 of 0.3-1.4 with an average of 1. 









2.5.5.5.2 Stimulation protocols in the fresh transfer group 
 
Of the 46 patients who achieved a fresh transfer, 37 had an antagonist stimulation protocol and 
9 had an overlap stimulation protocol. 22/37 of the antagonist group and 7/9 of the overlap group 





This RCT has demonstrated that the ongoing pregnancy and live birth rates were significantly 
higher in the frozen ET group compared to the fresh. Additionally, a significantly higher 
proportion of patients are able to attain the desired embryo transfer strategy in the frozen ET 
group compared to the Fresh ET group. However, although a higher proportion of embryos 
transferred implanted in the frozen embryo transfer group than in the fresh embryo transfer 
group, the variations were short of statistical significance. 
 
 
The two transfer strategies when using known euploid embryos are very different in their 
execution and each have their own challenges to take into consideration. There is increasing 
evidence in favor of transferring embryos created during IVF in an unstimulated uterine 
environment (Gomaa et al., 2016; Ozgur et al., 2015; Roque et al., 2015; Shapiro et al., 2014; 
Shapiro et al., 2011; Shi et al., 2014). This approach however necessitates embryo 
cryopreservation during the IVF cycle. With the adoption of vitrification as a cryopreservation 
method over the past few years the survival rate of blastocyst embryos has improved significantly 







making the transfer of frozen thawed embryos a pragmatic option for IVF patients and 
practitioners alike. While there have been studies comparing fresh vs frozen embryo transfer 
outcomes and PGS tested vs non PGS tested embryo transfers (Forman et al., 2014; Scott et al., 




To confirm that the improvement in implantation and ongoing pregnancy rates in the freeze all 
group was related to the transfer strategy alone we compared only embryos that had been 
biopsied on day 5 in the fresh and frozen groups (Table 23). The ongoing pregnancy and 
implantation rates all showed positive trends in favor of the frozen ET group but these did not 
reach significance, probably due to the smaller sample size. 
 
 
As part of the study analysis we assessed if the implantation potential of day 6 blastocysts was 
different to embryos ready for biopsy on day 5. We found almost identical implantation rates 
with both groups, 78% with day five embryos compared to 75% for embryos ready for biopsy by 
day six (p=0.8)(table 24). So to be able to include day 6 embryos in the cohort for transfer is a 
definite advantage for the freeze all group and leads to more patients reaching the goal of their 
intended transfer protocol compared to the fresh transfer strategy. 
 
 
Transferring fresh embryos on day 6 could be regarded as a disadvantage for the fresh transfer 
protocol,  since  usual  clinical  practice  is  to  transfer blastocysts on  day 5  of  embryo  growth. 







However, fresh transfer of tested embryos on day 5 is not possible with current NGS technology 
due to the length of time needed to run the assay (17 hours) before results are obtained. For this 
reason day 6 transfer is currently the standard procedure for fresh transfer of known euploid 
embryos when using NGS. Arguably, the ideal comparison for this study may have been to 
transfer both fresh and frozen embryos on day six, but the point of the present trial was to 
compare the two currently available options using NGS technology in daily practice. Moreover, 
the optimal window of implantation where the endometrium is most receptive is not precisely 
known and may differ from cycle to cycle and from patient to patient (Casper and Yanushpolsky, 
2016; Haouzi et al., 2009). Thus we elected to conduct fresh transfers before 12 midday on day 
six, as soon as the PGS results became available. A faster methodology for counting chromosomes 
is real time quantitative polymerase chain reaction (qPCR) where the turnaround time is 4 hours 
therefore allowing for same day transfer on day 5. In this study we were comparing the use of 
NGS for the two transfer strategies as this is the technology of choice for many PGS laboratories 
and one which is in place for clinical testing in the study center laboratory. Other studies are 
needed to compare fresh vs frozen transfers of euploid embryos using other technologies and 
this was outside the scope of this trial. 
 
 
The consequences of transferring embryos in a high estrogenic environment are higher rates of 
abnormal placentation (Farhi et al., 2010) and possible reduced endometrial receptivity (Arslan 
et al., 2007; Carmona-Ruiz et al., 2010) compared to cycles with more physiological levels of 
estradiol. Abnormal placentation includes incorrect placenta placement in the uterus such as 







placenta previa and vasa previa or abnormal cord insertion such as velamentous or marginal cord 
insertion. The risk of fetal maternal hemorrhage is high if the placenta or vessels lie over the 
cervix or if the cord is easily detached from the placenta during the birthing process. Farhi et al 
(Farhi et al., 2010) showed in a retrospective single center study that there seems to be a higher 
incidence of abnormal placentation in fresh ET cycles associated with estradiol levels above 2724 
pg/ml at the time of hCG and in a large Australian multicenter study of singleton pregnancies, 
Healy et al (Healy et al., 2010) found that there is a higher risk of obstetric hemorrhage after 




An insufficient placenta can be associated with an increase in the rate of lower term birth weight 
infants resulting from fresh ET cycles compared to frozen ET cycles (Farhi et al., 2010; Kalra et al., 
2011; Wennerholm et al., 2013). In the present study, maximum E2 levels for the fresh group 
reached an average of 3489pg/ml compared to an average of 1098pg/ml in the freeze all group. 
While the FET E2 levels were not as physiologically normal as during natural cycle conception 
they were three times lower than the fresh transfer group and did not exceed the levels above 
which an increase in abnormal placentation has been observed (Farhi et al., 2010). The present 
study did not assess placental defects of offspring however and the average weight of singleton 
offspring in each group was similar. 







In addition to biological concerns, infertility is psychologically challenging for patients, and stress 
related to infertility and undergoing a demanding IVF cycle should be taken into account while 
making treatment decisions. The uncertainty of possibly having no euploid embryos available for 
fresh transfer on the morning of day six could significantly increase ƉĂƚŝĞŶƚ ?Ɛ perceived stress. On 
the other hand, knowing in advance that a fresh transfer will not be attempted thus allowing 
time to carefully consider the results of the whole cohort of embryos may relieve some of that 
stress for the patient. 
 
 
It should be noted that fresh transfers also have several advantages. A fresh transfer avoids direct 
costs associated with cryopreservation and the subsequent frozen thawed embryo transfer. A 
fresh transfer also saves on future indirect costs of treatment, such as loss of earnings for 
monitoring visits during the frozen transfer cycle and travel costs for patients travelling from 
another state or even another country. The chance of a positive outcome is more immediate 
compared to a freeze all cycle where the patients often have to wait weeks or months to even 
attempt a transfer. Thus, it is also possible that some patients can regard a fresh transfer as less 
stressful. Either of the treatment protocols investigated in this study can be a reasonable option 
for patients using their own oocytes. On balance the non-stimulated uterine environment of the 
FET protocol may result in pregnancies with fewer obstetric complications as shown by previous 
studies of fresh vs frozen protocols using non tested embryos and IVF vs non IVF pregnancies 
(Englert et al., 1987; Farhi et al., 2010; Healy et al., 2010). 







While this study did reveal a significant improvement in live birth rate per transfer event using 
frozen thawed euploid embryos compared to fresh, it was unable to demonstrate a statistically 
significant improvement in live born offspring per transferred embryo between the two transfer 
strategies. Freezing all embryos allows for inclusion of all blastocysts in the cohort of embryos 
available for transfer which also results in a higher proportion of patients reaching their primary 
embryo transfer goal. In conclusion, our findings suggest a trend towards favoring the freeze-all 
option as a preferred transfer strategy when using known euploid embryos. Further randomized 
controlled trials using known euploid embryos need to be executed to further substantiate the 
outcome data described in the present study. 
Trial registration number: NCT02000349 







2.6 Specific aim 5 
 
To test the hypothesis that using NGS for PGS increases live birth rates and lowers 
miscarriage rates by reporting mosaicism compared to using aCGH . 




2.6.1 My personal contribution to the work 
 
I analyzed data generated from IVF cycles carried out in our own clinic. I summarized the data 
and wrote this chapter. 
 
 
2.6.2 Chapter summary 
 
This retrospective study of FET cycles using euploid embryos designated as such by aCGH or NGS, 
analyzed rates of euploidy, average number of euploid embryos per cycle, percentage of cycles 
with no euploid embryos, miscarriage rates and live birth rates per embryo, between the two 
platforms. The hypothesis was that as mosaicism is not reported using aCGH, if we are able to 
classify mosaicism by using NGS and avoid transferring mosaic embryos, live birth rates should 
be higher, euploidy rates should be lower and therefore less embryos would be available for 
transfer, the number of cycles with no normal embryos should be higher and miscarriage rates 
should be lower using NGS compared to aCGH. The only parameter that was significantly 
different was the overall euploidy rates for each age group which were lower with NGS. All other 







parameters were similar between the two platforms. The results of this study therefore may lead 
us to wonder if mosaicism is a real concern in preimplantation embryos. If it is a true 






As more detailed chromosomal abnormalities are detected in embryo biopsies by more 
sophisticated testing methods, one would expect a corresponding increase in live birth rates per 
embryo transferred. In the early days of PGS, FISH was used to detect only a maximum of 12 
chromosomes in a single cell. With the implementation of more advanced technologies such as 
qPCR, aCGH and NGS, the quantification of whole chromosome copy number in preimplantation 
embryos has now become possible. 
 
 
Array CGH was used to screen embryos for aneuploidy between 2010 and 2014 until converting 
to NGS on the Ion Torrent (Thermo Scientific) platform. NGS has higher resolution and a broader 
dynamic range compared to aCGH and therefore is able to detect mosaicism and smaller 
segmental anomalies in chromosomes than with aCGH. Historically, it was generally accepted 
that aCGH lacked the resolution necessary to reliably detect mosaicism. A mosaic result was 
classed as euploid or aneuploid depending on the percentage of mosaicism seen. Above 50% was 
aneuploid and below was euploid (verbal confirmation from industry leaders). 







As NGS technology detects these anomalies in blastocyst embryos one might assume that once 
transferred, the percent of babies born from NGS screened embryos would be higher than from 
those screened with aCGH. In this retrospective study, euploidy rates, percent of cycles with no 
normal embryos, average number of euploid embryos per cycle, miscarriage rates and live birth 
rates per transferred embryo were compared between aCGH and NGS screened embryos. 
 
 
2.6.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 





2.6.5.1 Euploidy rates between the two screening platforms 
 
Euploidy rates in both the own oocyte and donor oocyte group were significantly lower using 
NGS compared to aCGH in all but the 38-40 age group which only had a 3% difference in favor of 
aCGH (Figure 33 and table 25). 
 
 
2.6.5.2 Percent of cycles with zero euploid embryos per cycle 
 
The two platforms showed similar percentages of cycles that had no euploid embryos at all with 
only a trend towards NGS resulting a higher percentage in all age groups (table 25) 







2.6.5.3 Average number of euploid embryos per cycle 
 
There was no difference between the two platforms of the average numbers of euploid embryos 
available for each age group. However all of the maternal age groups apart from the 38-40 age 
group, had more embryos to biopsy in the NGS groups compared to the aCGH groups. This 
resulted in a lower percentage of euploid NGS embryos compared to those designated as euploid 

















Figure 26: Euploidy rates per age group and platform used for determination- aCGH 2010-2014, NGS 








































. <35 35-37 38-40 41-42 Donor egg 
(ave age 25) 
Total 
 aCGH NGS aCGH NGS aCGH NGS aCGH NGS aCGH NGS aCGH NGS 

























































4.0 4.0 2.8 3.0 1.8 1.7 1.4 1.2 6.7 6.8 
  































P value 0.5 0.09 0.8 0.08 0.5 0.9 
 
Table 25: comparing euploidy rates and number of cycles having no euploid embryos between aCGH (2011- 
December 2014) and NGS post reporting of mosaicism (May 2015-March 2017) 
 
 
2.6.5.4 Miscarriage rates: 
 
The percentage of fetal hearts visualized, resulting in a live born baby was compared for each 
maternal age group between NGS and aCGH. The loss rate per fetal heart was not statistically 
different between each platform (table 26) 
 
 
2.6.5.5 Live birth rates: 
 
Comparing the two screening method for Live births per embryo transferred resulted in no 
significant difference between an NGS screened embryo vs an aCGH screened embryo. There 
seemed to be a slight trend in favor of NGS screened embryos but to reach significance with a 2% 
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difference in live births per embryo transferred one would have to have 4900 embryos 

















Figure 27: Live birth rates per embryo screened with aCGH or NGS. 
 
 Patient own uterus GC uterus 
 <35 35-37 38-40 41-42 Donor egg 
(ave age 25) 
 aCGH NGS aCGH NGS aCGH NGS aCGH NGS aCGH NGS aCGH NGS 






















































P value <0.001 0.4 0.6 0.08 0.4 0.4 




























P value >0.05 NS 




























P value >0.05 NS 
Table 26: Outcomes of transfer cycles using embryos screened with aCGH or NGS (all embryos vitrified with 




























The evolution of molecular technologies brings with it the ability to identify more potential 
chromosomal abnormalities in preimplantation embryos (Capalbo et al., 2016b; Lai et al., 2017; 
Munne and Wells, 2017; Treff and Franasiak, 2017). Unlike aCGH, the NGS platform is able to 
determine mosaic profiles and distinguish these from full aneuploidies or noisy euploid results. 
Mosaic profiles can occur along with a full aneuploid profile in the same embryo (for example: 
monosomy 15, mosaic trisomy 12) or they can occur as a single or double mosaic profile without 
a full aneuploid result (for example: mosaic monosomy 18, mosaic trisomy 1). These embryos 
with only a mosaic result fall within a grey area of clinical IVF because they have both euploid and 
aneuploid cells present. If the euploid cells are present in the inner cell mass and proliferate in 
preference to the aneuploid cell line then the fetus could be normal. If the aneuploid cell line 
proliferates then the embryo may not be viable or give rise to an aneuploid fetus. 
 
 
In our own program, NGS on the Ion Torrent platform identified around 10% of embryos with an 
isolated mosaic result in patients less than 40. In patients over 40 we found 5% of embryos with 
an isolated mosaic result (own unpublished data). Older patients have higher aneuploidy rates 
so even though they seem to have lower mosaic rates, their mosaics exist more often alongside 
full chromosome aneuploidies. 














These 10% of embryos without a full aneuploidy, may have been called euploid by aCGH and may 
have been chosen for transfer in an FET cycle. These inadvertently transferred mosaics may never 
have implanted or may have resulted in a miscarriage. Therefore to have the slight at least 
perceived increase in live born babies per NGS screened embryo may be attributable to the 
weeding out of mosaic embryos. To expect the percent increase of live borns to match the mosaic 
embryo rate at 10% with NGS would be unrealistic as not all the undiagnosed mosaic embryos 







would be chosen for transfer, so the few that were inadvertently chosen could account for the 
small decrease in live borns from aCGH screened embryos. 
 
 
While there have been validation studies comparing the two technologies and their ability to 
predict ploidy status (Aleksandrova et al., 2016; Kung et al., 2015) there have been few studies 
comparing IVF outcomes using NGS and aCGH to determine ploidy. Yang et al in 2015 (Yang et 
al., 2015) carried out a study comparing implantation and pregnancy rates between the 2 
methodologies showing a similar small increase in implantation and pregnancy rates in the NGS 
group to the one seen in the present study. The latest study published by Lai et al(Lai et al., 2017) 
biopsied embryos from 45 patients and ran the amplified products on aCGH and NGS platforms 
concurrently to examine the differences in profiles on the same embryo sample. 









Figure 29: showing different interpretations of the same amplified DNA sample from the same embryo 
between the two testing platforms. (Lai et al 2017) Open access article distributed under the terms of the 
Creative Commons Attribution (http://creativecommons.org/publicdomain/zero/1.0/) 
 
 
As is shown in figure 29, some embryos diagnosed as euploid using aCGH show errors when 
analyzed by NGS. The second phase of the same study compared outcomes of FET cycles using 
aCGH and NGS screened embryos. Their findings were similar to the present retrospective 
analysis, with significantly higher implantation rates with NGS screened embryos compared to 
aCGH (53% vs 45% respectively, p= 0.04) and a trend towards improved ongoing pregnancy rates 
with NGS but not significantly (57% NGS vs 46% aCGH, p= 0.1). 







While average aneuploidy rates vary according to maternal age, within each age group there will 
always be outliers who will have no euploid embryos in their cohort. As NGS results in fewer 
euploid embryos available per cycle in all age groups compared to aCGH, the assumption was 
made that when using NGS, there would be more cycles that had no euploid embryos at all. As 
our data shows in table 25, there were no significant increases in the number of cycles with no 
euploid embryos available. 
The Preimplantation Genetic Diagnosis International Society (PGDIS) position statement on 
chromosomal mosaicism, published in 2016 (PGDIS, 2016), stated that less than 20% mosaic 
aneuploidy should be considered euploid, greater than 80% mosaic aneuploidy should be 
considered aneuploid and between 20-80% mosaicism should be classified as a mosaic result. 
These reporting guidelines, were based on the Illumina NGS platforms (MiSeq, NexSeq)and 
VeriSeq assay and these thresholds had little clinical data to support their determination. 
Reported rates of mosaicism in pre-implantation blastocysts vary depending on which platform 
and assay is used. When Array CGH was used for PGS, mosaicism was observed but not reported 
and results were classed as aneuploid (over 50% mosaic aneuploidy) or euploid (less than 50% 
mosaic aneuploidy). If the NGS result profile is clean and artefacts have not been introduced 
during sequencing or amplification (see figure 28) then a true mosaic result is easy to categorize 
but if the results are noisy then a mosaic result is more difficult to call and could be attributed to 
DNA degradation or sample mishandling. Critics of mosaic results argue that there is not enough 
evidence that these results firstly are fact or artifact and if they are fact what effect these results 
have on pregnancy outcome and the phenotype and genotype of live born offspring. Mosaic 







thresholds above and below which an embryo will be classified as mosaic rather than aneuploid 
or euploid have been established within the PGS community. Other NGS platforms such as the 
Ion Torrent PGM platform will also detect mosaicism but the threshold for classifying a mosaic 
result is higher than with the Illumina platform. In our own lab, the Ion Torrent platform resulted 
in isolated mosaic rates of around 10% of all blastocysts screened for aneuploidy compared to 
20% with the MiSeq Illumina platform 
 
 
However, the proportion of aneuploid cells in any mosaic sample may or may not reflect the 
extent of mosaicism in the whole embryo. If 10 cells are biopsied and one/ten is aneuploid, the 
percent of mosaicism would be stated as 10%. If 5/10 of the cells are aneuploid then the percent 
of mosaicism observed would be 50%. These results could have been from the same embryo and 
the biopsy could have been taken at different places on the trophectoderm. 
 
 




Biological challenges are two- fold: 1) sampling errors; as the mosaic determination can only be 
made based on the cells sampled from one site on the trophectoderm and 2) reciprocal errors; 
where deletion in one cell and duplication in another cell for the same chromosome, could be 
diagnosed as euploid when the total amount of DNA for the sample is analyzed. 







Analytical challenges are that the data points of euploid and aneuploid samples often overlap 
extensively. Smoothing algorithms are used to give a weighted average of the data points to 
discriminate between aneuploid, euploid or mosaic (Scott and Galliano, 2016). 
 
 
Because of the challenges involved in the technology, some practitioners question the validity of 
mosaic results (Gleicher et al., 2016; Greco et al., 2015) and infer that the results may be artefact 
or noise. If there is a rise in live birth rates when mosaicism is reported then the issue may indeed 
be real rather than a statistical average and should be taken into account when looking at 
embryos suitable to transfer. Further studies on the interpretation of mosaic results need to be 
performed. 







2.7 Specific aim 6 
To provide a framework for creating realistic expectations for patients planning 
for their fertility future 
 
Data presented in an abstract at ASRM 2016, entitled: Planning for the future: how many oocytes 
do patients need to harvest to achieve their fertility goals? Alison Coates Emily Mounts, Brandon 
Bankowski, Santiago Munne. Abstract poster ASRM annual meeting 2016 ((Coates et al., 2016b)) 
 
 
2.7.1 Personal contribution to the manuscript: 
 
I retrospectively analyzed PGS data on blastocyst embryos from patients undergoing IVF with PGS 
in a private IVF clinic in Portland, Oregon, USA and used the data to calculate the number of 
mature oocytes required to make one euploid blastocyst according to maternal age. 
 
 
2.7.2 Chapter summary: 
 
The IVF process is an increasingly complex one which can halt at any stage: cancelled cycle before 
oocyte retrieval, no eggs collected, no mature eggs, failure of fertilization, failure to cleave, 
failure of all embryos to progress to the blastocyst stage, no euploid embryos post biopsy, failure 
to thaw and then of course post transfer, failure to implant and failure to reach a live born 
offspring. As maternal age increases the incidence of an adverse event simultaneously increases 
as does the aneuploidy rate. Patients need to be aware of all the pitfalls that can occur as part of 
the IVF cycle and I attempted to provide new tools to show the frequency of these negative 







outcomes and by analyzing how many oocytes are needed to create one euploid blastocyst I 
created a tool for clinicians to use to better counsel patients on how many cycles they should 





One cycle of IVF may or may not result in the desired outcome of a live born infant or the creation 
ŽĨĞŶŽƵŐŚĞŵďƌǇŽƐƚŽĐŽŵƉůĞƚĞĂŶŝŶĚŝǀŝĚƵĂůƉĂƚŝĞŶƚƐ ?ĚĞƐŝƌĞĚĨĂŵŝůǇƐŝǌĞ ?DŽƌĞƚŚĂŶŽŶĞĐǇĐůĞ
may be required to achieve these goals. As maternal age advances, the number of euploid 
oocytes decreases (Harton et al., 2013) which results in fewer euploid embryos available for 
transfer. Patients therefore need to be counselled on how many cycles they should plan to 
complete to maintain a realistic expectation during the treatment cycle. With the development 
of successful oocyte vitrification protocols and the subsequent increase in popularity of elective 
oocyte freezing for fertility preservation, the optimal number of oocytes needed to produce a 
single euploid blastocyst at any given age, plays a part in fertility planning. Given the increasing 
rate of aneuploidy with maternal age, it is important to understand how many oocytes are ideally 
needed to later result in an adequate number of euploid embryos for transfer. 
 
 
This study includes a retrospective, single center, data analysis of fresh IVF cycles undergoing PGS 
for aneuploidy using high resolution Next Generation Sequencing (hrNGS) on the Ion Torrent 
PGM platform, and illustrates how many mature eggs are needed in the fresh cycle to create one 
euploid  blastocyst  based  on  maternal  age.  In  order  to  help  expectations  to  be  managed 







appropriately I also present data showing the percentage of oocyte retrievals that result in 
adverse events during the IVF cycle according to maternal age. 
 
 
2.7.4 Materials and Methods 
 
(See general Materials and Methods for stimulation, culture, vitrification and DNA quantification 
protocols. Section 2.7) 
 
 
2.7.4.1 Calculation of number of mature oocytes required to get one euploid blastocyst 
The determination of how many oocytes to target was derived by dividing the total number of 
mature eggs retrieved for each maternal age group by the final number of euploid blastocysts 
available post-biopsy, resulting in the number of mature oocytes retrieved per euploid blastocyst. 
(Total # mature eggs ÷ Total # euploid embryos = # of mature eggs per euploid blastocyst). 
Blastocysts with an inconclusive result were omitted from the analysis which accounted for 2.0% 
of the total number of blastocysts available. Assuming an approximate 55% live birth rate per 
transferred euploid embryo, the patient should aim to at least double this number of mature 
eggs for a goal of one child and quadruple it for a goal of 2 children. 
 
 
For oocyte cryopreservation cycles the calculation has to compensate for potential losses post 
thaw. Survival rates of vitrified oocytes are typically between 85-90%. To calculate the number 
of mature oocytes needed to freeze for future use, the number of fresh eggs should be increased 
by 10-15% to account for post thaw losses. 









2.7.4.2 Calculation of other events occurring throughout the IVF cycle 
 
Data was also analyzed to establish percentages of oocyte retrievals that result in no blastocyst 


































Number of mature eggs required to make one euploid blastocyst according to maternal 
age (ORM data January 2012-December 2016) 
"n"= number of eggs needed for one euploid blastocyst 
90 
20 
3.3 3.7 4.1 4 4.5 4.7 5.9 


































<30 30-34 35 36 37 38 39 40 41 42 43 44-46 
# cycles 641 68 277 113 123 111 121 135 116 90 50 34 28 
Ave # 
M2/cycle 





9.7 6.6 5.8 5.2 4.9 5.1 4.2 3.8 3.8 4 3.8 2.6 2.3 
Ave # 
euploid/cycle 
6.8 4.6 3.6 3.4 2.8 2.7 2 1.7 1.4 1.3 1 0.5 0.1 
# mature eggs 
to make one 
euploid 
blastocyst 
3.3 3.7 4.1 4 4.5 4.7 6 6.7 9.1 9.7 13 20 90 
Table 27: Data for figure 36 showing number of cycles and average numbers of oocytes and 





















Figure 31: Graph showing percentage of oocyte retrievals resulting in zero blastocyst formation 
according to maternal age 
Percent of egg collection cycles resulting in zero blastocyst formation according to 










































































Figure 32: Graph showing percent of PGS cycles that have no euploid embryos post biopsy 





















0 0.5% 1.4% 1.4% 2% 0 2% 2% 3% 3% 3% 6% 6% 
Table 28: Incidence of adverse events during the IVF cycle. 
Percent of CCS cycles that have no normal embryos according to maternal age (ORM 































Managing patient expectations during the IVF cycle is challenging. A cycle of IVF is physically, 
mentally and financially stressful for the patient. The majority of cycles will complete without an 
adverse event and will fall within the average expectations. However, when a patient falls outside 
of those expectations it helps to be able to understand what can go wrong before the cycle starts. 
Patients going through their first cycle of IVF are the least aware of upcoming events in the 
process. Patients find it difficult to comprehend exactly what is involved in an IVF cycle unless 
they have physically experienced it themselves even though clinical staff spend many educational 
hours explaining each part of the process in detail before it occurs. 
 
 
The IVF process is an increasingly complex one which can halt at any stage: cancellation before 
retrieval due to poor response to the medication, no eggs collected, no mature eggs, failure of 
fertilization, failure to cleave, failure of all embryos to progress to the blastocyst stage, no euploid 
embryos post biopsy, failure to thaw and then of course post transfer, failure to implant and 
failure to reach a live born offspring. Patients need to be aware of all the pitfalls that can occur 
as part of the IVF cycle and I attempted to provide educational tools to show the frequency of 
these negative outcomes. 
 
 
As maternal age increases so do the number of oocytes required to result in one euploid 
blastocyst (figure 36). The model presented here is useful when counselling patients vitrifying 
oocytes for fertility preservation, to facilitate an informed decision regarding the number of egg 







retrieval cycles they may require to achieve their future fertility goals. It is also useful to use in 
patient/ provider discussions for patients undergoing IVF for immediate family creation to plan 
for the desired family size. 
 
 
The minimum number of oocytes calculated for each age group is only a guideline as cycles and 
patients all vary a great deal but patients appreciate any information that may guide them in 
their estimation of financially and emotionally planning their desired family goal. 







3 General Discussion 
 
 




1. Some association between aneuploidy levels and morphokinetic criteria was established 
in human IVF embryos however this is by no means diagnostic. Similarly, analysis of cell 
free embryonic DNA found in spent culture media shows great promise as a non-invasive 
preimplantation genetic screen and further studies are planned and warranted. 
2. Patients undergoing ICSI with normal semen parameters showed no increase in 
embryonic aneuploidy rates compared to standard insemination patients with normal 
sperm, showing that the ICSI process itself does not create aneuploidy in embryos. 
3. Novel insights were provided in terms of the patient populations that may benefit from 
the use of PGS, specifically, male factor infertility patients and young oocyte donors. 
Namely that patients with suboptimal semen parameters were shown to have increased 
sex chromosome aneuploidy rates in embryos, and patients of young maternal age may 
still benefit from PGS when cryopreserving embryos for future use shown by the increase 
in live birth rates when PGS embryos are used for transfer. 
4. Results demonstrated that the optimal transfer strategy for euploid embryos in patients 
using their own oocytes was to freeze all embryos and transfer thawed embryos in a 
subsequent cycle. 







5. The use of NGS to screen embryos for aneuploidy should have resulted in higher live birth 
rates per transferred embryo compared to array CGH screened embryos, as mosaic 
embryos are reported by NGS but not array CGH (see section 2.6.2). As we are presumably 
avoiding mosaic embryos by using NGS the final outcome should be improved compared 
to other platforms. I found this to not be the case and live birth rates remained similar 
between the two screening platforms. 
6. A framework for creating realistic expectations for patients planning for their fertility 
future was provided which is currently being used clinically in my own IVF clinic. Patients 
undergoing oocyte cryopreservation find the metric used to calculate the number of 
oocytes needed to create one euploid embryo very useful and have been able to plan for 
multiple cycles depending on their response to the stimulation medication based on that 
equation. Patients also like to be made aware of any pitfalls that may occur during 
embryo creation cycles and the table of adverse events I created places some perspective 
on rates of occurrence. 
 
 
dŚĞ ĞŵďƌǇŽůŽŐŝƐƚ ?Ɛ ƌŽůĞ ŽĨ ĐŚŽŽƐŝŶŐ ĞŵďƌǇŽƐ ĨŽƌ ƚƌĂŶƐĨĞƌ ƐŽůĞůǇ ŽŶ ŵŽƌƉŚŽůŽŐǇ ĂůŽŶĞ ŝƐ
diminishing in many clinics. If we are able to determine ploidy status in an embryo the 
morphology becomes almost irrelevant. There is great variation in the rate of use of PGS between 
IVF clinics across the world. In the USA there are still clinics that never test embryos but just 
transfer untested embryos whatever the patient age. The number of clinics who utilize PGS in 
the majority of their patient cycles are increasing each year with improvements in testing 







technology. As I stated at the beginning of this thesis, in order to optimize embryo choice we 
have to be able to grow embryos in a stress free environment as closely aligned to the in-vivo 
environment as possible. If a lab is unable to successfully grow embryos to their fullest potential 
in-vitro then all of the innovative adjunct technology currently in use or under research to help 
choose the best embryo will be wasted. 
 
 
As aneuploidy accounts for the majority of IVF implantation failures and miscarriages (Spandorfer 
et al., 2004), to reduce the number of aneuploid embryos transferred is of benefit to many 
patients going through IVF treatment. With fewer failed cycles the length of time from cycle start 
to successful outcome is reduced and this effect is much greater in patients of advanced maternal 
age, but only if a euploid embryo can be found. Murugappan et al (Murugappan et al., 2016) 
recently stated that embarking on an IVF cycle with PGS for patients experiencing repeated 
pregnancy loss did not appear to reduce the time to viable conception compared to expectant 
management. However I would argue that patients who conceive with an aneuploid embryo and 
subsequently miscarry by definition will prolong the time taken to live birth due to wasted time 




In 2007 Mastenbroek published a randomized double blind study comparing the transfer of PGS 
vs non screened embryos. The biopsies of single cells were carried out on day 3 and the DNA 
analyzed with 8 probe FISH (Sebastiaan Mastenbroek et al., 2007). 408 women were randomized 







to the treatment or control group before the follicular aspiration. The results were a significant 
reduction in ongoing pregnancy rates in the PGS group compared to the control group (25% vs 
37% respectively p=0.01). This study was greatly criticized at the time for lack of reporting an 
error rate, poor biopsy technique, substandard fixation and FISH methods and inappropriate 
patient selection (Cohen and Grifo, 2007; Munne et al., 2007b). In 2011, Mastenbroek published 
a meta-analysis of PGS studies, again only considering day 3 biopsy with FISH analysis which 
concurred with the results of his own RCT (Mastenbroek et al., 2011). Hardarson et al in 2008 
(Hardarson et al., 2008) also carried out an RCT comparing pregnancy outcomes of PGS tested 
and non-tested embryos. Again day 3 biopsies were analyzed with 7 probe FISH. Ongoing 
pregnancies in the PGS group were 9% vs 25% for the non PGS group. 
 
As it has since been shown that the biopsy process itself on day 3 is detrimental to embryo growth 
(Scott et al., 2013b) and as there are limitations to FISH analysis of single cells, the Mastenbroek 
study conclusions may have had some validity. 
 
 
As the field has progressed over the last ten years, the development of trophectoderm biopsy 
followed by 24 chromosome analysis has repaired this damaged reputation to some extent and 
PGS for aneuploidy is now back in widespread use in many clinics especially in the USA with 
plentiful data to illustrate the effectiveness of the process. The arguments for the use of PGS in 
a clinical setting are that that implantation, ongoing pregnancy and live birth rates per embryo 
transferred  is  higher  for  a  known  euploid  embryo  compared to  an  unscreened  embryo for 







patients of advanced maternal age (Chen et al., 2015; Dahdouh et al., 2015b; Forman et al., 
2013a; Forman et al., 2013b; Forman et al., 2012b; Schoolcraft et al., 2010; Schoolcraft and Katz- 
Jaffe, 2013; Scott et al., 2012). 
 
 
The arguments against the use of PGS are that there has not yet been a large randomized 
controlled Intention to treat trial, which takes into account all cycles started to get to the desired 
outcome of a live birth and that the presence of mosaicism translates to an inaccurate picture of 
the whole embryo therefore why would we test at all (Gleicher et al., 2016; Orvieto, 2016; 
Orvieto and Gleicher, 2016). 
 
 
In the most experienced labs that are biopsying trophectoderm, vitrifying embryos with a high 
survival rate and using the latest DNA analysis techniques, one can still only expect around a 60- 




So why do so many embryos still fail? With the limitations of relying on the small representation 
of the biopsied cells presented for DNA analysis we are certainly missing some mosaic cell lines. 
Some of the embryos we transfer may be undetected mosaics and may be doomed to fail before 
implantation. Other lethal mutations at the gene level that we do not screen for, may be present 
in embryos. 







From the perspective of the embryo, metabolomic/proteomic profiles may eventually be used in 
conjunction with PGS. It is possible that if particular metabolites or amino acids can be found, 
that are utilized or excreted by the embryo that strongly correlate with high implantation 
potential, and if a method of detection could be developed that is translatable to clinical practice, 
the results could be used to rank euploid embryos amongst a cohort for preferential transfer. An 
embryo with undetected mosaicism from a trophectoderm biopsy, may have a 
metabolomic/proteomic profile that differs from an embryo with a pure euploid cell line. To use 
euploidy determination alongside a metabolomic /proteomic profile may accurately predict 
which embryo is likely to make a healthy baby and may give a holistic overview of the whole 
embryo rather than relying on a few cells from the trophectoderm which may or may not 
represent the chromosomal complement of the embryo as a whole. We need to continue 
research to find biologic markers, their presence or deficit that predicts a high chance of a live 
birth in an embryo. 
The long term effects (if any) of trophectoderm biopsy of a pre-implantation embryo have yet to 
be determined. It is possible that removing part of the trophectoderm has an effect on 
placentation which may affect fetal growth and development by restricting nutrition to the fetus. 
Offspring with compromised fetal nutrition can develop metabolic issues into adulthood. The 
future study that needs to be done is to assess placentation in offspring resulting from 
trophectoderm biopsied frozen thawed embryos. The 2 control groups in the study would be 
non-biopsied frozen thawed and non-biopsied fresh embryos. The ideal patient population to 
include in the study would be parous gestational carriers who typically have had normal vaginal 







deliveries with no complications to remove the uterine effect. These patients are not large in 
number in any one center and this data would be difficult to obtain. 
By definition, we are disrupting the trophectoderm layer by biopsying. As we do not know if there 
are any adverse long term effects, to be able to reliably ascertain the ploidy status of a blastocyst 
by a non-invasive method would be of benefit to our field. The non-invasive spent media PGS 
study carried out as part of this thesis showed some promise in amplifying cell free DNA with a 
novel amplification method. Cell free DNA quickly degrades and this novel MDA based method 
was able to capture these elusive short strands of DNA. The results obtained were only 
concordant with the nuclear DNA from the biopsied samples of frozen thawed embryos and less 
concordant when fresh embryos were used. Theoretically any cells damaged by the freezing 
process would release their DNA into the media which may have explained the difference 
between the two groups. Non-invasive PGS is still in ŝƚ ?Ɛ very early stages of development and we 
may never be able to rely on results from fresh embryo culture. However there may be a place 
for this technology where the patient wishes to thaw, test and refreeze previously untested 
embryos, to obtain ploidy status before transfer. For these cases we currently thaw, biopsy and 
then refreeze the embryos to obtain PGS results. Although there would still be 2 rounds of 
freezing, the stress to the embryo would be minimized by removing the invasive biopsy from the 
procedure. There are plans to carry out further studies to validate the method. 
 
 
Of course, choosing between embryos which is primarily what these screening tools could be 
used for, is only possible if there are multiple embryos available for a patient. If patients have 







very few embryos or only one, there are arguments that the patient should transfer an 
unscreened embryo. Part of infertility treatment is to psychologically allow each patient to fulfill 
their own desire to feel that they have given each embryo a chance and this reasoning is mostly 
seen in older patients with fewer embryos. The younger patient with many embryos in her cohort 




If we do find a proteomic/metabolomic profile to add to PGS that predicts implantation success 
or failure at a high rate, there would always be patients who would still require a transfer if an 
embryo was determined to be euploid post PGS but non-viable post non-invasive screen, 
therefore the goal of 100% sustained implantation may never be achieved for all patients. 
 
 
There will always be patients who wish to transfer unscreened embryos and some of those will 
result in a baby and some will not as has always been the case since IVF first began. Hopefully 
this thesis has provided the basis through which patients can make more informed choices. 
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